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ABSTRACT 
 
Shuai Shi 
 
Rational Design, Manufacture and Evaluation of Respirable TB Subunit Vaccines 
 
(Under the direction of Dr. Anthony J. Hickey, PhD, D.Sc) 
 
The purpose of this dissertation is to compare the in vitro immune response of newly 
designed respirable TB subunit vaccines based on Ag85B/TB10.4 and their different 
combinations in order to make a recommendation of the best antigen/antigen combination for 
future animal protection study. The second goal is to develop a particle size comparator to 
evaluate the batch-to-batch reproducibility of inhalation products.  
Antigens were expressed and purified as soluble recombinants. The solubility of 
TB10.4 and TB10.4-Ag85B was dramatically improved by recombinant fusion to the C-
terminal of a bacterial protein thioredoxin. A purification method involving three 
chromatographic steps and one enzymatic treatment was successfully developed to purify 
soluble TB10.4 and TB10.4-Ag85B to homogeneity. The secondary structure and melting 
temperature of Ag85B, TB10.4 and TB10.4-Ag85B were characterized by circular dichroism. 
Purified soluble recombinant antigens were encapsulated into polylactide-co-glycolide 
(PLGA) microparticles by emulsion/spray-drying. By employing the concept of Quality-by-
Design (QbD), the spray-drying parameters were successfully optimized to give the desired 
particle properties. Particle size was optimized to a target of 3 µm with a single mode and 
narrow size distributions. A mass median aerodynamic diameter (MMAD) of 3.3µm and a 
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fine particle fraction of 61.5% suggested that these particles are suitable for pulmonary 
delivery. PLGA microparticles encapsulating different antigens or antigen combination 
showed highly reproducible physicochemical properties such as size, surface charge and 
glass transition temperature. Moreover, antigen encapsulation did not compromise its 
integrity. 
In vitro evaluation of TB subunit vaccines demonstrated that antigens encapsulated 
into PLGA microparticles induced much stronger and sustained Ag85B specific MHC II 
immune response compared to antigen solution formulations. Moreover, our data suggested 
that antigen blend of Ag85B and TB10.4 induced much better Ag85B response than antigen 
fusion TB10.4-Ag85B.  
We also developed a particle size comparator to evaluate the batch-to-batch 
reproducibility of inhalation products based on orthogonal partial least square analysis 
(OPLS). It was shown that OPLS coupled with Pareto scaling gave the best performance in 
terms of consistency with the Product Quality Research Institute (PQRI) working group 
evaluation. In addition, OPLS-based comparator showed better performance than that based 
on chi-square ratio statistics proposed by PQRI.  
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CHAPTER 1: INTRODUCTION 
1.1 General introduction 
Tuberculosis (TB) poses a significant risk to the global public health. According to the 
World Health Organization (WHO) report 2009 (1), there were an estimated 9.27 million 
cases of TB in 2007. Most of the cases were from Asia (55%) and Africa (31%), with small 
proportions from the European region (5%) and the regions of Americas (3%). Although the 
number of cases per capita has been falling since 2004, the total number of TB cases 
increased in absolute terms due to population growth (1).  
Among the 9.27 million cases in 2007, it was estimated that 1.37 million (14%) were 
HIV-positive with majority of these cases in the African region and the Southeast Asia 
region. Of HIV-negative cases of TB in 2007, there were an estimated 1.3 million deaths. An 
additional 456, 000 deaths occurred among HIV-positive incident TB cases (1). TB is a 
major cause of death for people who are also infected by HIV and HIV is the main reason for 
the failure of TB control in high HIV settings (2). 
TB treatment requires a lengthy drug therapy which employs a combination of 
antibiotics such as rifampicin, isoniazid, ethambutol and pyrazinamide (3). Most TB 
regimens have an initial high-intensity phase followed by a continuation phase (4). Improper 
use of antibiotics is the main reason for the emergence of multidrug-resistant tuberculosis 
(MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) (3, 5). There is evidence 
for the evolution from susceptible strain to MDR and then to XDR tuberculosis over a period 
of slightly more than a decade (6). Acquisition of resistance results from genetic mutations in
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specific resistance-determining regions in the genome of Mycobacterium tuberculosis (MTB) 
(7, 8). Chan et al. suggested a multifaceted approach to prevent a more widespread epidemic 
of MDR-TB and XDR-TB, which includes a) rapid diagnostic assays to detect drug-resistant 
TB and b) development of new drugs to treat all forms of TB in a shorter period of time (9).  
Approximately 2 billion people are currently infected by MTB. In the next 10 years, it 
is estimated that nearly 1 billion people will be infected by MTB and develop the latent form 
of TB, 200 million people will exhibit the active disease, and 35 million people will die from 
infection (1). Unfortunately, the only commercially available vaccine against TB, Bacillus 
Calmette-Guérin (BCG), does not afford complete protection (10). Protection conferred by 
BCG during childhood wanes after approximately 10 to 15 years (11). Even more 
discouragingly, boosters of BCG with repeated doses did not provide additional protection as 
demonstrated in a clinical trial (12). In light of the drawbacks of BCG, a spectrum of new-
generation TB vaccines have been developed and studied, including modified BCG (13, 14), 
modified MTB (15, 16), naked DNA vaccine (17), viral-vectored vaccine (18), and subunit 
vaccine (19). 
1.1.1 Mycobacterium tuberculosis (MTB): the pathogen of tuberculosis 
1.1.1.1 Physiology of MTB 
Mycobacterium tuberculosis (MTB), the causative organism of tuberculosis, is a rod-
shaped bacterium that is 0.2-0.3 µm in width and 2-5µm in length (20). This bacterium 
requires oxygen to grow and is classified as an obligate aerobe. Therefore, in the classic case 
of tuberculosis, MTB is always found in the well-aerated upper lobes of the lung. MTB has 
very slow multiplication time of 15-20 hours, which is extremely slow compared to other 
bacteria (e.g. Escherichia coli (E. coli) divides roughly every 20 minutes).  
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The cell wall structure of MTB is very unique among other prokaryotes. MTB is 
surrounded by a thin layer of cytoplasmic membrane and a second layer of peptidoglycan and 
lipids (21). The lipid fraction of cell wall mainly consists of three components: 1) mycolic 
acids, 2) cord factor and 3) wax-D. Mycolic acids are unique alpha-branched fatty acids, 
which can make up 50% of the dry weight of MTB cell wall (22). The lipid shell formed by 
the strong hydrophobic mycolic acid regulates the permeability properties at the cell surface 
of MTB and affects the outcome of Gram staining. It is believed that mycolic acids are 
pivotal determinant of MTB virulence probably by preventing MTB from attack by oxygen 
radicals, cationic proteins, and lysozyme in the phagocytic granules of macrophages (23). 
Mycolic acids may also protect extracellular mycobacteria from complement deposition in 
blood (23). Cord factor was first associated with virulent strains of MTB by Robert Koch, 
who observed that cells in smears made from in vitro-grown colonies often formed 
distinctive serpentine cords. Trehalose dimycolate (cord factor) is responsible for the 
serpentine cording mentioned above. Cord factor, produced mostly abundantly by virulent 
strains of MTB, is also toxic to mammalian cells and is an inhibitor of polymorphonuclear 
leukocytes (PMN) migration (24). Wax-D is the major component of Freund’s complete 
adjuvant (CFA) (24). Generally, many properties of MTB have been associated with the high 
concentration of lipids in the cell wall including 1) impermeability to stains, 2) resistance to 
antibiotics, 3) resistance to acidic and alkaline compounds, 4) resistance to complement 
deposition, and 5) resistance to lethal oxidations in macrophages.  
1.1.1.2 Transmission of MTB 
Tuberculosis (TB) transmits through the air. People who are afflicted with active TB in 
their lungs are infectious. When these people sneeze, cough or spit, they expel infectious 
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aerosol droplets containing TB microorganisms, known as bacilli, into the air. Once a small 
number of these droplets are inhaled by healthy individuals, they may become infected 
because the dose of MTB to produce infections in human is very low. People with frequent 
and prolonged contact with TB patients have a higher risk of becoming infected, with an 
estimated infection rate of 22% (25). People at high risk also include those who inject drugs 
using unsanitary needles, patients in immunocompromised conditions such as HIV-positive 
patients, people who use immunosuppressant drugs, and children exposed to adults in high-
risk categories (1). 
1.1.1.3 Infection of MTB 
It has been shown in single case contact studies that only 20-50% of individuals that 
are exposed to MTB become infected (26). Around 5% of these infected people develop 
pulmonary disease or other clinical form of TB over a period of 2-5 years. However, the 
other 95% of infected people develop latent TB infection. Individuals with latent TB 
infection have an approximately 5% lifetime chance of reactivation, leading to the 
development of clinical TB (26). When the infection becomes active, 75% of the cases are 
pulmonary TB and the other 25% of the cases are collectively denoted extrapulmonary TB 
(25). The infection sites of extrapulmonary TB include the central nervous system in 
meningitis, the genitourinary system in urogenital tuberculosis, and bones and joints in Pott’s 
disease. In the most serious TB infection, miliary tuberculosis, the bacteria are disseminated 
throughout the system. 
The development of pulmonary TB can be characterized by several stages. In the first 
stage, inhaled MTB may multiply or may be eliminated by alveolar macrophages before the 
emergence of any lesion. Second, small caseous lesions may heal or stabilize before 
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detectable or may progress to the next stage. Third, large caseous lesions may grow locally or 
shed bacteria into the lymph and blood leading to secondary lung lesions, or they may heal or 
stabilize. Alternatively, caseous lesions may liquefy and introduce bacteria into the bronchial 
tree, making disease control more difficult (27). Generally speaking, the disease progress 
from one stage to the next is associated with weaker host defense.  
1.1.2 Alveolar macrophage host defense against Mycobacterium tuberculosis 
1.1.2.1 Recognition of M. tuberculosis by alveolar macrophage 
M. tuberculosis infects alveolar macrophages and multiplies inside the cellular 
compartment of macrophages (28). Meanwhile, the macrophage plays a very important role 
in host innate immune response against M. tuberculosis infection.   
In human macrophages, the primary receptors for MTB are the mannose receptor (MR), 
the complement receptor 3 (CR3) and the Toll-like receptors (TLR) (29, 30). Among them, 
TLRs are mostly studied. TLRs constitute a family of proteins, known as pattern recognition 
receptors, for the detection of MTB ligands and initiation of subsequent inflammatory 
immune responses (31, 32). TLR 2, as a heterodimer with TLR 1 or TLR 6, recognizes a 
triacylated lipoprotein from MTB; whereas TLR9 recognizes bacterial CpG DNA. It has been 
shown by several studies that TLR2 played a central role in MTB recognition (33-35). 
Recognition of MTB by TLRs ultimately activates NF-κB leading to the production of 
inflammatory cytokines and generation of antimicrobial activity (36-38).  
In contrast to cell surface pattern recognition molecules such as TLRs, the nucleotide 
oligomerization domain (NOD)-like receptor, NOD 2, serves as a cytoplasmic sensor for 
MTB (39). NOD 2 is a cytoplasmic protein containing a central nucleotide-binding domain, a 
leucine-rich region, and two caspase activation and recruitment domains (CARD). NOD 2 
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recognizes intracellular muramyl dipeptide (MDP), which is a peptidoglycan found on MTB 
(40, 41). Upon recognition, NOD 2 mediates the production of cryptdins or α-4 defensins 
(42), which exert bactericidal effect against MTB. In addition, NOD 2 also induces 
inflammatory response against MTB infection. It has been shown that NOD 2 plays a non-
redundant role in MTB recognition (43). 
1.1.2.2 Macrophage defense mechanisms against M. tuberculosis  
Alveolar macrophages employ several defense mechanisms to combat MTB. Nitric 
oxide, produced by the inducible nitric oxide synthase (iNOS), has powerful and necessary 
antimycobacterial activity in the mouse model of tuberculosis infection (44-46). However, 
the importance of iNOS and nitric oxide in killing MTB is still questionable in human 
macrophages (37, 47). It has been shown in one study that TLR induced antimicrobial 
activity in human macrophages was not dependent on iNOS activity and nitric oxide could 
not be detected in these infected cells (37). This suggests that human macrophages may 
employ a nitric oxide independent antimicrobial mechanism to combat MTB.  
Autophagy is another defense mechanism employed by macrophages (48). 
Macrophages stimulated with key cytokines such as interferon-gamma (IFN-γ) undergo 
autophagy which is necessary for the antimicrobial activity against MTB (48). In a separate 
study, hydrolyzed ubiquitin peptides showed direct antimicrobial activity against MTB (49). 
This activity was delivered in an autophagy dependent manner to phagosomes sequestering 
MTB (49).  
Vitamin D has also been suggested to induce antimicrobial activity in human 
macrophages. Treating MTB infected human macrophages with active vitamin D reduced the 
intracellular bacterial load; however, the concentration of vitamin D was above the 
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physiological concentrations in these experiments (50, 51). Further studies suggested that 
vitamin D induced antimicrobial activity was regulated by phosphatidylinositol-3 kinase and 
mediated by the production of oxygen intermediates via NADPH-dependent phagocyte 
oxidase (52).  
1.1.2.3 Effect of cytokines on macrophages 
Pro- and anti-inflammatory cytokines induced by innate and acquired immune 
response to MTB have distinct effects on macrophages. Successful outcome of MTB infection 
does not depend on a single cytokine but on cytokine networks established and maintained by 
macrophages and other immunocytes. Two important cytokines are reviewed below. 
Tumor necrosis factor-α (TNF-α) is a pro-inflammatory cytokine produced by 
macrophages upon exposure to microbial products derived from MTB (53). TNF-α activates 
macrophages to produce nitric oxide synthase 2 (NOS 2), an enzyme catalyzing the synthesis 
of nitric oxide, assisting infected macrophages to kill intracellular MTB (54, 55). It has been 
shown that mice deficient in TNF-α or TNF-α receptor had increased susceptibility to MTB 
and impaired granuloma formation upon infection (56, 57). The importance of this cytokine 
has also been demonstrated in humans since patients treated with TNF-α inhibitors were 
more susceptible to tuberculosis (58). 
Interferon-gamma (IFN-γ) is a prototypic cytokine of Th1 immune response. This 
cytokine plays an essential role in effective TB control (28). IFN-γ is produced by CD4+, 
CD8+ T cells and NK cells (28). It stimulates antimicrobial activity by two mechanisms: 1) 
the induction of NOS and subsequent release of nitric oxide in macrophages (28, 59), and 2) 
the induction of macrophage autophagy (48). Mice that failed to produce this cytokine had 
disseminated MTB infection upon aerosol or intravenous MTB challenge (60, 61). In humans, 
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the polymorphism in the IFN-γ promoter region is significantly associated with the 
susceptibility to develop active TB disease, which has been observed in several clinical 
studies (62-65).  
1.1.3 Interaction of Mycobacterium tuberculosis with dendritic cells 
1.1.3.1 Recognition of M. tuberculosis by dendritic cells 
Although alveolar macrophages serve as the long-term hosts for mycobacterium, MTB 
infects dendritic cells (DCs) as well. This interaction is pivotal for the development of 
protective immunity against MTB (66, 67).  
There is considerable evidence that mycobacteria and mycobacterial antigens can be 
phagocytosed by DCs (68). DCs lining the trachea may be one of the first cells that encounter 
MTB. A number of surface molecules have been considered to play an important role in the 
recognition of MTB by DCs including CD11b, CD11c, DEC-205, mannose receptor (MR) 
and DC-specific ICAM-3 Grabbing Non-integrin (DC-SIGN) (30, 69-72). DC-SIGN serves 
as a pattern recognition receptor for MTB. Depletion of this molecule with specific antibodies 
inhibits the interaction of DCs with mycobacteria, although other surface molecules are also 
expressed by DCs at high levels (73). This suggests that DC-SIGN is a preferred receptor on 
DCs for MTB recognition and interaction. 
DCs also take up mycobacterial antigens in a process termed cross-priming (74). 
Apoptosis of MTB infected macrophages produces extracellular vesicles containing 
glycolipids and protein antigens derived from MTB. These vesicles are taken up by DCs and 
mycobacterial antigens are presented in the context of major histocompatibility complex 
(MHC) class I and MHC class II molecules produced by DCs. 
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1.1.3.2 Activation of dendritic cells 
Phagocytosis of MTB by DCs results in the activation of NF-κB pathway which 
ultimately leads to the secretion of inflammatory cytokines and chemokines and the release 
of reactive oxygen and nitrogen intermediates (75, 76). Activation of NF-κB has also been 
implicated in the modulation of surface phenotype of infected DCs (77). MTB infection leads 
to increased surface expression of a number of molecules, for instance, MHC I, MHC II, 
CD40, CD54, CD 80 that are involved in the interaction with T cells (78-81).  
Once being infected by MTB or cross-primed by MTB antigens, DCs migrate to the 
nearest draining lymph node. During migration, DCs undergo a process of ‘maturation’ 
characterized by reduced capability of phagocytosis yet increased surface expression of 
MHC I/II and costimulatory molecules (82).  
1.1.3.3 Immune activation by M. tuberculosis infected dendritic cells 
Infected DCs present class I and class II epitopes of MTB in the complex of MHC I 
and MHC II molecules. Presented epitopes are recognized by corresponding naïve CD8+ and 
CD4+ T cells which express specific T cell receptors. Upon this mutual recognition and with 
the help of cytokines and costimulatory molecules expressed by DCs, CD4+ and CD8+ T 
cells are activated through a cascade of signal transductions followed by clonal expansion of 
T cells (82).  
Activated T cells circulate to the vicinity of infection sites and serve as effector cells 
by either activating diverse antimicrobial mechanisms inside infected macrophages (75, 76) 
or contributing to the formation of granuloma to contain the intracellular mycobacteria in a 
state of dormancy (83). It is generally accepted that CD4+ T cells are the pivotal component 
of protective immunity against tuberculosis since depletion of this cell population resulted in 
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loss of control of MTB growth (28). However, the contribution of CD8+ T cells to protective 
immunity against MTB is still controversial (84). Mice genetically deficient in β 2-
microglobulin and, therefore, with impaired CD8+ T cells failed to control MTB infection  in 
one study (85). However, in a recent study, knockout mice deficient in both CD4+ and CD8+ 
T cells, CD8+ T cells or CD4+ T cells were infected via aerosol MTB and monitored for 
survival rate and ability to control infection (86). The conclusion of this study suggested that 
CD8+ T cells were dispensable and not essential for the control of infection.  
The importance of CD8+ T cells is again confounded by another factor: host 
differences (84). In one study, human CD8+ T cells recognizing MTB-infected macrophages 
had the ability to directly kill intracellular MTB by a granule-associated protein, granulysin, 
which is toxic to the mycobacteria (87, 88). However, mice do not have a granulysin 
homologue. Therefore, data from mice studies suggesting that CD8+ T cells are not essential 
for MTB control must take into account this missing mechanism. 
1.1.4 Bacillus Calmette-Guérin (BCG) and its drawbacks 
BCG is the only commercially available vaccine against tuberculosis that is prepared 
from a strain of attenuated live bovine bacillus, Mycobacterium bovis, which has lost its 
virulence by being cultured for generations in an artificial medium. The distribution of BCG 
for human use started since the 1920s and more than three billion people have received this 
vaccine. However, the continuing debate on the benefits and drawbacks of BCG never 
stopped since the early use of this vaccine. The major conclusion about the benefit of BCG is 
that it protects efficiently against leprosy (89) and against the childhood manifestations of TB 
(meningeal or miliary) (90). The drawbacks of BCG include safety concern as it cannot be 
used in immunocompromised patients, loss of sensitivity to tuberculin as a diagnostic marker, 
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efficacy decay over time, variable efficacy in different clinical trials, and in particular the 
failure of BCG in a number of trials in the third world.  
One explanation of BCG failure is the mutation or loss of mycobacterial genes during 
culture. Since the first successful BCG vaccination, it has been distributed world-wide and 
propagated differently in various labs for several decades leading to both genotypic and 
phenotypic changes compared to the parent strain of BCG developed by Camille Guérin and 
Albert Calmette (91). These changes also exist among various daughter strains of BCG (91). 
These mutations may partly explain the variable protection efficacy of BCG. Berh and Small 
suggested that BCG may have lost important genes over time and gradually have been 
attenuated to impotence (92). Adding to this explanation are several other hypotheses 
including previous exposure to environmental mycobacteria (93); the deletion of protective 
antigens from BCG (94); failure of BCG to stimulate balanced CD4+ and CD8+ T- cell 
responses (95); age and route of administration (96); and lyophilization of vaccine (93).  
1.1.5 Advances in tuberculosis vaccine strategies 
Based on the understating of BCG, various new-generation tuberculosis vaccines have 
been developed to address one or more drawbacks of BCG. Theses vaccines underwent 
different development stages as listed in table 2.1 and will be discussed in detail below. 
1.1.5.1 Modified BCG 
Comparative genomics revealed the differences between BCG and MTB. A number of 
regions designated RD1-RD16 encompassing 129 reading frames have been identified (97). 
RD1 is the best characterized region of deletion, which is lost in all BCG substrains yet 
presents in all strains within the MTB complex (94). Reintroduction of RD1 led to a protein 
expression profile almost identical to that of virulent M. bovis and M. tuberculosis (94). By 
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extension, BCG::RD1 (with reintroduction of RD1 region) may improve the protection 
activity of BCG. There are ongoing pre-clinical studies scheduled to test this vaccine.  
Recombinant BCG overexpressing already-existed genes was also developed. For 
instance, rBCG30 is BCG Tice engineered to overexpress Ag85B (13, 98, 99). The phase I 
trial in US was completed in 2004. The results suggested that rBCG30 promotes levels of 
protection greater than conventional BCG without causing serious adverse events (99). This 
study also suggests that modifying BCG by overexpressing important genes, even already 
existed gene, may be a promising approach to improve vaccine performance. Another 
example belonging to this category is rBCG-Aeras 403 with BCG Danish as the template 
overexpressing several proteins including Ag85A, Ag85B and TB10.4 (100).  
Recombinant BCG with endosome-escaping capability was also developed to improve 
BCG performance based on the hypothesis that an optimal blend of both CD4+ and CD8+ T 
cell responses is critical to TB control. There is evidence suggesting that MTB antigens more 
readily gain access to the cytoplasmic compartment of host cells and, therefore, stimulate a 
more pronounced CD8+ T cell response compared to antigens derived from BCG (95). In 
support of this observation, MTB infection facilitated MHC I presentation of class I epitopes 
within ovalbumin while BCG infection was less effective in stimulating this process (101). In 
order for BCG to activate CD8+ T cells, BCG must either translocate from endosome to 
cytosol of the infected cells or induce apoptosis-mediated CD8+ T cell responses. 
Kaufmann’s group developed an rBCG vaccine, rBCG∆UreC:Hly+, with deleted BCG urease 
gene (ureC) and insertion of the Listeria monocytogenes Hly (listeriolysis) (102). UreC 
blocks the acidification of phagosome in infected cells and, therefore, deletion of this gene 
facilitates macrophage phagosome maturation. Hly is a sulphydryl-activated cytolysin that 
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creates pores in the membrane of early phagosomes and allows some leakage of rBCG from 
the phagosome to the cytosol of infected cells. In mouse-protection studies, vaccination with 
rBCG∆UreC:Hly+ induced better protective efficacy than with BCG (103). Also, it has been 
shown to protect significantly against the virulent MTB strain, Beijing/W (103). Both MTB 
and BCG produce various gene products to block apoptosis and, thus, inhibiting apoptosis-
mediated CD8+ T cell responses. Following this reasoning, Jacobs suggested that a pro-
apoptotic vaccine with deleted genes such as nlaA, which inhibits apoptosis of infected cells, 
may be superior to conventional BCG (104). Immunization with such vaccine may lead to 
apoptosis-mediated cross-priming and powerful cellular immune responses (105, 106). 
1.1.5.2 Modified MTB 
Virulent MTB is the cause of tuberculosis and, therefore, cannot be used as a vaccine. 
Molecularly attenuated MTB may have the desirable feature of effective vaccine which 
induces greater protective efficacy compared to BCG. One reason is that MTB contains over 
120 MTB specific genes not found in BCG, which represent a reservoir of antigens available 
for immune activation (107-109). However, the biggest concern for attenuated MTB vaccine 
is the danger of reversion of live MTB to virulent state (110). Other concerns include the 
potential release of antibiotic-resistance gene markers from live MTB vaccine to the 
environment as well as the public perception and acceptance for such vaccine (110).  
One example of attenuated MTB vaccine is developed by Soto’s group (16). The 
virulence was attenuated by inactivating PhoP, which regulates the expression of many MTB 
proteins. This vaccine has shown promising animal protection in early study; however, a 
second, independent, non-reverting mutation is probably required to satisfy human safety 
concerns (110).  
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Other examples in this category include mc26020 (panCpanDlysA) and mc26030 
(panCpanD∆RD1) (111, 112). In these mutants, gene products (PanC and PanD) involved in 
MTB lipid metabolism were disrupted, which greatly attenuated the growth of mutant MTB. 
Both attenuated MTB vaccines were safer than BCG in immunocompromised animals and 
offered similar levels of protection.  
1.1.5.3 Naked DNA and viral-vectored vaccines 
BCG immunization produced varying protective efficacy in different clinical trials, 
which may be explained in part by the hypothesis that previous exposure of human 
populations to environmental mycobacteria may bias the immune response towards a 
detrimental humoral response that cannot be overridden by a subsequent BCG vaccination 
(113). The consequence is that BCG induced immune response is limited whereas the 
immune response promoted by environmental mycobacteria is insufficient on its own to 
combat a subsequent MTB challenge. Vaccination with BCG, rBCG or attenuated MTB may 
not be ideal for people who have a significant risk of exposure to environmental 
mycobacteria, for instance, people in tropical regions (114). In this scenario, naked DNA or 
viral-vectored vaccines may be good alternatives. A recent study showed that immunization 
of mice with a recombinant adenoviral construct (Ad5) expressing the MTB antigen Ag85A 
(AdAg85A) by the intranasal route conferred protection superior to conventional BCG 
vaccination against an aerosol MTB challenge (115). Since Ad5 vector is prevalent in the 
environment, Aeras in collaboration with Crucell constructed Aeras 402 based on the less 
prevalent non-replicating Ad35 vector expressing multiple TB proteins including Ag85A, 
Ag85B and TB10.4 (116). A single dose vaccination of mice with this vaccine conferred 
protection against MTB challenge (110).  
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In the heterologous prime-boost vaccination strategy, DNA vaccines have been used as 
the booster for BCG prime immunization (110). There are two advantages to boost BCG with 
DNA vaccine: 1) existing BCG does not inhibit MTB antigen expression from DNA vaccine, 
and 2) DNA vaccines induce both CD4+ and CD8+ T cell responses rather than a biased 
CD4+ T cell response. In one study, mice were BCG primed followed by a booster with a 
DNA vaccine encoding Rv3407 (a 10-kDa protein of unknown function) (117). This study 
showed that mice were better protected with DNA booster compared to a single BCG 
vaccination.  
1.1.5.4 Subunit vaccines 
TB subunit vaccine consists of purified MTB antigens, adjuvants and delivery vehicles. 
Safety is one of the advantages of subunit vaccine; for instance, it can be used in 
immunocompromised patients such as HIV-positive patients and there is no concern of 
genome invasion with the use of subunit vaccine. Subunit vaccines may also serve as good 
booster for BCG in the prime-boost strategy.  
Antigen identification is the first step to develop TB subunit vaccine since there is a 
whole repertoire of proteins expressed either by BCG or MTB. MTB antigens that can 
activate T cells in previously infected animals and humans are considered as promising 
vaccine candidates. Initially, several of the most abundant proteins have been identified by 
biochemical approaches including Ag85 complex, DnaK, PhoS, GroES, MPT32, MPT46, 
MPT53, MPT63, and the 19-kDa lipoprotein (118-120). Immunological dominant antigens in 
the low molecular mass range were identified subsequently, for example, the 6 kDa early 
secretory antigenic target (ESAT-6) protein family (121, 122). Serological expression 
cloning approaches identified several important MTB antigens such as Mtb32 (a serine 
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protease secreted by MTB) and Mtb39 (a member of the PPE (proline-proline-glumatic acid) 
protein family) (123, 124). Several promising antigens such as Rv3407 (117) have been 
identified by proteomic approaches.  
Although each individual antigen has the potential to be developed as the subunit 
vaccine (e.g. a respirable TB subunit vaccine has been developed based on a single antigen 
Ag85B(125)), subunit vaccine consisting of antigen combinations may increase the 
opportunity for a better protection. Following this reasoning, recombinant fusion antigens 
were constructed by molecular engineering. For instance, Skeiky developed Mtb72F, which 
is a recombinant fusion of Mtb32 and Mtb39 (126); while Olsen developed Hybrid-1, a 
fusion of Ag85B and ESAT-6 (127). The efficacy of Mtb72F and Hybrid-1 have been tested 
in the mouse and guinea pig TB challenge models (126, 128-130), which demonstrated that 
once formulated in selected adjuvants both fusion antigens conferred protection as well as 
BCG.  
1.1.6 Antigen candidates for TB subunit vaccine 
1.1.6.1 Ag85B 
Ag85 complex is composed of three major secretory proteins Ag85A, 85B and 85C. 
This protein complex accounts for 41% of the total culture filtrate protein. The antigen Ag85 
proteins are homologous proteins that share very high sequence identity (68-79%). All three 
proteins contribute to MTB cell wall synthesis by catalyzing the transfer of one mycolic acid 
group from one trehalose 6-monomycolate (TMM) to another, giving rise to trehalose 6, 6’-
dimycolate (TDM or cord factor) and free trehalose. The three proteins are expressed at a 
steady-state ratio of 2:3:1 (Ag85A: Ag85B: Ag85C). Ag85B (~30 kDa), among three 
proteins, is the most abundant isoform secreted which contributes to almost one-quarter of 
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the total extracellular protein; whereas it is the least active form as shown in one in vitro 
assay (131). Ag85B is also highly expressed in infected human macrophages. In the 
phagosomes of infected human macrophages, Ag85B is found in the phagosome space as 
well as on the bacterial cell wall (132-134). 
Although Ag85B has been suggested as a drug target, searching Ag85B-specific 
inhibitors may not be a good idea since this enzyme shows least enzymatic activity compared 
to the other two Ag85 members (131). In one study, knockout of Ag85C from MTB resulted 
in a 40% decrease in the amount of cell wall linked mycolic acid, whereas knockouts of 
Ag85A and Ag85B had no noticeable effect (135). This study suggests that Ag85A and 
Ag85B have limited roles in MTB cell wall synthesis or their function can be compensated by 
Ag85C.  
From the vaccine standpoint, Ag85B is a leading antigen candidate because it is an 
immunodominant antigen which interacts with the immune system at an early stage of MTB 
infection and induces both humoral and cell-mediated immune responses (125). Therefore, 
Ag85B has a great potential to be developed as a prophylactic vaccine. Indeed, this antigen 
has been incorporated into various novel TB vaccine strategies such as recombinant BCG, 
DNA vaccine, viral-vector vaccine, naked DNA vaccine and subunit vaccine. The efficacy of 
these Ag85B-based vaccines varies depending on the vaccine vector, the route of 
administration, and co-incorporated antigens. 
1.1.6.2 TB10.4 
TB10.4 is a peptide of 96 amino acids long, which is a member belonging to ESAT-6 
protein family. The ESAT-6 family consists of 22 low molecular mass proteins, many of 
which are strongly immunogenic. TB10.4 has been found to be strongly recognized by BCG-
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vaccinated donors and in infected TB patients (19). TB10.4 is an ideal candidate to replace 
ESAT-6 for two reasons: 1) in TB patients TB10.4 is much more strongly recognized than 
ESAT-6 and 2) use of TB10.4 leaves ESAT-6 as a potential diagnostic marker to distinguish 
BCG vaccinated vs. MTB infected individuals (table 1.2).  
Majlessi’s group identified an MHC class I epitope, GYAGTLQSL, from TB10.4 
(136). This epitope can be efficiently recognized by cytotoxic T cells from MTB infected 
mice. A CD8+ T cell hybridoma restricted to this epitope, YB8, was also developed in this 
group. YB8 is able to recognize BCG infected macrophages and secrete interleukin-2 (IL-2). 
Billeskov identified another MHC I epitope of TB10.4, QIMYNYPAM (137). Their 
experiments showed that CD8+ T cells restricted to this epitope were induced at the onset of 
infection and were present throughout the infection at high numbers.  
1.1.7 Rationale for pulmonary vaccine delivery 
Vaccines are frequently administrated via the parenteral route such as intradermal and 
subcutaneous immunization. Pulmonary vaccine delivery represents an alternative route of 
immunization which has its unique advantages. Firstly, many pathogens utilize the 
respiratory tract as a portal of entry. For example, MTB is transmitted among individuals via 
the lungs, where the mycobacteria establish initial colonization. The mucosal surfaces lining 
the respiratory tract are the first defense system against pathogens. Therefore, immunity 
induced on mucosal surfaces by pulmonary vaccination is highly preferred at the early stage 
of infection with respect to pathogen neutralization. Secondly, pulmonary vaccination 
follows the natural route of infection for many pathogens and may induce immune responses 
mimicking the natural immunity produced by pathogens. Thirdly, a broader base of 
protection may be generated in the lungs considering the large surface areas in the deep lung, 
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where a large inter-related network of lymphoid tissues readily sharing antigenic information 
could be found. In addition to mucosal immunity, systemic immunity may also be activated 
via pulmonary vaccination. Fourthly, pulmonary vaccination is a noninvasive means of 
vaccine delivery, which eliminates the need for syringes and needles, ameliorates the pain 
and suffering associated with injections, improves patient compliance, and reduces waste 
disposal and the risk of transferring blood-borne infections. Fifthly, formulating vaccines into 
dry powders suitable for pulmonary delivery may possess a critical pharmaceutical advantage 
with respect to injectable vaccines, which is, increased stability. Liquid formulations or 
reconstitution of powder formulations for injection may cause potency loss of formulated 
antigens such as attenuated live bacteria, and purified protein antigens. (138-142). The 
advantage of lung immunization was shown in a recent publication where aerosol delivery of 
BCG significantly reduced lung pathology and bacterial burden both relative to untreated 
guinea pigs and to control guinea pigs vaccinated with the standard parenteral BCG (145). 
However, pulmonary BCG immunization only targets a specific population, i.e. neonates, 
because this population has a rare chance of prior exposure to environmental mycobacteria. 
Therefore, lung immunization by alternative vaccines such as TB subunit vaccine may 
benefit a larger population such as adults or immunocompromised patients.  
1.1.7.1 Immune responses induced by pulmonary vaccination 
In healthy humans, local immune system contributes 80% of all immunocytes. Local 
immunocytes are accumulated in different mucosa-associated lymphoid tissues (MALT), 
which form the largest lymphoid organ system (143). The MALT is a highly 
compartmentalized system which functions independently from the systemic immune system. 
Compared with systemic lymphoid tissue, the MALT is populated by functionally and 
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phenotypically distinct immunocytes such as B cells, T cells and accessory cell populations. 
Three roles have been suggested for mucosal immune system: 1) to protect mucosal surface 
against pathogen colonization, 2) to prevent uptake of undegraded antigens, and 3) to prevent 
the development of harmful immune responses.  
Pulmonary vaccine delivery targets immune cells in the lungs with the goal of inducing 
both mucosal and systemic immunity against respiratory infectious disease (138). Antigens 
delivered to the lung can be taken up by antigen presenting cells (APCs) such as alveolar 
macrophages, dendritic cells and B lymphocytes through direct or indirect pathways and 
presented to CD4+ and CD8+ T cells located in the mucosal inductive sites. These activated 
mucosal immunocytes (both B and T cells) then leave the inductive sites, drain into the 
lymph, enter the systemic circulation, and home to selected mucosal sites mainly of the 
mucosal origin, where they differentiate into effector or memory cells (144). Of particularly 
note, the homing of immunocytes is constricted by the expression and affinity of ‘homing 
receptors’ on immunocytes and corresponding ‘addressin’ molecules on endothelial cells 
(144). This phenomenon has an important implication, which is, mucosal immunity induced 
in deep lungs can be transmitted to other mucosal surfaces such as the upper respiratory tract 
and nasal-associated lymphoid tissue, which will encounter respiratory pathogens such as 
MTB. Mucosal immune responses involve both innate and adapted immunity. The adaptive 
humoral response is mainly mediated by secretory IgA (SIgA) antibodies, whose resistance 
to proteases makes them well suited to mucosal secretions. Cell-mediated immunity at the 
mucosal surface is predominantly mediated by CD4+ and CD8+ T cells (138).  
Mucosal immunity is the first line defense system against respiratory pathogens. A pre-
existing mucosal immunity induced by pulmonary vaccination can mount a quick immune 
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response once encountering respiratory pathogens. In addition to mucosal immunity, a 
systemic immunity is highly favored and always important to combat the pathogens. 
Although MTB infection mainly occurs in the lungs, it can be transmitted into other organs 
such as liver and spleen. To combat MTB in these organs, immunocytes, predominantly T 
lymphocytes have to migrate into these organs via systemic circulation, which demands a 
systemic immunity. Pulmonary vaccination also induces systemic immunity as reviewed 
previously (138). From the TB standpoint of view, systemic immunity can be induced once 
activated APCs migrate into local lymph nodes and present TB antigens (delivered by 
aerosol) to T lymphocytes in the nodes. Activated T lymphocytes may circulate back into the 
primary infection sites or migrate into other infected organs through the systemic circulation 
(110).   
1.1.7.2 Current status of pulmonary vaccine delivery 
Studies about pulmonary vaccination of animals are described elsewhere (138). For 
example, a BCG aerosol has been used to immunize guinea pigs through the lungs, which 
suggests that lung immunization with BCG aerosol results in an improved protection against 
MTB than that achieved by subcutaneous injection (145).  
Pulmonary vaccination of humans was realized in Soviet Union almost 40 years ago 
(146). Russian researchers found that pulmonary vaccination was as effective as 
subcutaneous vaccination against anthrax, brucellosis, plague, and tularemia (146, 147). 
Pulmonary delivery of BCG to people was conducted in USA in 1968 to compare 
tuberculosis pathology in human beings vs. in animals, which revealed similar pathology 
between humans and guinea pigs (148). Attenuated Francisella tularensis vaccine has been 
nebulized into human lungs for vaccination against virulent F. tularensis (149). The data 
 22
suggested that greater immunity to virulent strain challenge was achieved with pulmonary 
vaccination compared with parenteral administration. 
So far the only successful clinical case of pulmonary vaccination is a pulmonary 
measles immunization. In this study, approximately 4 million Mexican children were 
immunized by an aerosol of measles vaccine and showed a high rate of successful protection 
(150). Pulmonary delivery of measles vaccines has been shown to induce greater 
seroconversion compared to injected vaccines (151). 
1.1.8 Pulmonary vaccine delivery by aerosol technology 
Vaccines intended for pulmonary delivery requires unique formulation strategies. 
Formulations also vary depending on the device used for aerosolization. Generally speaking, 
three devices have this capability, including pressurized metered-dose inhalers (pMDIs), 
nebulizers and dry-powder inhalers (DPIs). Very few vaccines have been delivered by 
pMDIs since the hydrophobic propellant used to generate aerosol is not a friendly 
environment for most vaccines (both live and subunit vaccine). It has been shown by Brown 
and his colleagues that Streptococcus suis bacteria delivered by pMDI lost 50-70% of its 
antigenicity after aerosolization (152).  
Nebulizers have been most widely used for pulmonary delivery of vaccines. For 
instance, the measles vaccine, in one study, was successfully delivered into the lungs of 
Mexican school children by a Classical Mexican Device, which is an air-driven jet nebulizer 
(151). Vaccines such as BCG (153, 154) and attenuated rubella virus (155) have also been 
delivered by nebulizers. However, delivering vaccines by nebulizers has several 
disadvantages. First, operation of nebulizers requires special settings such as compressed air 
for jet nebulizers and power for ultrasonic nebulizers, which makes immunization inefficient 
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and time-consuming. Second, vaccines delivered by nebulizers should be in the liquid state. 
A liquid formulation of vaccine requires cold chain in the manufacture, shipping and storage, 
which ultimately increases the cost. In addition, unexpected temperature variation may cause 
potency loss of vaccines. Powder formulation increases the stability of vaccines and may not 
require the cold chain. However, reconstitution of the powder formulation may cause potency 
loss as shown in an example of measles vaccine (156). Reconstituted vaccine loses potency 
rapidly at both 25 and 37 ˚C. Third, the shear force generated during the nebulization process 
is a potential risk factor for vaccine potency (157). In one study, the potency of the measles 
vaccine was lost by 71% after the nebulizer was run continuously for 20 min (158). 
Dry powder delivery has several advantages over the other two delivery methods. 
Vaccines prepared in the dry powder form have greater stability in comparing to liquid 
formulation. A cold chain for storage may not be required and there is no need for 
reconstitution. Dry powders are delivered by dry-powder inhalers (DPIs), acting via either 
passive or active mechanisms (142). To enhance dispersion of small particles, an excipient 
such as lactose is commonly used. Depending on the dosing regimen, vaccines can be 
packaged into either single-dose or multi-dose DPIs. If moisture contact is a problem for the 
stability of vaccines, dry powder vaccines can be sealed into a foil blister which protects the 
powder from exposure to high humidity or other potential risks such as sunlight.  
1.1.9 Dry-powder vaccine formulation 
The rapid distribution, ease of operation and acceptance by the general public will 
most likely result in DPIs in mass immunization campaigns for many vaccines such as 
tuberculosis and measles vaccines (142). Therefore, dry-powder vaccine formulations will be 
reviewed here. 
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1.1.9.1 Antigens: the active ingredient of a dry-powder formulation 
Antigens are the critical component of a dry-powder vaccine formulation, which 
determines the immunogenicity. These include attenuated virus or bacterial strains, proteins 
purified from pathogen cultures, recombinant proteins purified from the heterologous 
expression system, and DNA encoding antigens from corresponding pathogens. The 
sequence or conformational information residing in antigens leads to the activation of B and 
T lymphocytes which eventually differentiate into the memory immunocytes.  
1.1.9.2 Adjuvants: the active excipient of a dry-powder formulation 
Adjuvants are needed for many vaccines especially for DNA and subunit vaccines 
because purified DNA and proteins are frequently poor immunogens (159, 160). Adjuvants 
can help elicit high and long-lasting immune responses with limited amount of antigens. 
Th1/Th2 immune responses can also be modulated by adjuvants to suit specific requirement 
of certain vaccines (161). As an example, Th1 immune responses have been suggested to 
play a pivotal role in TB control. With the use of a carefully chosen adjuvant, a favorable 
Th1 immune response may be induced.  
Different mechanisms have been implicated in adjuvancy such as depot effect, 
immunomodulation, and effective presentation of antigens to the immune system (141). 
Aluminum, oils, and emulsions are classical examples of the depot effect, which creates a 
depot (usually by injections) at the site of administration to attract immunocytes such as 
dendritic cells and macrophages. Alum, i.e. potassium aluminum sulfate, is the only FDA 
(Food and Drug Administration) approved adjuvant for human use (141). Although causing 
no severe side effects, alum suffers from a profound limitation since it is known to be 
deficient in inducing mucosal IgA responses (one advantage of mucosal vaccination such as 
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pulmonary vaccination) (141). Therefore, alum may not be an ideal adjuvant for a vaccine 
formulation intended for pulmonary delivery.  
Adjuvants also act by modulating cytokine networks and the function of immunocytes. 
Lipopolysaccharide (LPS), CpG motif, monophosphoryl lipid A (MPL), cholera toxoid (CT) 
and muramyl dipeptide (MDP) are in this category (138). Among them, MDP is the smallest 
component of mycobacterial cell wall which can induce the production of a series of 
cytokines such as IL-1α, IL-1β, and IL-6 (138). In addition, MDP is a water-soluble molecule 
which is completely miscible with antigens. Therefore, this molecule is a promising adjuvant 
for TB vaccine development. Adjuvants in this category, in general, induce stronger immune 
response compared to those acting on depot effect such as alum. However, none of these 
molecules have been approved for human use so far due to potential safety problems. This is 
because unexpected perturbation of the immune networks by these molecules may outweigh 
the potentially beneficial immunomodulation effect. In-depth studies of these compounds in 
both pre-clinical and clinical trials will eventually advance our standing of these molecules 
with respect to both adjuvancy and side effects. 
Adjuvants in the third category can effectively present antigens to the immune system. 
Biodegradable polymers, liposomes, microparticles and nanoparticles are representative 
adjuvants in this class (138). Antigens encapsulated in these adjuvants are easily taken up by 
the antigen presenting cells leading to efficient antigen presentation. In addition, these 
adjuvants also serve as delivery vehicles for pulmonary vaccines and their roles will be 
discussed later.  
1.1.9.3 Particulate systems 
Attenuated live viruses or bacteria are nano- to micro-sized particles by themselves, 
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which may not require a particular particulate system in the vaccine formulation. With 
respect to formulating subunit or DNA vaccines, particulate systems have been a common 
theme employed in various studies. Proteins and DNA are small in size, which are not 
suitable for aerosol delivery into the lungs unless they are formulated into the particulate 
system to facilitate dispersion. In addition, without the assistance of the particulate system, 
proteins and DNA have very limited potential to be taken up by the target cell populations, 
making the induction of immune responses unlikely. Formulating antigens into particulate 
systems have several advantages: 1) to protect the stability of formulated antigens, 2) to 
improve the aerosol dispersion and lung deposition of antigens, 3) to facilitate antigen uptake 
by target cells, and 4) to control the release of antigens from the particulate system. 
Depending on the targeted cells and intended use, either microparticulate system or 
nanoparticulate system can be employed to make vaccine formulations (138). 
Microparticulate systems have a characteristic size in the micron-size range with the 
target cell population of mainly macrophages (alveolar macrophages for lung immunization) 
and possibly dendritic cells (138, 141). This system includes liposomes, lipid-based and 
biodegradable polymer-based microparticles. Liposomes are widely used delivery vehicles 
which can be manufactured into both nano- and mirco-particles (162, 163). They are mainly 
composed of amphipathic lipids (either positively or negatively charged), and cholesterol 
mixtures at certain molar ratio. Protein and DNA antigens can be encapsulated into 
liposomes by different methods such as sonication, extrusion, spray-drying and lyophilization 
followed by milling (162, 164). Liquid liposome formulation may cause stability problem 
during storage or administration (e.g. nebulization) (165-167). Dry powder liposome 
formulations may circumvent this problem and can be delivered by dry-powder inhalers. 
 27
After being delivered into the lungs, liposomes target alveolar macrophages as demonstrated 
by the study of de Haan and his colleagues (168). In addition to liposomes, lipid-based 
microparticles have also been studied as carriers for pulmonary vaccine delivery (138). These 
microparticles are usually manufactured by spray-drying or solvent evaporation methods 
with greater stability and encapsulation efficiency compared to liquid liposome formulations. 
The cellular uptake of lipid particles by antigen presenting cells (APCs) can be regulated by 
modifying the surface properties. For example, IgG incorporated into the lipid microparticles 
facilitated antigen uptake via Fc receptor-dependent endocytosis (169).  
In addition to lipids, biodegradable polymers are frequently used to prepare 
microparticles because of their biocompatibility and well-controlled release profile of 
encapsulated antigens.  Polylactide-co-glycolide (PLGA) is a classical and model polymer, 
which is synthesized by means of co-polymerization of two monomers, the lactic acid and 
glycolic acid (170). The degradation products of PLGA are these two monomers, which 
under physiological conditions are byproducts of various metabolic pathways in the body. 
Therefore, PLGA shows very minimal systemic toxicity when used as the delivery vehicles, 
although it may cause trouble in lactose intolerant people. Controlled release of encapsulated 
drug or vaccine is another advantage of a PLGA based device (171, 172). The release is 
partly determined by the bulk erosion of this co-polymer, whose degradation is mainly 
mediated by the degradation of the ester bonds in the presence of water. The degradation of 
PLGA can be controlled by varying the ratio of two monomers where the higher the content 
of the glycolic acid, the shorter the time required for degradation. Owing to many unique 
advantages of PLGA, it has been studied as the delivery vehicle for TB subunit vaccine. For 
example, Kirby and his colleagues used PLGA microspheres to deliver a recombinant TB 
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antigen Ag85B-ESAT-6 (173). They manufactured PLGA particles within the desired sub-10 
µm range by the double emulsion method. A sustained antigen release from these 
microspheres was observed. Immunization of mice with this formulation resulted in a cell-
mediated immune response and specific antibody production. In another study, a 
recombinant TB antigen Ag85B was encapsulated into respirable PLGA microspheres by the 
emulsion/spray-drying method (125). This formulation induced significantly higher MHC II 
immune response specific to Ag85B in an in vitro antigen presentation assay. Other 
applications of PLGA in vaccine delivery are described elsewhere (174-176). 
Nanoparticulate-based dry powder pulmonary vaccines are also under active 
investigation (141).  Lipids and biodegradable polymers have been used in this system as 
well. The fundamental difference between nanoparticles and microparticles lies in their size 
difference and the resulting difference in target cell populations. It is generally believed that 
particles of a few hundred nanometers are favorably taken up by dendritic cells (DCs) either 
directly or indirectly via epithelia microfold cell (M-cell) relaying, although uptake by 
macrophages also occurs. The small size of nanoparticles makes them difficult to aerosolize 
due to strong particle-particle interactions. Also, once inhaled nanoparticles have a higher 
chance of being exhaled compared to microparticles. In order to make pulmonary delivery 
with nanoparticles a viable approach, porous nanoparticle-aggregate particles (PNAPs) of a 
few microns were developed, which are dried hollow particles of low density (177-180). 
PNAPs have good aerosolization properties to penetrate to the deep lung. The excipient 
matrix of the PNAPs is dissolved by the lung lining fluids, releasing antigen associated 
nanoparticles for uptake by immune-competent cells. Antigen associated nanoparticles are 
typically prepared by surface adsorption, encapsulation or covalent attachment methods 
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(181). These antigen-containing nanoparticles can then be formulated into PNAPs via spray-
drying either by spraying pure nanoparticles or in the presence of excipients such as L-
leucine (141). Upon careful control of the drying rate, where the rate of drying is faster than 
the diffusion of the nanoparticles, PNAPs are produced with the majority of nanoparticles 
gathering and eventually coalescing at the evaporation surface (141).  
Few studies of pulmonary vaccine delivery using nanoparticulate system have been 
conducted. Nevertheless, there are some reports on pulmonary DNA vaccine delivery with 
such system. Nanoparticles (225nm) composed of PLGA and polyethyleneimine (PEI, a 
cationic polymer) with loaded DNA were readily internalized by the human airway 
submucosal epithelial cells (Calu-3) in vitro after 6 h (182). This is a poof-of-concept study 
demonstrating that nanoparticles can transfer DNA encoding antigenic information into 
cultured cells, which may be mimicked in vivo by DNA transfer into the lung epithelial M-
cells. Benita and colleagues reported that pulmonary immunization of mice with 350-nm 
chitosan-DNA (encoding eight HLA-A*0201-restricted T-cell epitomes from MTB) 
nanoparticles induced increased levels of IFN-γ secretion compared to pulmonary delivery of 
plasmid in solution (183). In addition, the chitosan-DNA nanoparticles could induce the 
maturation of dendritic cells while chitosan solution alone could not. 
1.1.9.4 Dispersion of vaccines with carrier excipient 
To be efficiently delivered into the lungs, vaccine particles should have an 
aerodynamic diameter in the range between 1 and 5 µm (184). Depending on the nature of a 
vaccine formulation, excipients that facilitate powder dispersion may or may not be required. 
In the case of poor dispersion, certain excipient is included to improve vaccine aerosolization. 
Lactose is the only excipient approved for this use in the USA. It is milled, sieved or 
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spray-dried into approximately 100 µm particles, which provide a large surface for small 
particle adhesion. Once blended with other formulation components, small vaccine particles 
will adsorb onto the surface of carrier lactose particles. This effectively reduces the self 
aggregation of small particles. Another reason to include this sugar into the formulation is to 
help accurate dosing of small quantity of active pharmaceutical ingredient. Lactose fines are 
found to improve the dispersion possibly by occupying the active sites on the surface of large 
carrier lactose particles or by the deaggregation mechanism and, therefore, may be included 
in the dry-powder formulation (185). Besides lactose, other carriers such as trehalose, 
mannitol, glucose and sorbitol also have the potential to be used as the carriers in DPIs (186).  
1.1.10 Particle size characterization of dry powders 
Particle size is one of the most important quantitative descriptors of the specific 
properties of dry powders. With respect to the size of a single particle, three characteristic 
diameters are projected area diameter (dp), equivalent volume diameter (dv) and 
aerodynamic diameter (da). The projected area diameter is obtained from the two-
dimensional image of a particle (187). It is equal to the diameter of a circular disc with the 
same projected area as the particle being examined. The equivalent volume diameter 
represents the diameter of a sphere of the same volume as the particle. The aerodynamic 
diameter is proposed since both dp and dv have limited application in studying particle 
deposition in the respiratory tract. The da is a representative diameter of aerosol particles, 
which is equal to the diameter of a unit density sphere that has the same terminal setting 
velocity as the actual particle (188).  
VTS = ρ0da2g/18η = ρpdv2g/18ηχ 
VTS: terminal settling velocity, ρ0: unit density, ρp: particle density 
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g: the acceleration of gravity, η: air viscosity, χ: shape factor 
da: aerodynamic diameter, dv: equivalent volume diameter 
This equation suggests that the terminal settling velocity increases proportionately to 
the particle size, i.e. a large particle is more likely to deposit by inertial impaction compared 
to a small one. Second, density has significant impact on the aerodynamic diameter. As 
suggested by this equation, two particles of the same volume diameter may have different 
aerodynamic diameters due to density difference (low-density particle has smaller 
aerodynamic diameter). This property has wide applications. For example, low-density 
particles (either hollow or porous) with large volume diameter but small aerodynamic 
diameter suitable for pulmonary delivery have been manufactured to circumvent the particle 
uptake by alveolar macrophages (189). These particles can effectively reach deep lung 
without being actively internalized by macrophages and, therefore, increase the systemic 
concentration of administrated drugs. In addition, aerodynamic diameter is also affected by 
particle shape. Non-spheres have a shape factor greater than unity leading to an aerodynamic 
diameter smaller than its equivalent volume diameter (188). Particle shape has also been 
utilized in aerosol delivery. For example, the needle-like particles can deliver more drugs to 
the deep lung at the same aerodynamic diameter to the spherical particles assuming the same 
density and drug loading (190). However, attention should be paid to modifying particle 
shape since adverse effect may be associated with the irregular particle shape such as 
decreased cellular uptake and irritating the lung lining cells.  
Mono-dispersed spherical particles (all have the same size) can be fully described by a 
single diameter. In reality, most powders are composed of particles with different sizes and 
probably different shapes. In order to characterize the powder as a whole rather than 
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individual particles, various diameters, based on the statistical moment analysis, have been 
devised to describe the same particle population such as the count median diameter (CMD), 
count mean diameter, length median diameter (LMD), length mean diameter, surface median 
diameter (SMD), surface mean diameter, volume or mass median diameter (VMD or MMD), 
volume or mass mean diameter, diameter of average surface, diameter of average mass and 
mass median aerodynamic diameter (MMAD) (188). These descriptors are representative 
diameters of a particle population not of a single particle. Among these diameters, SMD, 
VMD, and MMAD are population averages of corresponding dp, dv and da of individual 
particles. There are also quantitative descriptors to describe the breadth of the particle size 
distribution. For a Gaussian distribution, standard deviation is such a descriptor. If the log-
normal distribution is assumed for a powder, the geometric standard deviation (GSD) is a 
better descriptor, which in contrast to the standard deviation is a dimensionless measure 
(188).  
GSD = D84% / D50% = D50% / D16% = [D84% / D16%] 1/2 
D84%: diameter at the cumulative percentile of 84% 
D50%: diameter at the cumulative percentile of 50% 
D16%: diameter at the cumulative percentile of 16%  
An alternative descriptor irrespective of the nature of particle size distribution is the 
span, which is commonly reported where laser diffraction technique is used to measure the 
volume median diameter (VMD) of a powder. VMD and span are frequently used to 
characterize the geometric size and distribution of a powder (191).  
          Span= (D90%-D10%) / D50% 
D90%: diameter at the cumulative percentile of 90% 
 33
D50%: diameter at the cumulative percentile of 50% 
D10%: diameter at the cumulative percentile of 10% 
In contrast, MMAD and GSD are widely used to characterize the aerodynamic size and 
distribution of a powder (191). Their values can be derived by examining the aerodynamic 
particle size distribution profiles, which are determined by cascade impaction (192). Cascade 
impactor, which operates on the basis of inertial impaction, is used to perform such 
experiment (188, 193). This device consists of a series of stages with decreased orifice size at 
each succeeding stage. Collection surface is below each stage, which serves to obstruct the 
path of airflow. Particles are drawn into the cascade impactor via the conveying air produced 
by a vacuum pump. Particles are accelerated increasingly from the top to the bottom since the 
orifice size decreases at each successive stage. Therefore, big particles with large inertia and 
stopping distance tend to deposit on the upper stages of an impactor while small particles can 
align their motion to that of the airstream and travel through next stages. This allows particles 
to be separated on different stages based on their aerodynamic diameters (figure 1.1a). 
Subsequent chemical or gravimetrical analysis reveals the mass deposition on each stage, 
which after certain transformation is plotted against the cut-off particle size of each stage on 
the log-probability paper (figure 1.1b). Mass median aerodynamic diameter (MMAD) and 
geometric standard deviation (GSD) can be derived from such distribution.  
1.1.11 Particle size comparator to evaluate batch-to-batch reproducibility of inhalation 
products 
The key issue in powder technology is the batch-to-batch reproducibility. For mono-
dispersed powder, reproducibility can be ensured by manufacturing different batches of 
particles with the same size. A simple t-test can tell whether reproducibility is achieved. For 
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poly-dispersed powder, reproducibility should be evaluated based on the whole particle size 
distribution rather than the median diameter. Aerodynamic particle size distribution (APSD), 
measured by cascade impaction, is an in vitro aerodynamic characterization of the inhalation 
products such as nebulizers, metered-dose inhalers and dry-powder inhalers. This distribution 
has significant impact on drug deposition in vivo. A change of APSD may shift drug 
deposition from the deep lung to the upper respiratory tract or even to the mouth and throat, 
which may eventually affect the site of action. Therefore, batch-to-batch reproducibility 
should be routinely examined to ensure the quality of an inhalation product. In the second 
scenario, if drug manufacturers plan to develop a generic version of an inhalation product, an 
APSD profile sufficiently similar to that of the original product should be shown. In other 
words, establishing equivalence is the key in this case.  
To evaluate the batch-to-batch reproducibility or to determine equivalence, a particle 
size comparator should be available. The Product Quality Research Institute (PQRI) in 
collaboration with the Food and Drug Administration (FDA) has developed a comparator 
based on the chi-square ratio statistics (194-196). Due to the poor performance of the 
proposed comparator, it was not recommended for APSD profile comparison with detailed 
explanations in a 2007 report (195). However, their research did point out the desired feature 
of a potentially useful size comparator. This includes: 1) the capability to deal with the 
multivariate measurement; 2) the capability to resolve the covariance associated with the 
mass deposition; 3) having sufficient power to detect the difference; and 4) a combination 
statistical test may be needed.  
1.2 Problem statement 
Tuberculosis (TB) is the second leading infectious cause of mortality in the world. 
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Bacillus Calmette-Guérin (BCG) is the only vaccine currently marketed for TB. However, 
the prophylactic use of BCG has demonstrated varying levels of efficacy in distinct 
populations and different field trials. In addition, the efficacy of BCG wanes in 10 to 15 years 
and boosting BCG vaccinated individuals with a second dose of BCG does not confer 
additional protection. Therefore, there is an urgent need to develop more potent TB vaccines. 
A TB subunit vaccine represents a promising candidate either on its own or as a booster for 
BCG in the heterologous prime-boost vaccination strategy. However, most antigens selected 
for existing TB subunit vaccines have been recombinant antigens purified from inclusion 
bodies. Antigens purified this way may adopt different conformations than their native 
counterparts. Therefore, it is highly favored to purify antigens in their soluble forms standing 
the best chance to maintain native conformation. For multiple-antigen vaccination strategy, it 
remains unknown whether antigen fusion or a blend of multiple antigens is better for vaccine 
development. So far, many TB vaccines under development were delivered via the parenteral 
routes. There has been less research investigating alternative delivery systems and 
administration routes for TB vaccines. Pulmonary delivery of TB vaccine may be a 
promising route of administration since the lung is the primary site of MTB infection and 
lung immunization may induce beneficial mucosal immunity. Microparticulate system, 
among various delivery systems, is especially suitable for pulmonary vaccine delivery 
because it facilitates both vaccine deposition into the lungs and antigen uptake by antigen 
presenting cells in the lungs. However, a successful formulation of antigens into the 
microparticulate system remains a difficult task with respect to both microparticle 
engineering and activation of immune response. In addition, it remains challenging to 
determine equivalence or evaluate batch-to-batch reproducibility of inhalation products since 
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there is no generally accepted particle size comparator available at the moment.  
1.3 Hypotheses and specific aims 
1.3.1 Research goals 
The first goal is to compare the in vitro immune response of newly designed respirable 
TB subunit vaccines based on Ag85B/TB10.4 and their different combinations (antigen blend 
vs. antigen fusion) in order to make a recommendation of the best antigen/antigen 
combination for future animal protection study. The second goal is to develop a particle size 
comparator to evaluate the batch-to-batch reproducibility of inhalation products with an 
ultimate goal to use it as a quality evaluation tool for making highly reproducible TB subunit 
vaccines for lung delivery and immunization. 
1.3.2 Hypotheses 
The following hypotheses will be tested in this research. 
z H1: Milligram quantities of soluble recombinant antigens can be obtained by rational 
design of the expression constructs. 
z H2: PLGA-rAg microparticles can be manufactured with a target size by optimizing 
spray-drying parameters.  
z H3: PLGA-rAg microparticles can induce stronger and prolonged immune response in 
vitro compared to antigen solutions. 
z H4: Particle size comparator constructed on the basis of orthogonal partial least square 
analysis has a better performance than that developed on the basis of chi-square ratio 
statistics. 
1.3.3 Specific aims 
Aim I:  Recombinant antigen design, expression, purification, and characterization. 
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(a) In order to obtain soluble TB10.4 in milligram quantities, this protein was fused to the C-
terminal of thioredoxin (Trx) in a modified pET32-b vector resulting in a fusion protein 
Trx-TB10.4. It was expressed in E. coli and purified by nickel-affinity chromatography. 
A method was developed to obtain free TB10.4 from the fusion protein Trx-TB10.4 by 
protease treatment followed by a combination of chromatographic steps.  
(b) Rationally design an expression construct that can express a recombinant fusion of 
Ag85B and TB10.4 with the following properties: 1) improved solubility and 2) 
milligram quantities.  Molecular engineering was employed to make the construct. 
Protein purification was performed by fast protein liquid chromatography (FPLC). In 
addition, inclusion body was resolubilized followed by in vitro protein refolding to purify 
mis-folded protein. 
(c) The purity of the recombinant proteins was determined by SDS-PAGE. The pH-
dependent stability of recombinant proteins was studied by dynamic light scattering (DLS) 
at various pH. The secondary structure and thermo-stability of proteins was probed by 
circular dichroism.  
Aim II:  Manufacture and characterization of respirable PLGA-rAg microparticles. 
(a) PLGA-rAg microparticles were manufactured by primary emulsion/spray-drying method. 
The spray-drying parameters were systematically optimized by a half-factorial design in 
order to achieve a target particle size of approximately 3 µm and a yield greater than 15%.  
(b) PLGA-rAg microparticles were characterized with respect to: 1) morphology by SEM, 2) 
thermal property by DSC, 3) surface property by IGC, 4) geometric size distribution by 
laser diffraction, 5) aerodynamic size distribution by cascade impaction, 6) antigen 
integrity by SDS-PAGE, 7) flow property and 8) release profile. 
 38
Aim III:  Study of in vitro immune responses induced by PLGA-rAg microparticles. 
(a) Ag85B-specific MHC II immune response was studied with an in vitro antigen 
presentation assay by employing two cell lines with THP-1 as the antigen presenting cell 
and DB-1 as the CD4+ T cell hybridoma specifically recognizing an MHC II epitope 
within Ag85B. Different PLGA-rAg formulations were compared based on the amount of 
IL-2 secretion. Six-day antigen presentation assay was used to compare the response 
kinetics of particle formulations to that of solution formulations.  
(b) TB10.4-specific MHC I immune response was studied with an in vitro antigen 
presentation assay by employing two cell lines with Raw264.7 as the antigen presenting 
cell and YB8 as the CD8+ T cell hybridoma specifically recognizing a MHC I epitope 
within TB10.4.  
Aim IV: Development of a particle size comparator to evaluate batch-to-batch reproducibility 
of inhalation products. 
(a) Monte Carlo simulation to recover 55 realistic scenarios of aerodynamic particle size 
distribution profiles proposed by the Product Quality Research Institute (PQRI).  
(b) An algorithm was developed to compare particle size distribution profiles based on 
orthogonal partial least square analysis. 
(c) Different data pretreatment methods were studied with respect to a better comparator 
performance. 
(d) The performance of the particle size comparator was evaluated and compared with the 
original comparator proposed by the PQRI based on the chi-square ratio statistics. 
1.4 Summary 
In this dissertation, soluble recombinant antigens, Ag85B, TB10.4 and TB10.4-Ag85B, 
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were obtained in specific aim I with high solubility and yield by rational design of the 
expression constructs. They were characterized with respect to their pH-dependent stability 
and thermal property. The accomplishment of aim I provided antigens for the next stage of 
formulation development. Recombinant antigens were subsequently encapsulated into PLGA 
microparticles with a target size suitable for pulmonary delivery. The manufacturing 
parameters were systematically optimized and prepared TB subunit vaccines were 
characterized with respect to several physicochemical properties. In specific aim II, a deep 
understanding of particle manufacture, particle physicochemical properties and particle-
antigen interaction was developed. The efficacy of respirable TB subunit vaccines was tested 
by in vitro antigen presentation assays in specific aim III, which offered invaluable 
information about the nature of induced immune responses. In the last specific aim, a particle 
size comparator based on orthogonal partial least square analysis was developed with a better 
performance to evaluate the batch-to-batch reproducibility of inhalation products. Detailed 
results are discussed in the following chapters.  
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Table 1.1 Summary of new-generation tuberculosis vaccines 
Vaccine Description Development stage Researchers 
Modified BCG 
BCG::RD1 BCG Pasteur with reintroduced of 
RD-1 locus 
Ongoing pre-clinical 
studies 
S. Cole 
rBCG30 BCG Tice overexpressing Ag85B Phase I trial completed  M. Horwitz, D. 
Hoft, T. Littlejohn 
rBCG-Aeras403 BCG Dannish with endosome 
escape and overexpression of 
Ag85A, Ag85B and TB10.4 
Ongoing pre-clinical 
studies; Phase I clinical 
trial planned  
R. Sun, D. Hone, 
M. Stone, J. Sadoff
rBCGΔUre:Chly+ BCG Pasteur with endosome 
escape 
Phase I clinical trial 
planned 
S. Kaufmann 
Modified MTB 
M.tuberculosis PhoP Mtb MT103 strain with deleted phoP
gene 
Ongoing pre-clinical 
studies 
B. Martin, B. 
Gicquel 
M.tuberculosis mc26020 Mtb H37Rv with deletion of the lysA 
and the panCD locus 
Phase I clinical trial 
planned 
W. Jacobs 
M.tuberculosis mc26030 Mtb H37Rv with deletion of the 
panCD and RD-1 locus 
Phase I clinical trial 
planned 
W. Jacobs 
Viral-vectored and naked DNA vaccines 
Aeras 402 (Ad35.TB-S) Non-replicating Ad35 expressing 
Ag85A, Ag85B and TB10.4 
Phase I clinical trial 
planned 
Aeras, Crucell 
Rv3407 DNA Plasmid encoding Rv3407 gene Ongoing preclinical 
studies  
H. Mollenkopf, L. 
Grode, J. Mattow 
Subunit vaccines 
Mtb72F Recombinant fusion protein of 
Mtb39 and Mtb32 
Phase I clinical trial 
completed 
Y. Skeiky, S. Reed 
Hybrid-1 (Ag85B-ESAT6) Recombinant fusion protein of 
Ag85B and ESAT6 
Phase I clinical trial 
completed 
P. Andersen 
BCG: Bacillus Calmette-Guérin, MTB: Mycobacterium tuberculosis, RD1: region deleted 1 
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Table 1.2 Expression of four proteins belonging to the ESAT6 family in different 
mycobacterium strains.   
 Expression of proteins in different strains Strain TB10.4 TB10.3 CFP10 ESAT6 
M. tuberculosis H37Rv + + + + 
M. bovis + + + + 
BCG Danish + + - - 
+: protein expressed in bacteria 
-: no expression in bacteria 
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Figure 1.1 Particle size characterization of micafungin aerosol by Andersen cascade impactor. 
a, mass deposition of micafungin at each site of  the cascade impactor; b, log-probability plot 
of micafungin particle size distribution. 
 
 
 
CHAPTER 2: RECOMBINANT ANTIGEN DESIGN, EXPRESSION, 
PURIFICATION, AND CHARACTERIZATION 
In this chapter, the study focused on antigen design, expression, purification and 
characterization. Ag85B was previously purified as a soluble recombinant antigen (125). The 
effort in this study was to make the second antigen TB10.4 and the fusion antigen of Ag85B 
and TB10.4 soluble as well. This is because a fair comparison of antigens requires them 
prepared from the same source. The soluble recombinant form was chosen in this study. A 
so-called “pro-protein” approach was used to improve the solubility of TB10.4 and fusion 
antigens, where they were fused to the C-terminal of thioredoxin (Trx). The solubility of Trx-
TB10.4 was dramatically improved. Compared to Trx-Ag85B-TB10.4, the solubility of Trx-
TB10.4-Ag85B was increased by at least ten fold. Free TB10.4 and TB10.4-Ag85B were 
obtained by treating Trx-TB10.4 and Trx-TB10.4-Ag85B respectively with the TEV protease 
to remove the N-terminal thioredoxin. Soluble TB10.4 and TB10.4-Ag85B were 
subsequently purified to homogeneity with milligram quantity by a combination of 
chromatographic steps. A partial success was also achieved to purify TB10.4-Ag85B from 
the inclusion body. Circular dichroism (CD) was performed to study the secondary structure 
of the purified recombinant antigens. TB10.4 showed a reversible structure change. TB10.4-
Ag85B purified from the soluble fraction showed similar thermal behavior as Ag85B with a 
characteristic melting temperature of approximately 75˚C whereas TB10.4-Ag85B purified 
from the inclusion body showed a completely different CD spectra and thermal behavior. In 
summary, the solubility and yield of TB10.4 and TB10.4-Ag85B was greatly improved by 
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rational design of the expression constructs. In addition, soluble Ag85B was also purified to 
homogeneity with well characterized secondary structure and thermal behavior. 
2.1 Introduction 
Ag85 complex (Ag85A, B and C) is the most abundant protein secreted by MTB (131), 
which attracts considerable interests for TB vaccine development. Ag85B has been shown to 
be among the most potent antigen species yet identified, which induces both humoral and 
cell-mediated immune responses in MTB-infected patients (197, 198). Ag85B encapsulated 
in poly lactide-co-glycolide (PLGA) induced significant amount of IL-2 production in an in 
vitro antigen presentation assay (125). Together with ESAT-6, a TB subunit vaccine 
comprised of these two antigens induced high levels of protective immunity in mice and 
reached the level of BCG-induced protection (199). An rBCG vaccine expressing Ag85B 
(rBCG30) induced greater protective immunity against aerosol challenge with MTB than 
conventional BCG in a highly susceptible guinea model (14). TB10.4 is a protein belonging 
to the ESAT-6 protein family comprising ESAT-6, CFP-10, TB10.4, and TB10.3 (122, 200). 
TB10.4 is strongly recognized by BCG-vaccinated donors and was even more strongly 
recognized in TB patients in comparing to ESAT-6 (201). Substitution TB10.4 for ESAT-6 
allows the use of ESAT-6 as a diagnostic marker to distinguish MTB infected individuals 
from healthy BCG vaccinated individuals since ESAT-6 is only expressed in MTB but not in 
BCG (19). Therefore, a recombinant fusion of Ag85B and TB10.4 (Ag85B-TB10.4) was 
designed in Andersen’s group, which has been shown to provide strong protection against 
MTB comparable to BCG (19).  
Although possible to purify native antigens from the MTB cultures, it is much easier 
and safer to express them in E. coli as recombinant antigens (202). Moreover, molecular 
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engineering can be employed to redesign antigens of interest and combine the advantages of 
different antigens (110). A similar strategy has been used to produce recombinant antigens 
for other vaccines such as anthrax vaccine (203) and influenza vaccine (204). In terms of 
protein purification, it is generally preferred to obtain recombinant antigens from the soluble 
fraction of E. coli culture. However, most antigens currently explored for TB subunit vaccine 
development were frequently purified from the inclusion body (IB) as reported by several 
research groups (19, 201, 205, 206). The reason for IB formation is due to the tendency of 
incorrect folding and aggregation when proteins are over-expressed in the heterologous 
expression system such as E. coli (207, 208). 
Thioredoxin is a 12 KD protein involved in several cellular functions such as sulfate 
metabolism, reduction of protein disulfides and as a cofactor for T7 DNA polymerase (209). 
It has a characteristic tertiary structure termed thioredoxin fold, which renders this protein 
highly stable and soluble (210, 211). When fused N-terminally to other proteins, thioredoxin 
remarkably increased the solubility of the fusion proteins, for example, mammalian cytokines 
and growth factors (212). Another advantage is that thioredoxin is localized on the 
cytoplasmic face of the adhesion zones between the outer and inner cell membranes (213). It 
can be exploited for rapid purification given that this property is retained by the fusion 
protein (212).  
Circular dichroism (CD) has been widely used to study protein secondary structure and 
tertiary structure. Near-UV CD (250-350 nm) provides information on protein tertiary 
structure, although the signal is orders of magnitude below the far-UV CD (190-250 nm). 
Therefore, near-UV CD mainly serves as a quality control tool to compare proteins prepared 
by different methods or from different lots. With far-UV CD, protein secondary structures 
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can be investigated because different secondary structures have distinct CD spectra in this 
region.  Deconvolution can be employed to analyze the complex CD spectra by dissecting 
out each contribution component, i.e. the secondary structure. In addition, CD can be used to 
study protein thermal stability by following the signal at the peak absorption wavelength as a 
function of temperature change. Compared to NMR or X-ray, CD offers less structural 
information of proteins; however, it is a fast and non-destructive technique which can be 
used on a routine basis to study protein stability and structure (214).  
In this chapter, solubility enhancement by N-terminal thioredoxin fusion was utilized 
in several recombinant antigens such as TB10.4, Ag85B-TB10.4, and TB10.4-Ag85B. In 
order to study the effect of construct design on antigen folding, the solubility and yield of 
Trx-TB10.4-Ag85B was compared to that of Trx-Ag85B-TB10.4. A conformation 
comparison was made between TB10.4-Ag85B purified from the inclusion body and its 
soluble counterpart by circular dichroism (CD). CD was also used to study antigen thermal 
stability.  
2.2 Materials and Methods 
Constructs design 
Four constructs were designed as shown in figure 2.1a-d. a: Trx-TB10.4. TB10.4 was 
amplified from the H37Rv genome by the following primers 5’-
ATGGATCCATGTCGCAAATCATGTACAACTAC-3’ (F) and 5’-GTAGAATTCC 
TAGCCGCCCCATTTGGCGGCTTCGGCCGTGT-3’ (R). The PCR product was digested 
with BamH I and EcoR I and ligated into a customized pET32b vector, in which a TEV 
protease cleavage site was introduced between the (His)6-tag and the multiple cloning sites. b: 
His-Ag85B-TB10.4. His-Ag85B was encoded in the pRSET-B vector (courtesy of Dr. 
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Douglas Kernodle, Vanderbilt University). TB10.4 was amplified from the H37Rv genome 
by the following primers 5’-ATGCATGGCGCCGGCATGTCGCAAATCATGTACAACT 
ACC-3’ (F) and 5’-GTAGAATTCCTAGCCGCCCCATTTGGCGGCTTCGGCCGTGT-3’ 
(R). The PCR product was digested with Nar I and EcoR I and ligated in frame with His-
Ag85B to generate the fusion molecule His-Ag85B-TB10.4. c: Trx-Ag85B-TB10.4. Both 5’-
TAAGGATCCTTCTCCCGTCCGGGTCTGCCGGTC-3’ (F) and 5’-ATAGAATTCCT 
AGCCGCCCCATTTGGCGGCTTC-3’ (R) were used to amplify Ag85B-TB10.4 by using 
His-Ag85B-TB10.4 as the template. The PCR product was then introduced into the 
customized pET32b vector between BamH I and EcoR I restriction sites. d: Trx-TB10.4-
Ag85B. TB10.4 was amplified by 5’-ATCGGATCCATGTCGCAAATCATGTACAAC-3’ 
(F) and 5’-GCCGCCCCATTTGGCGGCTTC-3’ (R). Ag85B was amplified by 5’-
PTTCTCCCGTCCGGGTCTGCCGGTC-3’ (F, with 5’ phosphate) and 5’- 
ATAGAATTCTCAGCCGGCGCCTAACGAACT-3’ (R). The two PCR fragments were 
ligated by T4 DNA ligase and re-amplified to obtain the fusion protein. The PCR product 
was then inserted into the customized pET32b vector between BamH I and EcoR I restriction 
sites.  
Expression of recombinant antigens 
Recombinant Ag85B and Trx-TB10.4 were expressed in E. coli BL21 (DE3) strain 
(Stratagene). Typically, 1L Luria-Bertani (LB) broth with 50 µg/ml carbenicillin was 
inoculated with 20 ml of an overnight culture of E. coli and grown at 37˚C until the OD600 
reached 0.6–0.8. The culture was induced by addition of 100 µM isopropyl- β -
thiogalactopyranoside (IPTG) and grown at 18˚C overnight. Recombinant His-Ag85B-
TB10.4, Trx-Ag85B-TB10.4 and Trx-TB10.4-Ag85B were expressed in E. coli Origami B 
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strain (Novagen) either with or without a plasmid expressing chaperon GroEL /GroES. 50 
µg/ml carbenicillin, 12.5 µg/ml tetracycline, 15 µg/ml kanamycin and 20 µg/ml 
chloramphenicol were supplemented into the medium. L-arabinose (1mg/ml) and IPTG (100 
µM) were used to induce chaperon and antigen expression respectively at 18˚C overnight.  
Antigen purification from the soluble fraction 
E.coli cells were pelleted, washed twice with phosphate buffered saline (PBS), re-
suspended in PBS containing 1mM phenylmethylsulphonyl fluoride (PMSF) and then probe-
sonicated 3 times. The resulting preparation was centrifuged at 15,000 rpm for 30 min. The 
soluble fraction of the recombinant antigens resides in the supernatant while inclusion body 
remains in the pellet. To purify soluble His-Ag85B, the supernatant was passed through a 
nickel column (Ni SepharoseTM 6 Fast Flow, Amersham Biosciences, Piscataway, NJ). The 
eluted proteins were further purified by a Superdex 75 column (Amersham Biosciences, 
Piscataway, NJ) with 20 mM 3-(N-morpholino)propanesulfonic acid (MOPS), 0.4 M sodium 
chloride, pH 7.0 as the eluting buffer at a flow rate of 1ml/min. Soluble Trx-TB10.4, Trx-
Ag85B-TB10.4 and Trx-TB10.4-Ag85B were purified on a nickel column first. Eluted 
proteins were dialyzed against Tris-HCl buffer (pH 7.4) to eliminate imidazole. Dialyzed 
proteins were treated with TEV protease (His-tagged) at a ratio of 25:1 (w/w) overnight at 
4˚C. The reaction mixture was spiked with 10 mM imidazole before loading onto the nickel 
column. Protein unbound to the nickel column was collected and the same procedure was 
repeated two more times (figure 2.2a). Proteins were concentrated to 5ml and further purified 
on a Superdex 75 column (for TB10.4) or Superdex 200 column (for TB10.4-Ag85B) eluted 
with 20 mM MOPS, 0.4 M sodium chloride, pH 7.0 as the eluting buffer at a flow rate of 
1ml/min.  
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Antigen purification from the inclusion body 
To purify antigen from the inclusion body, the pellet from 1L culture was first washed 
with PBS three times. 30 ml of Tris-HCl buffer (pH 7.4) containing 8M urea was then added 
to resolubilize the inclusion body at 4˚C for 4hr followed by centrifugation at 15, 000 rpm for 
1hr. The supernatant was passed through a 0.2 µm filter to eliminate any insoluble matters. 
1ml urea-resolubilized protein was then added dropwise into a beaker containing 50 ml Tris-
HCl (pH 7.4) buffer with gentle mixing on ice. The diluted protein was passed through a 0.2 
µm filter immediately after the dilution. Antigen in the filtrate was then purified by a 
combination of nickel-affinity and size-exclusion chromatography as described above.  
SDS-PAGE, native-PAGE, image analysis and antigen concentration determination 
A precast 12% SDS-PAGE gel (Biorad, Hercules, CA) was used to determine the 
purity of the recombinant antigens. A precast 10% Tris-glycine native gel (Biorad, Hercules, 
CA) was used for native-PAGE. The gel was stained with Coomassie blue. The intensity of 
the bands in the gel was analyzed in ImageJ (http://rsbweb.nih.gov/ij/). The antigen 
concentration was determined by BCATM protein assay kit (Thermo Scientific, Rockford, IL).  
Effect of buffer pH on antigen stability 
Citrate-phosphate buffer covering the range from pH 3 to pH 8 was prepared to study 
antigen stability at different pH. Antigen stock in MOPS buffer (20mM, pH7.0) was diluted 
20 times into the citric-phosphate buffer with the corresponding pH. This dilution ensures 
that the pH of the citric-phosphate buffer was not changed significantly by the introduction of 
MOPS buffer. The diluted antigen solution has a concentration between 0.05mg/ml and 
0.1mg/ml. The samples were left at room temperature for an appropriate time period as 
shown in figure 2.4. The size and distribution of antigen aggregates was measured by photon 
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correlation spectrometry (PCS) employing the particle sizer (NICOMP particle sizing 
systems, AutodilutePAT Model 370, Santa Babra, CA) in the NICOMP mode and repeated 
three times. 
Multiple sequence alignment, protein structure simulation and pI prediction 
Sequence alignment of ESAT-6 family members TB10.4, TB10.3, ESAT-6 and CFP-
10 was carried out in ClustalW (http://align.genome.jp/). The 3D coordinates for Ag85B 
(PDB accession #: 1F0N) were downloaded from protein database bank (PDB) and 
reconstructed in PyMOL (http://pymol.sourceforge.net/). Since there is no crystal structure 
available for TB10.4, SWISS-MODEL (http://swissmodel.expasy.org/) was used to simulate 
the structure of TB10.4 based on sequence homology. The first approach mode identified 
CFP-10/ESAT-6 (PDB accession #: 1wa8) as the template for simulation. Simulated 
structure of TB10.4 was constructed in PyMOL. ProtParam (http://www.expasy.ch/cgi-
bin/protparam) was used to predict the isoelectric points (pI) of the proteins listed in table 2.1. 
Circular dichroism (CD) to study antigen secondary structure and thermal stability 
Applied Photophysics Pistar-180 circular dichroism was used for this study. Buffer 
exchange was first performed to keep antigens in the CD compatible buffer (10mM 
potassium phosphate buffer, pH 7.4). The final antigen concentration for CD study ranges 
from 0.2 to 0.3 mg/ml. A full scan from 260 nm to 185 nm was first taken on each antigen at 
20˚C. The wavelength corresponding to the peak was selected to follow with temperature 
ramping from 20˚C to 94˚C (1˚C/min). The selected wavelength was 220 nm for TB10.4, 216 
nm for Ag85B and 218 nm for TB10.4-Ag85B. A full CD spectrum was also taken at 94˚C 
and then antigen samples were cooled to 20˚C, at which a full CD spectrum was recorded 
again. Blank spectrum (buffer only) was subtracted from all antigen CD spectrums. Best fit 
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based on residual analysis was selected for curve fitting.  
2.3 Results 
2.3.1 Production of soluble Trx-TB10.4 and TB10.4 
Expression of His-TB10.4 (encoded in pRSET-B vector) led to the exclusive formation 
of inclusion body in E. coli. However, fusion of thioredoxin to the N-terminal of TB10.4 
dramatically increased the solubility of Trx-TB10.4 (figure 2.1a) in comparing to His-TB10.4. 
Figure 2.3a shows that the major band corresponding to Trx-TB10.4 (29KD, lane 1) was 
cleaved into two fragments corresponding to the thioredoxin and TB10.4 respectively. 
Surprisingly, TB10.4 released from the enzymatic (TEV protease) cleavage was remarkably 
soluble and could be purified to homogeneity by a combination of chromatography (figure 
2.2a and 2.2c). The sharp peak in figure 2.2c represents TB10.4 while the small preceding 
peak may represent protein impurities or large aggregate of TB10.4. Figure 2.3b shows that 
TB10.4 can be purified to homogeneity (lanes 3 and 4).  
2.3.2 TB10.4 exists as an oligomer 
As shown in figure 2.2b, the Superdex 75 column was first calibrated with the protein 
standards. TB10.4 was eluted from the same column corresponding to a molecular weight of 
27KD. This apparent molecular weight is slightly greater than the calculated molecular 
weight of a TB10.4 dimer (22.6KD). To further characterize this protein, TB10.4 was run on 
a native gel with Ag85B and thioredoxin for comparison (figure 2.3c). Both Ag85B (34KD) 
and thioredoxin (19KD) exist as monomer based on their elution volume from the Superdex 
75 column. Figure 2.3c clearly shows that TB10.4 migrates faster than Ag85B yet slower 
than thioredoxin, which together with the chromatographic data suggest that TB10.4 exists as 
an oligomer.  
 52
2.3.3 Effect of pH on Trx-TB10.4 and TB10.4 stability 
As listed in table 2.1, all proteins studied are predicted to have the isoelectric point (pI) 
in a narrow acidic range (from 4.82 to 5.24). For Trx-TB10.4, significant protein aggregation 
was observed at pH 4 and pH 5; while no detectable aggregation was found at lower pH (< 4) 
or higher pH (> 5) monitored by photon correlation spectroscopy (figure 2.4a). The 
aggregation of Trx-TB10.4 starts immediately after diluting protein stock into appropriate 
buffer (pH 4 or 5). The aggregates may sustain in suspension for a couple of hours but 
precipitate out eventually. The aggregation of TB10.4 occurs at a lower pH range than that of 
Trx-TB10.4 as shown in figure 2.4b. This difference between the two proteins may be 
explained by the presence of thioredoxin in Trx-TB10.4, which is predicted to increase the pI 
of the fusion protein as shown in table 2.1.  
2.3.4 Production of soluble Trx-TB10.4-Ag85B and TB10.4-Ag85B 
Initial expression of His-Ag85B-TB10.4 (figure 2.1b) led to exclusive formation of 
inclusion body. Since the solubility of the recombinant antigen is a major concern, the fusion 
molecules were redesigned. In light of the success of Trx-TB10.4, two new molecules were 
constructed as shown in figure 2.1c (Trx-Ag85B-TB10.4) and figure 2.1d (Trx-TB10.4-
Ag85B). Figure 2.5a shows that the solubility of Trx-TB10.4-Ag85B was dramatically 
increased in comparing to Trx-Ag85B-TB10.4 (> 10 fold increase analyzed in ImageJ). 
However, the solubility of Trx-Ag85B-TB10.4 is only slightly better than that of His-Ag85B-
TB10.4. In order to obtain free TB10.4-Ag85B, the fusion protein Trx-TB10.4-Ag85B was 
treated with TEV protease. The reaction mixture was loaded onto a nickel column and this 
procedure was repeated three times as shown in figure 2.5b and 2.6a. Fraction that was not 
trapped on the nickel column was further purified on a Superdex 200 column as shown in 
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figure 2.6b. In this way, soluble TB10.4-Ag85B could be purified to homogeneity (figure 
2.5c). 
2.3.5 Increasing the yield of Trx-TB10.4-Ag85B by co-expression of chaperon proteins 
Compared to Trx-TB10.4, the yield of Trx-TB10.4-Ag85B was relatively low (table 
2.1). This may be explained by: 1) the latter protein being nearly twice the size of the former 
one, which consumes more energy to synthesize; 2) the greater tendency for Trx-TB10.4-
Ag85B to form inclusion body. Since the first explanation is an intrinsic property of the 
fusion protein, the improvement was focused on the second possibility. Chaperon proteins 
GroEL/GroES were co-expressed with Trx-TB10.4-Ag85B, which increased the yield by at 
least 40% (figure 2.7). However, such improvement was minimal for Trx-Ag85B-TB10.4 
(figure 2.7).  
2.3.6 Purification of Trx-TB10.4-Ag85B and TB10.4-Ag85B from the inclusion body 
Although thioredoxin fusion improves the folding of Trx-TB10.4-Ag85B significantly, 
a large quantity of mis-folded proteins was still found in the inclusion body (lane 3, figure 
2.8). An effort was made to purify this protein from the inclusion body. The sharp peak in 
figure 2.8 represents Trx-TB10.4-Ag85B from the inclusion body, which was almost purified 
to homogeneity as demonstrated by SDS-PAGE (figure 2.8, lane 4). Trx-TB10.4-Ag85B 
purified from the inclusion body was also cleavable by TEV protease, evidenced by the 
appearance of two new polypeptides corresponding to TB10.4-Ag85B and thioredoxin 
respectively (figure 2.8, lane 5). Further purification of TB10.4-Ag85B was performed with 
the same procedure as described previously. 
2.3.7 Study antigen secondary structure and thermal stability by circular dichroism 
Figure 2.9a shows the tertiary structure of Ag85B which is composed of alpha-helixes, 
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beta-sheets and linking loops. Based on sequence homology between TB10.4 and three other 
ESAT-6 family members (figure 2.9c), the structure of TB10.4 was simulated and 
constructed as shown in figure 2.9b. Significantly different from Ag85B, the structure of 
TB10.4 is dominated by alpha-helixes by prediction.  
The CD spectrum of TB10.4 at 20˚C (figure 2.10a, blue trace) again indicates that this 
antigen adopts an alpha-helix conformation. The results of thermal stability study suggest 
that TB10.4 lost its secondary structure gradually with temperature increase (figure 2.10aa). 
The CD spectrum recorded at 94˚C (figure 2.10a, yellow trace) indicates a dramatic loss of 
secondary structure at high temperature. Surprisingly, TB10.4 almost fully regains its 
secondary structure when cooled to 20˚C, suggesting a reversible structure change (figure 
2.10a, pink and black traces in comparing to the blue trace).  
Remarkably, in contrast to TB10.4, Ag85B shows a clear melting temperature (Tm) at 
73.7˚C (figure 2.10bb). Moreover, Ag85B was not able to fully recover its secondary 
structure when cooled to 20˚C (figure 2.10b, green and light blue traces in comparing to the 
red trace), suggesting an irreversible structure change of this antigen.  
The CD spectrum of soluble TB10.4-Ag85B (figure 2.10c) mimics that of Ag85B 
(figure 2.10b) but differs significantly from that of TB10.4 (figure 2.10a). The spectrum also 
suggests an irreversible structure change for soluble TB10.4-Ag85B (figure 2.10c, green and 
light blue traces in comparing to the red trace). A Tm of 75.1˚C was observed for soluble 
TB10.4-Ag85B (figure 2.10cc). In contrast, TB10.4-Ag85B purified from the inclusion body 
showed a reversible structure change (figure 2.10d, green trace in comparing to the red trace). 
Moreover, no Tm was observed for this protein (figure 2.10dd). These data considered 
together suggest that TB10.4-Ag85B purified from the inclusion body with the current 
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method does not regain the conformation adopted by its soluble counterpart. 
2.4 Discussion 
Protein overexpression in E. coli frequently led to the formation of inclusion body (207, 
208). High concentration of denaturant was always used to resolubilize the inclusion body 
followed by protein renaturation (215). Although there are some rules to follow, successful 
protein renaturation is case dependent, which requires an extensive screen of buffers (216). 
With respect to mass production of recombinant proteins, obtaining protein from the 
inclusion body has several drawbacks (215). First, the use of a large amount of denaturant 
increases the cost of production. Second, removal of denaturant requires additional quality 
control. Third, it is difficult to know whether renatured proteins fully regain their 
conformation and function especially for proteins that have no enzymatic activities. Despite 
these disadvantages, recombinant TB antigens such as Ag85B (206), TB10.4 (201), Ag85B-
ESAT-6 (205) and Ag85B-TB10.4 (19) were frequently purified from inclusion bodies and 
formulated into TB vaccines without comparing their conformations to that of corresponding 
native antigens or soluble counterparts.  
A comparison of this nature may be necessary since antigen obtained from the 
inclusion body may adopt a significantly different conformation (depending on renaturation) 
compared to its soluble counterpart or native antigens and may also mount different immune 
responses (217). For instance, it was reported that although T cells stimulated by differently 
folded prion protein (PrP) recognized similar immunodominant epitopes, the cytokine 
profiles in response to different conformers were significantly different (217). In addition, the 
humoral response induced by one conformer led to the production of predominantly IgG1 
isotype antibody; however, IgG2b was significantly produced with the other conformer 
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immunization (217). This study indicates that both humoral and cell-mediated responses to 
these differently folded conformers of the same protein are quite different. This may also 
hold true for TB antigen induced immune response. Therefore, it is highly favored to purify 
recombinant antigens from the soluble fraction, standing the best chance to fold correctly. 
One possibility for inclusion body formation is that protein disulfide bonds are 
mismatched (215). However, this is not the case for TB10.4 since there is no cysteine residue 
in its primary sequence. Another explanation could be that recombinant proteins are treated 
as exogenous when expressed in E. coli, whose folding machinery may not be suited to 
certain exogenous proteins (212). Not surprisingly, the N-terminal fusion of thioredoxin 
greatly improved the solubility of Trx-TB10.4 possibly because thioredoxin is an endogenous 
bacteria protein and its first appearance after translation can prime the bacterial folding 
machinery (212).  It is also possible that overexpression of thioredoxin or its fusions can alter 
the redox environment of E. coli cytoplasm creating a different folding environment (212). 
However, fusion of thioredoxin to the N-terminal of Ag85B-TB10.4 only slightly increased 
the solubility of Trx-Ag85B-TB10.4 in comparing to His-Ag85B-TB10.4. In contrast, the 
solubility of Trx-TB10.4-Ag85B was increased at least ten fold in comparison to Trx-
Ag85B-TB10.4. These observations can be explained by two possibilities. First, the order of 
the fusion protein may be involved in solubility enhancement.  As suggested by the terminal 
structure of Ag85B (figure 2.9a), seven residues were out of the secondary structure at the N-
terminal while only three such residues exist at the C-terminal. TB10.4, however, has the 
same number of such residues at each terminal (figure 2.9b). These residues may serve as 
flexible linkers for its fusion partner. Therefore, recombinant antigen designed in the Trx-
TB10.4-Ag85B direction may have a longer flexible linker in comparing to Trx-Ag85B-
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TB10.4 between the two fusion moieties. Shorter linker in the later design may hamper the 
folding of the fusion antigen. Second, the solubilization effect of thioredoxin on TB10.4 
could be greatly diluted or compromised by the longer spacer Ag85B (285 AAs) in the Trx-
Ag85B-TB10.4 design.  
The structure of TB10.4 lends some insights into its oligomerization. This structure 
may result in an extensive exposure of hydrophobic residues to the aqueous environment and 
thus increasing Gibbs free energy. Protein oligomerization may reduce the exposure of 
hydrophobic residues and thus minimizing Gibbs free energy and maximizing entropy (218). 
Oligomerization was also reported for CFP-10 and ESAT-6 (formation of a heterodimer), 
another two members in ESAT-6 family (200).  
For some proteins, aggregation occurs near the isoelectric point (pI) since their surface 
charges are neutralized at this pH. Trx-TB10.4 and TB10.4 belong to this class of protein. It 
should be noticed that further decrease of pH to 3 does not lead to detectable Trx-TB10.4 
aggregation, which can be explained by the fact that proteins are recharged below pI and 
ionic exclusion may outweigh hydrophobic interaction. However, it is still unknown whether 
Trx-TB10.4 possesses the same conformation at this low pH as in physiological conditions. 
Ag85B which has a predicted pI of 5.24, on the other hand, does not aggregate at the testing 
pH range. There are two possible explanations for this observation. First, the globular 
structure of Ag85B renders this protein highly resistant to pH change. Second, the actual pI 
for Ag85B may be significantly different from the predicted. The pI prediction by ProtParam 
is based on protein primary sequence, which does not take the tertiary structure into account. 
Some amino acids contributing to pI may hide inside the core of Ag85B and have limited or 
no access to the aqueous environment.  
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Circular dichroism (CD) is a useful tool to study protein secondary structure (174). 
Ag85B and soluble TB10.4-Ag85B have similar CD spectrum and similar pattern of thermal 
stability. The structural characteristics for these two proteins are 1) the presence of a clear 
melting temperature; 2) irreversible structure change. It should be noted that the slope of the 
sigmoidal fit is steeper for soluble TB10.4-Ag85B than for Ag85B, which could be explained 
by the contribution of TB10.4 in the fusion protein. Soluble TB10.4 and TB10.4-Ag85B 
purified from the inclusion body, on the contrary, underwent a reversible structure change 
while lacking a clear melting temperature. Protein structure may explain the different 
behaviors in the CD experiments. Ag85B, which has a globular structure, is resistant to the 
temperature increase to a certain extent. At the melting temperature, the intramolecular forces 
are not strong enough to hold the tertiary structure thus a dramatic loss of CD signal occurs. 
Since the loss of conformation is so dramatic and fast, Ag85B may not be able to recover all 
intramolecular interactions correctly when cooled. In contrast, structure loss of TB10.4 took 
place gradually all the way with temperature increase. This may explain the reversible 
structure change when TB10.4 was cooled. Although soluble, TB10.4-Ag85B purified from 
the inclusion body does not regain the confirmation adopted by its counterpart purified from 
the soluble fraction. It may adopt an intermediate conformation. Since the main purpose of 
this study is to purify large quantities of soluble antigens, no further effort was made to 
optimize the renaturation condition for TB10.4-Ag85B. This could be an interesting topic for 
the future study.   
Only partial success was achieved to purify TB10.4-Ag85B from inclusion bodies, in 
other words, we were only able to resolubilize TB10.4-Ag85B from its insoluble aggregates 
and maintain its solubility after denaturant removal whereas the conformation of TB10.4-
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Ag85B was not recovered. Initial trial to renature this protein at high protein concentration 
failed possibly because protein refolding is a first order reaction and protein aggregation is at 
least a second order reaction (219). Therefore, aggregation is favored over refolding at high 
protein concentrations. A rapid dilution procedure was then used to decrease the protein 
concentration by slowly diluting concentrated TB10.4-Ag85B into buffers with constant 
stirring. This procedure led to a partial success with soluble yet incorrectly folded TB10.4-
Ag85B as evidenced by CD differentiation. There are two explanations for this result. First, 
rapid dilution procedure caused a shock-decrease of the denaturant concentration used for 
resolubilization and, therefore, TB10.4-Ag85B may not have enough time to fold correctly 
but otherwise became a soluble molten globule or even less ordered structure. Second, the 
renaturation buffer used in our experiment is not optimal. Renaturation buffer is always 
protein dependent, which requires conditions such as redox state and pH empirically 
optimized for each protein. However, no reagent was added into our renaturation buffer to 
control the redox conditions.  
Based on our understanding of protein aggregation and research experience in protein 
refolding, we can envision how to achieve a full success of refolding TB10.4-Ag85B into its 
native conformation in the future. Factors we may consider include protein concentration, 
rate of denaturant removal (on-column refolding rather than dialysis), buffer pH and redox 
conditions, renaturation excipients such as dithiothreitol (DTT) and L-arginine, as well as 
temperature, and pressure (219, 220). 
2.5 Summary  
In this chapter, soluble antigens, Ag85B, TB10.4 and TB10.4-Ag85B, were expressed 
in E. coli and purified to homogeneity in large quantities. In addition, TB10.4-Ag85B is a 
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complete new fusion molecule designed in our lab representing a novel antigen candidate for 
TB subunit vaccine. Rational design of the expression constructs dramatically increased the 
solubility and yield of recombinant antigens leading to mass production of these antigens 
feasible. Circular dichroism experiments showed a significant conformation difference 
between TB10.4-Ag85B purified from the inclusion body and its soluble counterpart. The pH 
and thermal stability data provide invaluable information that will guide further formulation 
development based on these antigens. 
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Table 2.1 Characterization of recombinant antigens 
Protein AAs MW (KD) pIa Solubility Yield (mg/L) 
Ag85B 318 34 5.24 Sb 5 
His-TB10.4 129 14 5.23 IBc N/A 
Trx-TB10.4 269 29 5.16 S 14 
TB10.4 105 11.3 4.82 S 4 
Trx-Ag85B-TB10.4 554 60 5.05 WSd+IB N/A 
Trx-TB10.4-Ag85B 554 60 5.05 S+IB 2.5 
TB10.4-Ag85B 390 42 4.85 S 1 
His-Ag85B-TB10.4 414 45 5.02 IB N/A 
a: isoelectric point (predicted by ProtParam, see materials and methods) 
b: soluble; c: inclusion body; d: weekly soluble 
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Figure 2.1 Construct design for recombinant antigens. a, Trx-TB10.4 in customized pET32b 
vector; b, His-Ag85B-TB10.4 in pRSET-B vector; c, Trx-Ag85B-TB10.4 in customized 
pET32b vector; d, Trx -TB10.4-Ag85B in customized pET32b vector. 
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Figure 2.2 Purification of TB10.4 by nickel-affinity and size-exclusion chromatography. a, 
chromatogram of TB10.4 purified by nickel-affinity column; b, calibration of Superdex 75 
column with protein standards (cytochrome c: 12.4KD; carbonic anhydrase: 29KD; bovine 
serum albumin: 66KD; β-amylase: 200KD). The log-transformation of protein molecular 
weight was linearly correlated with the elution volume (inset, upper left corner); c, 
chromatogram of TB10.4 further purified by Superdex 75 column. 
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Figure 2.3 SDS-PAGE and native-PAGE analysis of recombinant antigens. a, SDS-PAGE 
analysis of Trx-TB10.4 and its digestion products. lane 1: Trx-TB10.4; lane 2: Trx-TB10.4 
was treated with TEV protease and then passed through the nickel column. The flow-through 
was collected; lane 3: proteins bound to the column were eluted and collected; lane 4: 
duplicate of lane 2; lane 5: duplicate of lane 3; b, SDS-PAGE analysis of purified antigens. 
lane 1: Ag85B; lane 2: Trx-TB10.4; lane 3 and 4: TB10.4; c, native-PAGE analysis of 
purified antigens. lane 1: Ag85B; lane 2 and 3: TB10.4; lane 4: thioredoxin. 
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Figure 2.4 Effect of buffer pH on antigen stability (n=3, mean ± SD). a, buffer pH on Trx-
TB10.4 stability; b, buffer pH on TB10.4 stability. For PCS (photon correlation spectrometry) 
intensity greater than 300, the size and distribution could be accurately calculated and labeled 
in the figure. For overnight incubation, the protein aggregates precipitate out from the 
solution and no PCS intensity was recorded.  
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Figure 2.5 SDS-PAGE analysis of recombinant fusion antigens. a, SDS-PAGE analysis of 
nickel column purified antigens. lane 1: Trx-Ag85B-TB10.4 (indicated by asterisk); lane 2: 
Trx-TB10.4-Ag85B (indicated by asterisk); b, TB10.4-Ag85B released by TEV protease 
treatment was analyzed by SDS-PAGE. lane 1: Trx-TB10.4-Ag85B was treated with TEV 
protease overnight; lane 2: eluant of first pass through nickel column; lane 3: eluant of 
second pass through nickel column; lane 4: eluant of third pass through nickel column; lane 5: 
10 times concentrate of the third eluant. c, TB10.4-Ag85B was further purified by GPC200 
column. lane 1: 1 µg TB10.4-Ag85B; lane 2: 3 µg TB10.4-Ag85B; lane 3: 3 µg TB10.4-
Ag85B prior to GPC200 purification. 
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Figure 2.6 Purification of TB10.4-Ag85B by nickel-affinity and size-exclusion 
chromatography. a, chromatogram of TB10.4-Ag85B purified by nickel-affinity column; b, 
chromatogram of TB10.4-Ag85B further purified by Superdex 200 column. 
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Figure 2.7 Comparison of the yield of two recombinant antigens with or without the co-
expression of chaperons. Chromatograms were shown of antigens purified by nickel-affinity 
chromatography. 
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Figure 2.8 Purification of Trx-TB10.4-Ag85B and TB10.4-Ag85B from the inclusion body. 
Inset (upper left corner). lane 1, soluble Trx-TB10.4-Ag85B was treated with TEV protease; 
lane 2, same as lane 1 but different loading; lane 3, urea resolubilized Trx-TB10.4-Ag85B; 
lane 4, Trx-TB10.4-Ag85B in lane 3 was purified by nickel column; lane 5, purified Trx-
TB10.4-Ag85B in lane 4 was cleaved by TEV protease into two fragments. 
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Figure 2.9 Structures of Ag85B and TB10.4. a, structure of Ag85B (PDB accession #: 1F0N); 
b, structure of TB10.4 (simulated); c, multiple sequence alignment of ESAT-6 protein family 
members TB10.4, TB10.3, ESAT-6 and CFP-10. 
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Figure 2.10 Study antigen secondary structure and thermal stability by circular dichroism 
(CD). a, CD spectrum of TB10.4; aa, thermal stability study of TB10.4; b, CD spectrum of 
Ag85B; bb, thermal stability study of Ag85B; c, CD spectrum of soluble TB10.4-Ag85B; cc, 
thermal stability study of soluble TB10.4-Ag85B; d, CD spectrum of TB10.4-Ag85B purified 
from the inclusion body; dd, thermal stability study of TB10.4-Ag85B purified from 
inclusion body. 
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CHAPTER 3: MANUFACTURE AND CHARACTERIZATION OF RESPIRABLE 
PLGA-rAg MICROPARTICLES 
In the last chapter, recombinant antigens were designed, expressed, purified and 
characterized. These antigens include Ag85B, TB10.4, and TB10.4-Ag85B. In this chapter 
we will discuss how to make vaccine formulations by encapsulating antigens into PLGA 
microparticles (PLGA-rAg). PLGA was selected as the delivery vehicle for several reasons: 
1) PLGA has well documented safety profile; 2) the release from PLGA can be controlled by 
varying the ratio of two building monomers; 3) the density of PLGA particles is low which is 
particularly suitable for pulmonary delivery. PLGA-rAg microparticles were manufactured 
by emulsion/spray-drying method. Since the particle size is primarily determined by spray 
drying, this process was optimized systematically with a half-factorial design. The condition 
that gave rise to the target particle size and yield was chosen to prepare subunit vaccine 
formulations. In addition to antigens, an adjuvant muramyl dipeptide (MDP) was also 
included in the formulation. There are a total of six formulations made under the optimized 
condition including: PLGA (blank particles), PLGA-MDP (adjuvant included), PLGA-MDP-
Ag85B, PLGA-MDP-TB10.4, PLGA-MDP-TB10.4+Ag85B (blend), and PLGA-MDP-
TB10.4-Ag85B (fusion). The first two formulations serve as the control while the rest are 
subunit vaccine formulations. These formulations were characterized in terms of particle size, 
aerodynamic size and distribution, flow properties, surface charge, energy and morphology, 
thermal behavior, antigen integrity, and release profiles. Such characterizations provide a 
comprehensive understanding of the physicochemical properties of the manufactured
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microparticles. In this chapter, optimization of the spray-drying parameters will be discussed 
first followed by a detailed physicochemical characterization of the prepared formulations. 
3.1 Introduction 
Poly (lactide-co-glycolide) (PLGA) is a copolymer that has been used in a number of 
FDA approved therapeutic devices due to its biodegradability and biocompatibility (221). For 
example, Lupron Depot® is a commercially available drug delivery device using PLGA for 
the treatment of advanced prostate cancer (222, 223). In addition, there have been numerous 
reports employing PLGA to encapsulate insulin for improved pharmacokinetics and 
pharmacodynamics as well as reduced dosing frequency (224-226). PLGA has also been 
employed to manufacture tuberculosis subunit vaccine by several research groups. For 
example, Lu et al reported that PLGA microspheres containing recombinant Ag85B could 
induce significant interleukin-2 secretion in vitro (125). Kirby et al reported that Ag85B-
ESAT6 encapsulated in PLGA microspheres induced a cell-mediated immune response and 
raised specific antibodies after immunization of the mice (173).  
For the purpose of pulmonary delivery of vaccines, recombinant antigens should be 
encapsulated into PLGA particles with an aerodynamic size range from 1 to 5 µm (138). This 
requires the selection of the right microencapsulation technique, which in turn depends on the 
active ingredients, the nature of polymer and the intended use. In general, five rules should 
be considered in terms of choosing the microencapsulation method: 1) the biological activity 
and physicochemical stability of the active ingredients should not be adversely affected by 
the encapsulation procedure; 2) the size of manufactured microparticles should meet the 
requirement; 3) the yield of microparticles with the required particle size range should be 
acceptable; 4) the microparticles should have good flow properties with little aggregation or 
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adherence; 5) the microencapsulation procedure should have a good scalability. There are 
three common methods widely used to manufacture microparticles including 
emulsion/solvent evaporation (227), phase separation (228) and spray drying (229).  
Two successive steps are involved in the emulsion/solvent evaporation method. The 
first step is emulsion, which can be a single emulsion or double emulsion. Single emulsion 
involves only one emulsion procedure such as oil-in-water (o/w) or oil-in-oil (o/o) emulsion. 
Polymers are usually not water soluble and, therefore, dissolved in a water immiscible 
solvent (usually a volatile organic solvent). Active ingredients depending on their solubility 
in the organic solvent can either dissolve or disperse as particles in the polymer solution 
(228). This mixture is then emulsified into a large quantity of a second phase such as water in 
o/w emulsion or oil in o/o emulsion in the presence of an emulsifier. In contrast to the single 
emulsion, double emulsion involves two emulsion processes, for instance, water-in-oil-in-
water (w/o/w) double emulsion and oil-in-water-in-oil (o/w/o) double emulsion. The w/o/w 
double emulsion is well suited to encapsulate water-soluble substances such as hydrophilic 
drugs and peptides/proteins into PLGA microparticles (173). Water-soluble substances are 
first dissolved in a small volume of aqueous buffer, which is then emulsified into a large 
volume of oil phase containing dissolved PLGA. The primary emulsion is then transferred to 
an aqueous solution for the preparation of the second emulsion either by homogenization or 
sonication. Oil-in-water emulsifier is always used to make the second emulsion, for instance, 
poly (vinyl alcohol) (PVA) is selected for the purpose of preparing PLGA microspheres 
(173). Solvent evaporation is the second step of the emulsion/solvent evaporation method, 
which hardens the oil droplets leading to the formation of microparticles (228, 230). This is 
usually done by evaporating the volatile organic solvent at reduced pressure with constant 
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stirring but can also be done at ambient conditions. The solidified microparticles are then 
washed and collected by filtration, centrifugation, or sieving. After lyophilization or drying at 
appropriate conditions, these particles are ready for use or storage. A number of drugs have 
been encapsulated into PLGA microparticles by the emulsion/solvent evaporation method 
(231-233). However, a few disadvantages are associated with this method. First, the 
encapsulation efficiency is relative low for hydrophilic drugs which tend to diffuse into the 
water phase during the second emulsion process. Second, the residual organic solvent is 
difficult to remove completely by sole evaporation. Third, this method is difficult to scale up 
due to various factors that are involved.  
Phase separation is another method to manufacture microparticles. This method relies 
on decreasing the solubility of polymer in its solvent by adding an organic nonsolvent (228). 
Two phases are formed during this process with the polymer containing coacervate phase and 
the other phase depleted in polymer. Similar to the emulsion/solvent evaporation method, 
hydrophilic drugs are first dissolved in an aqueous buffer followed by emulsifying into the 
polymer solution to create the primary w/o emulsion. However, evaporation is not used to 
harden the particles. Rather, an organic nonsolvent is added into the emulsion with stirring to 
extract the solvent out of the polymer solution. This leads to the phase separation of the 
polymer, which then forms soft coacervate droplets that entrap the active ingredients. The 
coacervates are hardened by transferring to a large volume of organic nonsolvent for further 
extraction and separation (228). The hardened microparticles can be collected by similar 
ways as described in the first method. Phase separation method is less used then the solvent 
evaporation method for several reasons: 1) it requires a large quantity of organic solvent; 2) 
particles prepared by this method have poor flow characteristics due to particle 
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agglomeration; 3) it is a non-equilibrium system and, therefore, the formulation and process 
variables have a very significant impact on the characteristics of the final microparticles 
(228). 
The third method to prepare PLGA microparticles is spray drying (229). Compared to 
the other two methods, spray drying has its unique advantages such as convenience, delicate 
controlling system, reproducibility and scalability. Encapsulation of hydrophobic drugs is 
relatively easy. They can be co-dissolved with PLGA in the organic solvent. In this way 
drugs are dissolved (homogeneously distributed) in the matrix of PLGA microparticles after 
spray drying. For hydrophilic drugs/proteins which are immiscible with the solvent, they can 
be either dispersed as solid particles in the polymer solution or first dissolved in an aqueous 
buffer followed by emulsifying into the polymer solution. The resulting preparation is then 
spray dried to yield the desired microparticles. One concern with this method is that 
hydrophilic drugs/proteins may not be homogeneously distributed in the matrix of PLGA 
microparticles but rather exist as a separate phase, i.e. fine drug particles dispersed in the 
large polymer particles (172). It is possible to circumvent this problem by dissolving PLGA 
in a water miscible organic solvent such as acetone which is then mixed with an aqueous 
solution of hydrophilic drugs/proteins. This approach assumes that mixing two solutions does 
not cause precipitation of either the polymer or the drugs from the system. The size of spray-
dried particles can be controlled to some extent by the polymer concentration, drug loading 
and the nature of solvent but to large extent by the spray-drying process (191, 229). Solutions 
fed into the spray drier are dispersed by the atomization gas to create fine droplets, which are 
then dried in the drying chamber with heated air flow. The temperature of the drying air is 
well controlled to provide enough heat transfer to evaporate water and the organic solvent but 
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pose no risk to the encapsulated drugs. With solvent removal, PLGA particles get hardened 
and are subsequently removed from the air stream by the centrifugal forces generated in the 
cyclone. The yield is relatively low at bench-size production but can be very high once scaled 
up. Both the size and yield are controlled by spray-drying parameters, which should be 
optimized for the desired features.  
Particle characterization is an integrative part of the powder technology (234, 235). 
Particle size is one of the most important characters of a powder. The geometric size and 
distribution can be measured by a laser diffraction particle sizer, which works on the 
principle that large particles diffract light to a small angle while small particles diffract light 
to a large angle. Geometric size is important in terms of particle uptake by target cells. The 
aerodynamic particle size and distribution can be obtained with a cascade impactor based on 
the Stokes’ law. This size determines the lung deposition of delivered aerosol particles. In 
addition to size, particle size distribution is also an important index with a narrow size 
distribution highly desired. Particle morphology can be examined by a scanning electron 
microscope. The surface structure of particles has great impact on particle aggregation and 
flow properties, which will ultimately affect particle delivery and deposition. To characterize 
the thermal behavior of a powder, differential scanning calorimetry (DSC) is typically used 
by measuring the difference of heat flow. Useful thermodynamic parameters such as the glass 
transition temperature and the change of heat capacity can be obtained by DSC.  
 In this chapter, the spray-drying parameters were first systematically optimized in 
terms of both particle size and yield by employing the concept of Quality-by-Design (QbD). 
Under optimized conditions, TB subunit vaccines were prepared by encapsulating different 
recombinant TB antigens/antigen combinations into PLGA microparticles in the presence of 
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an adjuvant muramyl dipeptide. Manufactured particles were extensively characterized in 
terms of particle size, surface energy, charge and morphology, thermal property, antigen 
integrity and release profiles.  
3.2 Materials and Methods 
Preparation of recombinant antigens 
Recombinant antigens Ag85B, TB10.4 and TB10.4-Ag85B were expressed in E. coli 
and purified by a combination of nickel-affinity and size-exclusion chromatography as 
described in the second chapter. The homogeneity of purified antigens was determined by 
SDS-PAGE under reducing conditions. 
Microparticle preparation 
Poly (lactide-co-glycolide) (PLGA, lactic/glycolic ratio 75:25, MW 84.7 kDa, intrinsic 
viscosity 0.68 dL/g in CHCl3) was purchased from Durect (Lactel® Absorbable Polymers, 
Pelham, AL, USA). Muramyl dipeptide (MDP) was purchased from Sigma (St. Louis, MO, 
USA). Dichloromethane (DCM) was purchased from Burdick & Jackson (HPLC grade, 
Muskegon, MI, USA). To optimize spray-drying condition, PLGA (700 mg) was dissolved in 
200 ml DCM (0.35%, w/v). MDP (adjuvant, 3.5 mg) and bovine serum albumin (BSA, 1mg) 
were dissolved in 2.4 ml phosphate buffered saline (PBS, pH7.4). The aqueous and organic 
phases were probe sonicated for three 10s periods on an ice bath immediately prior to spray 
drying. The emulsion was spray-dried through a 0.7-mm diameter nozzle of a Buchi mini 
spray-dryer (B-191, Buchi, Flawil, Switzerland) according to the half-factorial design (table 
3.1) constructed in the statistical software Design-Expert®. Particles were collected from the 
jar and cyclone wall of the spray dryer. These particles were labeled as PLGA-MDP-BSA. 
To prepare subunit vaccines for in vitro antigen presentation assay, recombinant TB antigens 
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rather than BSA were encapsulated into PLGA microparticles with the same procedure as 
described above except that they were manufactured under optimized spray-drying condition. 
These formulations include PLGA, PLGA-MDP, PLGA-MDP-TB10.4, PLGA-MDP-Ag85B, 
PLGA-MDP-TB10.4+Ag85B and PLGA-MDP-TB10.4-Ag85B. The loading of MDP in all 
these formulations is 0.5%. The loading of Ag85B in PLGA-MDP-Ag85B and PLGA-MDP-
TB10.4+Ag85B is 0.14%. The loading of TB10.4 in PLGA-MDP-TB10.4 and PLGA-MDP-
TB10.4+Ag85B is 0.048%. The loading of TB10.4-Ag85B in PLGA-MDP-TB10.4-Ag85B is 
0.188%, which corresponds to 0.14% Ag85B and 0.048% TB10.4.  
Characterization of PLGA microparticles 
Encapsulation efficiency: 50mg of PLGA-rAg microparticles were dissolved in 5ml of 
DMSO and 25 ml of 0.05 M NaOH solution containing 0.5% (w/v) SDS (sodium dodecyl 
sulfate) were added and incubated at room temperature for 1 h. The concentration of antigens 
was determined by the BCA method. The encapsulation efficiency is the ratio of calculated 
antigen amount to that of theoretical amount.  
Projected area diameter and particle morphology: microparticles were first suspended 
in water and then dispersed onto the surface of the stub, which was subsequently dried in a 
desiccator. Stubs were coated with gold-palladium alloy using a sputter coater (Polaron 5200, 
Structure Probe Incorporated Supplies, West Chester, PA, USA) and then examined under 
the scanning electron microscope (Hitachi S-4700). 
Volume median diameter (VMD, Dv, 50): a small amount of each PLGA-rAg 
formulation was first suspended in the PBS buffer supplemented with 0.1% Tween 80 by 
bath sonication for 1 min. Approximately 1 ml of the suspension was added into the sample 
cell which had a volume of 15 ml PBS buffer under constant stirring. The ideal suspension 
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concentration was achieved at a laser obscuration of 0.15 to 0.25. Dv,10, Dv,50, Dv,90 and the 
span were measured by  the laser diffraction particle sizer (Malvern 2600, Worcestershire, 
UK).  
Mass median aerodynamic diameter (MMAD): MMAD was measured by an eight 
stage non-viable Andersen cascade impactor (Andersen, Smyrna, GA) operated at a flow rate 
of 60 L/min. The plates of the cascade impactor were coated with 1% silicon oil dissolved in 
hexane in order to reduce particle bouncing. Sodium fluorescein (1% w/w) was incorporated 
into PLGA-MDP-BSA microparticles during preparation. The particles were discharged from 
a dry powder inhaler device (Inhalator®, Boehringer Ingelheim, Germany) and sampled into 
the cascade impactor. Mass deposition at each stage, the sampling inlet (throat) and 
preseparator was calculated based on the fluorescein content assayed by UV 
spectrophotometry at 490nm. 
Bulk and tapped density: approximately 1g PLGA-MDP-BSA microparticles were 
placed in a graduated cylinder. The mass/volume before tapping was calculated as bulk 
density. The tapped density was obtained following about 100 taps which allowed the 
powder volume to plateau. Carr’s compressibility index (CCI) was calculated as (tapped 
density-bulk density)/tapped density. Hausner ratio was calculated as tapped density/bulk 
density. 
Static angle of response: static angle of response was measured by pouring PLGA-
MDP-BSA microparticles through a glass funnel onto a flat collection surface until the angle 
of response did not change with the addition of powder. The angle to the horizontal surface 
was measured. Greater than 1g of microparticles was needed for this experiment. 
Thermal analyses: thermal analyses were carried out with differential scanning 
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calorimetry (Perkin Elmer DSC 6, Wellesley, MA). Known quantities of PLGA-rAg 
microparticles were sealed in an aluminum pan. An empty pan was used as the reference. 
Different temperature ramping rates were used from 10˚C/min to 40˚C/min for each sample. 
Three experiments were performed to check the reproducibility. 
Zeta potential: PLGA-rAg microparticles were suspended in the PBS buffer at a 
concentration of approximately 0.2 mg/ml. This suspension was then transferred into a 
sampling cuvette and thermostated at 37˚C for 2 min before the start of measurement. Zeta 
potential was measured by a Malvern Zetasizer (NanoZS, Malvern Instruments Inc., 
Worcestershire, UK).   
Surface free energy: surface free energy of PLGA-MDP-BSA microparticles was 
studied by inverse gas chromatography (IGC). IGC experiments were performed with a 
Hewlett-Packard 5890 Series II GC with flame ionization detector as described previously 
(236). A series of alkanes (C6-C10) were used as probes. Dry N2 was used as the carrier gas 
with a flow rate of 30 mL/min. Oven temperature was controlled at 25 ˚C. PLGA 
microparticles were packed into the deactivated glass columns and then plugged with 
silanated glass wool at each end of the column. After installation, packed columns were 
allowed to equilibrate at 25 ˚C for 2 h before making injections. Injections were made by 
using a 1 µL-Hamilton syringe and infinite dilution was ensured by the detector response.  
SDS-PAGE analysis of antigen integrity 
To study the effect of spray drying on antigen integrity, 5 mg PLGA-rAg 
microparticles encapsulating different antigens were weighed after two-month storage. 300 
µL SDS sampling buffer with dithiothreitol (DTT) as the reducing agent was added into 
microparticles and extracted for 30 min at room temperature. The mixture was then boiled 
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for 5 min at 95 ˚C to denature the protein followed by centrifugation at 12, 000g for 10 min. 
5 µg soluble antigens were also boiled for 5 min at 95 ˚C after mixing with SDS sampling 
buffer containing DTT.  20µL samples from each preparation were loaded into a 12% SDS-
PAGE gel (Biorad, Hercules, CA). Proteins were visualized by Coomassie Blue staining. 
PLGA microparticle release profile 
PLGA microparticles encapsulating BSA (90 mg) were put into 5 ml PBS (0.1% 
Tween 80) solution. The tubes were placed in a shaker bath at 37˚C running at 60 
strokes/min. A volume of 0.6 ml suspension was removed at selected intervals and 
centrifuged for 10 min at 8, 000 g. 0.5 ml of supernatant was removed and stored. The rest of 
the sample and 0.5 ml fresh medium were added back into the dissolution vial. Bicinchoninic 
acid assay was used to determine BSA concentration and MDP was quantified by HPLC. 
HPLC conditions for MDP were: C18 reversed phase column (4.6×25 mm), mobile phase: 
95% phosphate buffer (25 mM, pH 3.0) and 5% methanol at a flow rate of 1 ml/min and UV 
wavelength of 200 nm.  
Statistical analysis 
Multivariate statistical analysis was performed in Design-Expert® software to optimize 
the spray-drying conditions.  
3.3 Results 
3.3.1 Half-factorial design for optimization of spray-drying parameters 
Spray-drying method was employed to produce poly (lactide-co-glycolide) (PLGA) 
microparticles. Variables playing pivotal roles in the spray-drying process include 
atomization pressure, spray flow, aspirator flow, inlet temperature and pump feeding rate. In 
order to dissect out the contribution of each variable and their interactions with respect to 
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achieving favorable particle properties, a half-factorial design (25-1) was constructed in 
Design-Expert® as shown in table 3.1 (16 design points plus 4 midpoints to check 
reproducibility), where five process variables and four response variables were listed with 
corresponding set and measured values. Among the four response variables, volume median 
diameter (VMD) and the yield were used to optimize the spray-drying parameters 
simultaneously. The optimization criteria were as follows: a) a VMD around 3µm (greater 
macrophage uptake), b) a yield greater than 15% (cost saving), c) a single mode of size 
distribution and a span less than 1 (uniformity) and d) mass median aerodynamic diameter 
(MMAD) between 1 and 5µm (aerosol delivery to the lung). Among these, MMAD was not 
an independent variable since it was determined by VMD, particle density, aggregation states 
and dispersion. 
3.3.2 Analysis of spray-drying parameters with respect to size and yield respectively 
Process variables were first analyzed with respect to size (VMD) since this is the most 
important factor determining particle aerosolization and macrophage uptake. The half-normal 
plot in figure 3.1a suggests that spray flow (B), inlet temperature (C), aspirator flow (D) and 
the interaction between spray flow and inlet temperature (BC) are main contributors in 
determining particle size. B and C contribute almost 75% of the overall effect; while together 
with D and BC, they contribute almost 85% of the overall effect based on statistical analysis. 
Pump feeding rate and atomization pressure showed minimal effect on particle size in the test 
range. According to above analysis, spray flow and inlet temperature deserve most attention 
with respect to target particle size. As shown in figure 3.1b, VMD decreased when spray 
flow and inlet temperature increased. In addition, VMD was more sensitive to spray flow.  
Process variables were next analyzed with respect to the yield. Figure 3.1c clearly 
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suggests that only spray flow (B) and aspirator flow (D) have statistically significant 
contributions. Spray flow accounts for 80% of the overall effect and aspirator flow accounts 
for 15% of the overall effect according to statistical analysis. However, it should be noticed 
that the effect of spray flow is negative, indicating that particle yield decreased with the 
increase of spray flow. None of other variables or interactions was statistically significant. 
Therefore, attention should be drawn to these two variables to achieve greater yield.  
3.3.3 Simultaneous optimization of spray-drying parameters 
Multivariate statistical analysis was employed to optimize spray-drying parameters to 
achieve target particle properties proposed above. A desirability function was used to make 
an overall assessment of the desirability of the combined response variables, particle size and 
yield. In the desirability plot as shown in figure 3.1d, only one parameter combination 
(marked by the red dot) leads to a desirability of 1 while all other combinations give rise to 0. 
The optimized spray-drying conditions are as follows: atomization pressure (3 bars), spray 
flow (700 L/hr), pump feeding rate (4 ml/min), aspirator flow (100%) and inlet temperature 
(55 ˚C). Although the mode and span listed in table 3.1 were not used for optimization, 
particles prepared under optimized condition showed a unimodal and narrow size distribution, 
which meet the proposed criteria for optimization. The encapsulation efficiency for different 
PLGA-rAg formulations is 83.2±2.5% for Ag85B, 84.8±2.4% for TB10.4, 84.4±1.8% for 
TB10.4+Ag85B (blend), and 82.3±2.5% for TB10.4-Ag85B (fusion). 
3.3.4 Morphology analysis of spray-dried microparticles 
First, 6 batches of particles with a VMD around 3µm and 1 batch with the largest 
VMD from the optimization experiments were selected and imaged by SEM (figure 3.2a). 
The projected area diameter revealed by SEM images was always smaller than VMD 
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obtained from the laser diffraction experiment (figure 3.2a). Spray-dried PLGA particles 
showed a wrinkled and irregular surface morphology for all batches except the one with a 
VMD of 9.58µm. PLGA-rAg microparticles (subunit vaccines) prepared for efficacy 
evaluation were also imaged by SEM as shown in figure 3.2b, these particle preparations all 
had very similar surface morphology although different proteins were encapsulated, 
indicating a high reproducibility of particle preparation under optimized spray-drying 
conditions.  
3.3.5 Particle size analysis of microparticles 
Particle sizes for six PLGA-rAg formulations were listed in table 3.2. All formulations 
have a VMD of approximately 3.0µm, Dv, 10 of 2.2µm and Dv, 90 of 4.4µm. Again, these data 
suggested a high reproducibility of particle preparation under optimized conditions. 
Aerodynamic diameter of PLGA microparticles was measured with PLGA-MDP-BSA. 
Figure 3.3a suggests that 80% of the total mass was deposited inside the impactor yet very 
little deposition was observed below 1.1µm. Fine particle fraction (FPF) of the emitted dose 
was 61.5±6.4% and FPF of the total dose was 37.0±5.5%. It should be noticed that particle 
size distribution deviated from the ideal log-normal distribution with a MMAD of 3.3±
0.2µm and GSD of 2.7±0.1 (figure 3.3b).  
3.3.6 Flow property of microparticles 
The flow characteristics of PLGA-MDP-BSA microparticles were evaluated. The bulk 
density of these powders is 0.071 g/ml. The tap density is 0.094 g/ml. Calculated Carr’s 
compressibility index (CCI) is 24.5% and Hausner ratio is 1.32. It is generally accepted that 
the free-flowing powder has a CCI less than 20% (237) and a Hausner ratio less than 1.20 
(238). Powder with a CCI greater than 30% and a Hausner ratio greater than 1.50 always 
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means poor flow property. Therefore, our powder showed an intermediate flow characteristic. 
Powder with a large static angle of response suggests poor flow property due to large 
cohesive forces within the powder. It is accepted that a free-flowing powder should have a 
static angle of response less than 40˚ (237). The measured static angle of response for PLGA-
MDP-BSA microparticles is 37 ± 2˚, which is pretty close to 40˚. All these data suggest that 
PLGA microparticles have intermediate flow characteristics between free-flowing powder 
and poor-flowing powder.  
3.3.7 Effect of scanning rate on the glass transition temperature of microparticles 
The glass transition temperature (Tg) of microparticles was measured by DSC 
experiments. As shown in figure 3.4a, the Tg of PLGA microparicles increased with a faster 
scanning rate. A polynomial equation of the second order could better describe the change of 
Tg as a function of the scanning rate (figure 3.4aa). Similar phenomenon was observed for 
two other formulations: PLGA-MDP (figure 3.4b and bb), and PLGA-MDP-Ag85B (figure 
3.4c and cc). Such a dependence of Tg on the scanning rate could be explained by the fact 
that polymer may not respond quickly enough to the temperature change at fast ramping rate 
and thus displaying a lag of glass transition. Another interesting phenomenon that deserves 
attention is that DSC trace scanned for the first time at 10˚C/min does not overlap with the 
two traces from subsequent scans at the same ramping rate (figure 3.4a). This is also true for 
PLGA-MDP formulation (figure 3.4b) and PLGA-MDP-Ag85B formulation (figure 3.4c). 
One possible explanation is that the first DSC trace may represent the thermal history of 
microparticles (e.g. particle preparation and storage) whereas subsequent scans more likely 
represent the true material thermal behaviors.   
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3.3.8 Thermal characterization of PLGA-rAg formulations and MDP 
Since the glass transition temperature (Tg) is affected by the scanning rate and thermal 
history, a comparison of themograms for all six PLGA-rAg formulations was made at the 
same scanning rate of 10˚C/min after the second scan. Thermal analysis in figure 3.5a 
suggests that all formulations have very similar glass transition temperature of approximately 
44 ˚C. Detailed thermodynamic parameters were calculated and listed in table 3.3, which 
again showed almost equivalent thermal behavior for all formulations. The DSC thermogram 
of MDP was shown in figure 3.5b, which suggests that MDP has a melting temperature of 
approximately 125˚C and decomposes above 160˚C. 
3.3.9 Surface energy and charge characterization of microparticles 
The dispersive surface free energy of PLGA-MDP-BSA microparticles at 25 ˚C is 
31.65 mJ/m2 based on the IGC experiment as shown in figure 3.6. Surface free energy was 
calculated from the slope of the linear line covering a series of non-polar probes. 
Tetrahydrofuran (THF) and ethyl acetate were used as the polar probes, which showed a 
deviation from the linear line. This could be explained by the specific interaction between 
non-polar probes and PLGA microparticles. Surface charges of different PLGA-rAg 
formulations were also measured. These particles were negatively charged with a zeta 
potential of approximately -25 mV for all formulations (table 3.2, last column). The negative 
charge may be explained by the presence of ionized carboxyl groups on the microparticle 
surface (239).  
3.3.10 Effect of spray-drying on antigen integrity  
Antigen integrity may be compromised during spray-drying because of the process 
temperature and atomization pressure. SDS-PAGE was performed to investigate whether 
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spray drying or PLGA encapsulation compromised antigen integrity. As shown in figure 3.7, 
antigens prior to and post processing migrated to the same position. No degradation or 
truncated fragments were visible on the gel. However, this experiment was performed under 
reducing condition and, therefore, protein aggregation or structure change was not able to be 
detected by this assay. Alternatively, protein aggregation could be studied by size-exclusion 
chromatography while secondary/tertiary structure change could be studied by circular 
dichroism at far-UV or near-UV regions. 
3.3.11 Release profiles of microparticles 
The release of BSA and MDP from PLGA microparticles was characterized in a 10-
day period. As shown in figure 3.8, MDP exhibited almost complete burst release during the 
first half hour and no release from the subsequent sampling period. In contrast, BSA showed 
an initial burst release of 58% in the first half hour. Subsequent release exhibited a sustained 
manner with another 25% released during the first six-day period.  
3.4 Discussion 
The half-factorial design (25-1) reduced the number of spray-drying experiments from 
25 to 24. An advantage of this particular design lies in that it is a resolution V design, which 
means that both main effects and two-factor interactions are not confounded with each other. 
Particle size is the most important particle property which affects both lung deposition and 
alveolar macrophage uptake (192, 240-242). Hirota et al. reported that the most efficient 
delivery of rifampicin-loaded PLGA microspheres into alveolar macrophage was achieved by 
the phagocytosis of 3 µm particles (240). Therefore, a volume median diameter (VMD) of 3 
µm was selected as the optimization target. Statistical analysis showed that spray flow and 
inlet temperature were main contributors in determining particle size, by reducing droplet 
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size and facilitating evaporation rate respectively. Unexpectedly, atomization pressure 
showed minimal effect on particle size, which, however, did affect the maximal spray flow 
achieved at given pressure. With respect to particle yield, only spray flow and aspirator flow 
were significant contributors yet they exerted effects in the opposite direction. Smaller 
droplet was created by higher spray flow and thus collected less efficiently by the centrifugal 
force. Higher aspirator flow created greater centrifugal force and thus increasing the 
collection efficiency. Interestingly, no interaction between these two factors was observed. In 
addition to particle size and yield, the risk of thermal denaturation of antigens during spray 
drying should be considered. As described in the previous chapter, the melting temperature 
for Ag85B and TB10.4-Ag85B was 73.7˚C and 75.1˚C respectively. Therefore, the inlet 
temperature was kept as low as 55˚C to avoid potential antigen denaturation. Spray flow was 
maintained at high level (700L/h) for acceptable particle sizes. Maximal aspirator flow was 
used to compensate the low yield caused by high spray flow.  
PLGA particles were frequently spheres prepared by the double emulsion-solvent 
evaporation method (173, 243). In contrast, particles prepared by primary emulsion/spray 
drying method showed irregular surface morphology, in agreement with previous report (125, 
244). Such morphology may explain why particles with a VMD of 3µm had a mass median 
aerodynamic diameter (MMAD) of 3.3 µm. MMAD is correlated with VMD by multiplying 
the square root of particle density (244). Theoretically, the low density nature of PLGA 
particles should result in significantly smaller MMAD than VMD. However, the irregular 
surface morphology of PLGA particles may greatly increase the contact surface area of 
nearby particles, which again increased particle aggregation. These aggregates may be partly 
deaggregated after being discharged from the dry powder inhaler yet a complete dispersion 
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of particles was not achieved. This may also explain why few particles were deposited on 
stages with cutoff diameters less than 1.1µm (figure 3.3a), resulting in a distribution 
significantly deviating from an ideal log-normal distribution (figure 3.3b). Therefore, 
although PLGA particles prepared under optimized conditions showed narrow primary size 
distributions, they underwent incomplete deaggregation and existed as heterogeneous 
aggregates when delivered as aerosols. However, the MMAD and fine particle fraction of the 
aerosols were still acceptable and no excipients such as lactose were blended with PLGA 
particles.   
Thermal analyses of PLGA particles revealed a glass transition temperature (Tg) of 
approximately 44˚C. This temperature had important implications for particle storage. 
Polymers exist in rubbery state above Tg and have increased mobility compared to the glassy 
state (245). Polymer annealing would likely to occur above this temperature, which may 
affect particle morphology, microstructure and ultimately the release kinetics of encapsulated 
antigens (172). In order to minimize polymer annealing, PLGA particles should be stored 
below the Tg. In addition, moisture contact should be avoided since water serves as a 
plasticizer to lower the Tg (246). Therefore, PLGA particles are recommended to store with 
desiccant at either room temperature or in the fridge.  
Emulsifiers were not used to prepare the primary water-in-oil emulsion since they 
might influence phagocytosis (247-249). The high initial burst of MDP and protein from 
PLGA microparticles indicates that the primary emulsion was not sufficiently stable to retain 
the internal water phase. Therefore, it is possible that a portion of MDP and protein are 
associated with microparticle surfaces after spray drying via electrostatic and hydrophobic 
interactions (250). In addition, both MDP and BSA are water soluble molecules immiscible 
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with the PLGA polymer. Rather than dissolved in the matrix of PLGA, they were more likely 
to be dispersed in the matrix by occupying internal voids. Channels/pores may directly 
connect these voids to the particle surface, thus, leading to a high burst release before the 
bulk erosion of PLGA occurs (172). All these mechanisms may explain the high initial burst. 
Interestingly, the sustained release phase of BSA was absent for MDP. The nearly complete 
burst release of MDP may be partly explained by the rapid diffusion of this small molecule 
which has a molecular weight two orders of magnitude below BSA.  
3.5 Summary 
In this chapter, various recombinant antigens/antigen combinations purified from the 
previous chapter were encapsulated into PLGA microparticles (PLGA-rAg) by primary 
emulsion/spray drying method. By employing the concept of Quality-by-Design (QbD), the 
spray-drying parameters were successfully optimized with a half-factorial design to give the 
desired particle size and yield. Antigen integrity was not compromised by the formulation 
procedure (i.e. encapsulation, spray drying) as evidenced by the SDS-PAGE experiment. 
Manufactured microparticles have a mass median aerodynamic diameter around 3.3 µm 
suitable for pulmonary delivery and a volume median diameter of approximately 3 µm ideal 
for cellular uptake by alveolar macrophages. Thermal characterization suggested that these 
formulations should be better stored in the fridge with a desiccant present to avoid polymer 
plasticization. In summary, TB subunit vaccine formulations were prepared and extensively 
characterized with respect to their physicochemical properties. Highly reproducible PLGA-
rAg microparticles (subunit vaccines) were obtained, which sets the foundation for the next 
stage of vaccine development, that is, in vitro efficacy study which will be discussed in the 
next chapter.  
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Table 3.1 Half-factorial design (25-1) to optimize the spray-drying parameters 
  Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Res1 Res2 Res3 Res4
Run Atomization  Spray Flow Inlet Temp Aspirator Pump VMD Yield Mode Span
  Bar L/hr ˚C % ml/min µm %     
1 4 700 75 100 8 2.79  27.86  1 0.76 
2 3 550 65 75 6 3.87  42.32  2 0.92 
3 2 400 75 100 8 6.40  66.71  3 1.80 
4 2 400 55 50 8 9.58  46.57  2 1.56 
5 4 700 55 50 8 4.21  5.86  2 0.95 
6 2 700 75 100 4 2.98  22.14  2 1.10 
7 3 550 65 75 6 3.77  39.66  2 0.88 
8 4 700 75 50 4 3.26  6.43  2 0.78 
9 2 700 55 50 4 5.05  1.14  2 1.03 
10 2 400 75 50 4 5.74  47.00  2 1.25 
11 4 400 55 50 4 7.74  46.71  1 1.33 
12 4 400 75 50 8 6.28  45.14  1 1.37 
13 4 400 55 100 8 8.27  69.57  2 1.54 
14 3 550 65 75 6 3.75  39.32  2 0.91 
15 2 700 55 100 8 3.32  24.29  2 0.98 
16 2 700 75 50 8 4.27  2.86  2 0.89 
17 4 400 75 100 4 5.43  49.86  2 1.36 
18 2 400 55 100 4 7.19  64.57  3 1.62 
19 3 550 65 75 6 3.80  40.57  2 0.90 
20 4 700 55 100 4 3.06  18.71  1 0.65 
Labeled in red are four experimental runs to check reproducibility 
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Table 3.2 Particle size and surface charge characterization of spray-dried microparticles (n=3, 
mean ± SD) 
Formulation Dv,10 (µm) Dv,50 (µm) Dv,90 (µm) Zeta Potential (mV)
PLGA 2.36 ± 0.06 3.06 ± 0.06 4.34 ± 0.34 -26.8 ± 5.2 
PLGA-MDP 2.21 ± 0.07 2.97 ± 0.08 4.53 ± 0.26 -25.7 ± 4.7 
PLGA-MDP-Ag85B 2.16 ± 0.08 3.10 ± 0.10 4.26 ± 0.32 -25.2 ± 4.9 
PLGA-MDP-TB10.4 2.43 ± 0.05 3.02 ± 0.09 4.45 ± 0.28 -26.1 ± 5.0 
PLGA-MDP-TB10.4+Ag85B 2.27 ± 0.08 2.95 ± 0.12 4.58 ± 0.41 -24.4 ± 5.1 
PLGA-MDP-TB10.4-Ag85B 2.12 ± 0.06 3.08 ± 0.07 4.31 ± 0.35 -24.6 ± 3.9 
Dv, 10: diameter at the cumulative percentile of 10% 
Dv, 50: diameter at the cumulative percentile of 50% 
D v, 90: diameter at the cumulative percentile of 90% 
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Table 3.3 Thermal characterization of spray-dried microparticles (n=3, mean ± SD) 
Formulation ΔCp (J/g*˚C) Tg onset (˚C) Tg end (˚C) Tg (˚C) 
PLGA 0.478 ± 0.014 43.6 ± 0.2 46.7 ± 0.1 44.9 ± 0.1 
PLGA-MDP 0.476 ± 0.008 42.2 ± 0.1 45.9 ± 0.1 43.9 ± 0.1 
PLGA-MDP-Ag85B 0.495 ± 0.010 42.6 ± 0.1 45.8 ± 0.2 44.0 ± 0.2 
PLGA-MDP-TB10.4 0.451 ± 0.018 41.9 ± 0.2 45.5 ± 0.1 43.5 ± 0.1 
PLGA-MDP-TB10.4+Ag85B 0.456 ± 0.011 41.6 ± 0.2 45.1 ± 0.0 43.1 ± 0.0 
PLGA-MDP-TB10.4-Ag85B 0.473 ± 0.013 42.9 ± 0.3 45.6 ± 0.2 43.8 ± 0.3 
ΔCp: difference in heat capacity 
Tg: glass transition temperature 
Tg onset: the onset of glass transition temperature 
Tg end: the end of glass transition temperature 
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Figure 3.1 Optimization of spray-drying parameters. a, half-normal plot with respect to 
particle size (VMD); b, response surface plot of particle size (VMD) as a function of spray 
flow and inlet temperature; c, half-normal plot with respect to particle yield; d, desirability 
plot with respect to the simultaneous optimization of both particle size (VMD) and yield. 
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Figure 3.2 Morphology analyses of spray-dried microparticles. a, SEM images of seven 
batches of microparticles prepared according to the half-factorial design. Experimental run 
numbers labeled in figure 3.2a correspond to the run number in table 3.1; b, SEM images of 
six PLGA microparticle formulations with different antigens encapsulated. Particles were 
prepared under optimized spray-drying conditions. 
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 102
 
 
 
 
 
 
 
 
 
 
b 
 
 
 103
Figure 3.3 Aerodynamic particle size analysis of spray-dried microparticles prepared under 
optimized conditions. a, relative mass deposition measured by Andersen cascade impactor 
(n=3, mean ± SD); b, log-probability plot of the mass distribution shown in a. 
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Figure 3.4 Effect of scanning rate on the glass transition temperature (Tg) of three PLGA 
formulations. a, DSC thermograms of PLGA recorded at different scanning rates; aa, 
regression analysis of Tg as a function of the scanning rate for PLGA; b, DSC thermograms 
of PLGA-MDP recorded at different scanning rates; bb, regression analysis of Tg as a 
function of the scanning rate for PLGA-MDP; c, DSC thermograms of PLGA-MDP-Ag85B 
recorded at different scanning rates; cc, regression analysis of Tg as a function of the 
scanning rate for PLGA-MDP-Ag85B. 
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Figure 3.5 Thermal characterization of different PLGA-rAg formulations and MDP by DSC. 
a, DSC thermograms of different PLGA-rAg formulations (1: PLGA, 2: PLGA-MDP-
TB10.4-Ag85B, 3: PLGA-MDP-Ag85B, 4: PLGA-MDP-TB10.4+Ag85B, 5: PLGA-MDP-
TB10.4, 6: PLGA-MDP); b, DSC thermogram of MDP. The scanning rate was 10˚C/min. 
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Figure 3.6 Characterization of the surface free energy of microparticles. C6: hexane, C7: 
heptane, C8: octane, C9: nonane, C10: decane, THF: tetrahydrofuran. 
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Figure 3.7 SDS-PAGE analysis of antigen integrity after spray drying (lane 1: Ag85B (s: 
solution), 2: Ag85B (p: powder), 3: TB10.4 (s), 4: TB10.4 (p), 5: TB10.4+Ag85B (s), 6: 
TB10.4+Ag85B (p), 7: TB10.4-Ag85B (s), 8: TB10.4-Ag85B (p)). Difference in band 
intensity was due to different loading. 
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Figure 3.8 Release profile of microparticles (n=3, mean ± SD). a, MDP release profile; b, 
protein (BSA) release profile. 
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CHAPTER 4: STUDY OF IN VITRO IMMUNE RESPONSES INDUCED BY PLGA-
rAg MICROPARTICLES 
In the last chapter, various antigens and antigen combinations have been successfully 
encapsulated into PLGA microparticle formulations. In this chapter, we studied the in vitro 
immune responses induced by these formulations. Ag85B specific MHC II immune response 
was first studied to compare different formulations. The kinetic study was performed with 
two antigen combinations (TB10.4-Ag85B and Ag85B+TB10.4) to compare a) antigen blend 
vs. antigen fusion and b) particle formulation vs. solution formulation with respect to 
inducing Ag85B specific MHC II response. TB10.4 specific MHC I immune response was 
also studied in this chapter. Our data suggested that PLGA-rAg induced a predominant MHC 
II immune response in vitro. Among all formulations tested, powder formulations are much 
more powerful than solution formulations in terms of generating Ag85B specific MHC II 
response. Among powder formulations, Ag85B induced the strongest IL-2 response. A 
comparable IL-2 response was also induced by the antigen blend (Ag85B+TB10.4). However, 
this response was decreased more than 50% by the fusion antigen (TB10.4-Ag85B). Kinetic 
study again suggested that particle formulation induced a much stronger and prolonged 
Ag85B specific MHC II response compared to solution formulation. In addition, antigen 
blend showed continuously higher MHC II immune response than antigen fusion up to six 
days. The titration of TB10.4 immune response suggested a lack of sensitivity of this antigen 
presentation assay currently. 
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4.1 Introduction 
Cell mediated immune (CMI) response is believed to play a key role in TB control 
since Mycobacterium tuberculosis (MTB) is an intracellular organism (84). CD4+ and CD8+ 
T cells are two major mediators of CMI. CD4+ T cells recognize epitopes presented by major 
histocompatibility complex (MHC) class II molecules on the surface of antigen presenting 
cells (APCs). After activation, CD4+ T cells secret a spectrum of cytokines to act on MTB 
infected cells. There are numerous studies to support the pivotal role of CD4+ T cells in 
combating tuberculosis (28). One evidence comes from the increased susceptibility of 
subjects tested positive for human immunodeficiency virus (HIV) to tuberculosis (251). This 
was correlated to the diminished CD4+ T cells in HIV positive subjects. CD8+ T cells 
recognize MHC I epitopes presented by APCs. Activated CD8+ T cells not only secret 
cytokines but also induce cytotoxic T cell killing (84). However, in contrast to CD4+ T cells, 
the evidence for an essential role of CD8+ T cells in tuberculosis is not very compelling. For 
many years, researchers in this field almost ignored this T cell subset. This is because MTB 
lives primarily within vacuoles inside the cell rather than in the cytoplasm, which makes 
cross-presentation of antigens to CD8+ T cells less likely to happen. Recent studies with 
gene-disrupted mice provided stronger data supporting the role of CD8+ T cells in TB 
control (85, 86, 252-254). In one study, it was concluded that classically restricted (TAP-1 
dependent) CD8+ T cells contribute to in vivo protection against MTB (252). In another study, 
it has been shown that depletion of CD8+ T cells led to the reactivation of latent tuberculosis 
in a murine model (255). To develop new tuberculosis vaccines, it is widely accepted that 
CD4+ T cells should be targeted for vaccine design. In addition, more and more researchers 
believe that CD8+ T should also be considered in vaccine design (84).   
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In vitro antigen presentation assay serve as a surrogate assay to evaluate vaccine 
efficacy by employing APCs and T-hybridoma cell lines. The advantage of such assay lies in 
its capability to screen many different formulations in a fast and high-throughput manner 
without sacrificing animals. However, the limitation of this assay is two fold. First, only 
epitope specific response can be probed since T-hybridoma is developed against specific 
epitopes within antigens. Study of other epitopes requires the development of more T-
hybridoma cells lines restricted to each epitope. The second limitation is associated with the 
degree of in vitro-in vivo correlation of this assay, that is, to what extent the result from the in 
vitro assay can be correlated to the in vivo performance of vaccines. Despite these limitations, 
in vitro antigen presentation assays have been widely used to study vaccines in their early 
stage of development (125). 
An in vitro antigen presentation assay to study Ag85B specific MHC II immune 
response was developed in Dr. Boom’s group (256). This assay employed THP-1 cell as an 
APC and DB-1 T hybridoma as the CD4+ T cell line restricted to an MHC II epitope within 
Ag85B (Ag85B97-112) (256). THP-1 is a cell line of human origin which presents epitopes in 
the context of human MHC molecules. DB-1, a murine T-hybridoma, was derived from 
transgenic mice with human MHC genes. Therefore, DB-1 is restricted to human HLA 
alleles and responds to antigens presented by human APCs. Upon cell recognition, the 
activation of DB-1 leads to IL-2 secretion which can be easily quantified by IL-2 ELISA. 
This assay has been successfully employed to evaluate Ag85B specific MHC II immune 
response in vitro (125).  
The second assay was developed in Dr. Majlessi’s group to study TB10.4 specific 
MHC I immune response by employing Raw264.7 cell as the APC and YB8 cell as the CD8+ 
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T-hybridoma restricted to an MHC I epitope within TB10.4 (TB10.420-28) (136). Both 
Raw264.7 and YB8 cells are of mice origin and have been shown to be able to recognize 
each other when TB10.420-28 epitope was loaded onto the MHC I molecule of Raw264.7 cell. 
The activation of YB8 cells leads to the secretion of IL-2 into medium which can be easily 
quantified by ELISA.  
4.2 Materials and Methods 
Cells and media 
THP-1 cells (American Type Culture Collection) were maintained in RPMI 1640 
(Invitrogen Corp., Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) (Hyclone, Logan, UT), 50 µM 2-mercaptoethanol, 1 mM sodium pyruvate, 
nonessential amino acids, 1% antibiotics/antimycotics (Invitrogen Corp., Grand Island, NY). 
The CD4 T-hybridoma DB1 cells (kindly provided by Dr. W. Henry Boom, Case Western 
Reserve University) were derived from transgenic mice with human MHC genes for HLA-
DR1. They are restricted to human HLA alleles and respond to human MHC II molecules 
presenting Ag85B97–112 epitope. DB-1 cells were maintained in DMEM (Invitrogen Corp., 
Grand Island, NY) supplemented as indicated above (complete DMEM). Raw 264.7 cells 
(American Type Culture Collection, ATCC) were maintained in ATCC-formulated DMEM 
supplemented with 10% heat-inactivated FBS and 1% antibiotics/antimycotics. The CD8 T-
hybridoma YB8 cells (kindly provided by Dr. Laleh Majlessi, the Pasteur Institute) responds 
to mouse MHC I molecules presenting TB10.420-28 epitope. YB8 cells were maintained in 
ATCC-formulated DMEM supplemented with 10% heat-inactivated FBS and 1% 
antibiotics/antimycotics.  
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In vitro antigen presentation assay for Ag85B specific MHC II immune response 
Ag85B specific MHC II immune response was evaluated by a modified CD4 T cell 
hybridoma recognition assay as shown in figure 4.1a. THP-1 cells were incubated in 96-well 
flat-bottom plates (105 cells/well) with 20 ng/ml of phorbol myristate acetate (PMA, Sigma, 
St Louis, MO) for 24 h to promote adherence. Cells were washed once with PBS and 
incubated with 5 ng/ml of recombinant human IFN-γ (Endogen, Woburn, MA) for 24 h to 
promote differentiation. The cells were washed twice with PBS prior to antigen exposure. 
Antigen solutions were added into THP-1 cells at a concentration of 28ng/well for Ag85B, 
9.3ng/well for TB10.4, and 37.3ng/well for TB10.4-Ag85B (corresponds to 9.3ng/well 
TB10.4 and 28ng/well Ag85B). A blend of TB10.4 (9.3ng/well) and Ag85B (28ng/well) 
were also added into THP-1 cells for Ag85B+TB10.4. Antigens encapsulated in PLGA 
microparticles were added at corresponding same concentrations as antigen solutions. DB-1 
T-hybridoma cells (105 cells/well) were added 6 h later after antigen exposure. The cells 
were co-incubated at 37˚C for 24 h and supernatants were harvested to measure the amount 
of IL-2 secreted by DB-1 with mouse IL-2 ELISA (Biosource, Camarillo, CA). 
In vitro antigen presentation assay for TB10.4 specific MHC I immune response 
TB10.4 specific MHC I immune response was evaluated by a CD8 T cell hybridoma 
recognition assay as shown in figure 4.1b. Raw264.7 cells were seeded in 96-well flat-bottom 
plates (105 cells/well). Cells were incubated with 2 ng/ml of recombinant mouse IFN-γ 
(Endogen, Woburn, MA) for 24 h to promote differentiation. The cells were washed twice 
with PBS prior to antigen exposure. To titrate TB10.4 specific MHC I response, the 
homologous MHC I peptide (GYAGTLQSL, donation of Dr. Laleh Majlessi) was added to 
Raw264.7 cells at series of concentrations from 0.1ng/ml to 10µg/ml. Recombinant antigen 
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solutions were added at 5µg/well for Ag85B, 1.67µg/well for TB10.4, 6.67µg/well for 
TB10.4-Ag85B (corresponds to 1.67µg/well TB10.4 and 5µg/well Ag85B). A blend of 
TB10.4 (1.67µg/well) and Ag85B (5µg/well) were also added into Raw264.7 cells for 
Ag85B+TB10.4. Antigens encapsulated in PLGA microparticles were added to Raw264.7 
cells at a concentration of 28ng/well for Ag85B, 9.3ng/well for TB10.4, 
28ng/well+9.3ng/well for Ag85B+TB10.4, and 37.3ng/well for TB10.4-Ag85B (corresponds 
to 9.3ng/well TB10.4 and 28ng/well Ag85B). YB8 T-hybridoma cells (105 cells/well) were 
added 6 h later after antigen exposure. The cells were co-incubated at 37˚C for 24 h. 
Supernatants were harvested to measure the amount of IL-2 secreted by YB8 by mouse IL-2 
ELISA assay.  
Six-day antigen presentation assay for Ag85B specific MHC II immune response 
THP-1 cells (105 cells/well) were first stimulated with PMA and IFN-γas described 
previously. THP-1 cells were then pulsed with soluble TB10.4-Ag85B (6.67µg which 
corresponds to 1.67µg TB10.4 and 5µg Ag85B), Ag85B+TB10.4 (5µg Ag85B+1.67µg 
TB10.4), PLGA-MDP-TB10.4-Ag85B (37.3ng which corresponds to 9.3ng/well TB10.4 and 
28ng/well Ag85B) and PLGA-MDP-Ag85B+TB10.4 (28ng/well Ag85B and 9.3ng/well 
TB10.4) respectively followed by further incubation for 6 h. The cells were then washed 
extensively with PBS to remove the antigen solution or microparticles. DB-1 (105 cells/well) 
were added at each time point (from day 1 to 6). After 24 h co-incubation, the supernatant 
was harvested for mouse IL-2 ELISA assay. 
Six-day antigen presentation assay for TB10.4 specific MHC I immune response 
Raw264.7 cells were seeded at a concentration of 105 cells/well and stimulated with 
IFN-γ. Cells were then exposed to either soluble antigens or PLGA-rAgs at the same 
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concentrations as described previously. YB8 T-hybridoma cells (105 cells/well) were added 
after each interval (from day 1 to 6) and co-incubated at 37˚C for 24 h. Supernatant was 
harvested to measure the amount of IL-2 secreted by YB8.  
Statistical analysis 
ANOVA was used for statistical comparisons. The statistical significance was set at 
p<0.05.  
4.3 Results 
4.3.1 PLGA-rAg induced Ag85B specific MHC II immune response 
The effect of different formulations in generating Ag85B specific MHC II immune 
response was first studied after one-day antigen exposure as shown in figure 4.2. Not 
surprisingly, neither control PLGA microparticles nor PLGA-MDP-TB10.4 induced any 
detectable IL-2 secretion due to the absence of Ag85B specific epitope in these formulations. 
Among powder formulations, particles encapsulating Ag85B induced the strongest IL-2 
secretion. The blend of Ag85B and TB10.4 induced a comparable amount of IL-2 secretion 
(p>0.05). However, IL-2 elicited by the fusion antigen TB10.4-Ag85B was decreased by 
54.8% compared to the blend of Ag85B and TB10.4 (p<0.05). In contrast to the powder 
formulation, antigen solutions at the same concentration failed to induce IL-2 secretion for all 
tested antigen or antigen combinations. 
4.3.2 Kinetic study of PLGA-rAg induced Ag85B specific MHC II immune response 
Prolonged epitope presentation may be an advantageous property for a vaccine. The 
ability of PLGA-MDP-TB10.4-Ag85B (fusion) and PLGA-MDP-Ag85B+TB10.4 (blend) to 
present epitope over time was studied (figure 4.3). In this experiment, antigen solutions were 
used at a concentration of 178 fold higher since they failed to induce IL-2 secretion at the 
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same concentration as in the particle formulation (figure 4.2). Although a much higher 
concentration was used, IL-2 elicited by TB10.4-Ag85B or Ag85B+TB10.4 solution was 
continuously lower than that induced by the particle formulation. For antigen solutions, IL-2 
secretion peaked at day 2 yet decreased rapidly afterwards and only 20% of the peak IL-2 
concentration was observed at day 6. Ag85B+TB10.4 induced slightly better IL-2 secretion 
than TB10.4-Ag85B for the first three days and there was no significant difference between 
them after day 3. In contrast, both PLGA-MDP-TB10.4-Ag85B and PLGA-MDP-
Ag85B+TB10.4 induced a prolonged IL-2 secretion. IL-2 concentration was fairly stable in 
the first four days and declined afterwards. However, approximately 70% of the peak IL-2 
was still observed at day 6. Moreover, particle formulation of antigen blend (Ag85B+TB10.4) 
induced continuously higher concentration of IL-2 than antigen fusion (TB10.4-Ag85B).  
4.3.3 Study of TB10.4 specific MHC I immune response 
In order to study TB10.4 specific MHC I immune response, the in vitro antigen 
presentation assay was first titrated with the homologous TB10.4 peptide (GYAGTLQSL) at 
various concentrations. IL-2 secretion could only be induced at two highest concentrations of 
TB10.4 peptide. At a peptide concentration of 10µg/ml, IL-2 secretion was 74pg/ml; at a 
peptide concentration of 1µg/ml, IL-2 secretion was 25.5pg/ml (figure 4.4). All lower peptide 
concentrations failed to induce IL-2 secretion as indicated in figure 4.4 with IL-2 
concentrations below the lower limit of detection. Experiments with TB antigens suggest that 
neither antigen solutions nor PLGA-rAgs could induce IL-2 secretion either after one-day 
antigen exposure or six-day antigen exposure. A simple calculation of TB10.4 epitope 
concentration in PLGA-rAg microparticles indicates that such in vitro antigen presentation 
assay doesn’t have enough sensitivity to detect TB10.4 specific MHC I immune response.  
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4.4 Discussion 
Antigen solutions failed to elicit Ag85B specific IL-2 secretion at the same 
concentration as in the particle formulation. However, IL-2 was induced by antigen solutions 
at much higher concentration possibly because the cellular uptake of soluble antigens into 
endosomes is concentration dependent (257). Encapsulation of antigens into PLGA 
microparticles induced significant amount of IL-2 secretion even at very low antigen 
concentration. The data from figure 4.3 showed that the powder formulation of TB10.4-
Ag85B or Ag85B+TB10.4 induced a stronger response even at a concentration two orders of 
magnitude below the solution formulation. This suggests that PLGA microparticles increased 
the potency of encapsulated antigens. Similar observation has been reported with other 
antigens. For instance, intranasal instillation of encapsulated protective antigen in the 
microspheres resulted in a significant increase in the percentage of activated CD4+ T cells, 
whereas instillation of the soluble antigen failed to do so (258). The adjuvancy of 
microparticles can be partly attributable to the enhanced cellular uptake of these particles by 
antigen presenting cells (APCs). Microparticles less than 10 µm in diameter can be 
effectively taken up by macrophages or dendritic cells via active phagocytosis (258). In 
contrast, soluble antigens gain access to APCs primarily via pinocytosis which is a process 
utilized by cells to take up extracellular fluid. Therefore, encapsulated antigens can be more 
effectively and efficiently brought into the intracellular compartment by PLGA 
microparticles. At least two signals are required for naïve CD4+ T cells to be activated by 
APCs. Signal one is delivered by APCs by presenting class II epitope to CD4+ T cells, while 
only specific cytokines or co-stimulatory molecules on the surface of APCs can offer signal 
two. In the absence of signal two, signal one fails to activate naïve T cells. This may explain 
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why antigen solution poorly induced IL-2 secretion even at very high concentration since 
soluble antigen is less likely to generate sufficient signal two required for CD4+ T cell 
activation. In contrast, PLGA microparticles have been shown to significantly increase the 
expression of co-stimulatory molecules on the surface of APCs (259).  
Compared to Ag85B alone or antigen blend, there is a more than 50% decrease in IL-2 
secretion induced by the fusion antigen TB10.4-Ag85B. A possible explanation for this 
observation is that the fusion of TB10.4 and Ag85B alters the structure of the fusion antigen 
and may affect the processing of Ag85B epitopes inside endosomes, which may ultimately 
affect Ag85B specific MHC II epitope presentation.  
The kinetic study of Ag85B specific MHC II immune response illustrated another 
advantage of microparticle formulation, that is, prolonged epitope presentation and IL-2 
secretion. This prolonged immune activation may be correlated to the sustained release of 
proteins from PLGA microparticles. The rapid decrease of IL-2 secretion observed with the 
solution formulation can be explained by the fact that soluble antigens are quickly used up 
after cellular uptake via pinocytosis. The results from this in vitro study also have important 
implications for the potential in vivo performance of PLGA-rAg. In order for naïve T cells to 
be activated, APCs bearing TB epitopes have to transit from the place where they receive the 
vaccine to the local lymph node and present epitopes to the T cells (28). Epitope presentation 
should be available once APCs reach the local lymph node. In addition, a continuous 
presentation for a certain period of time may be required for a successful T cell activation. 
Antigen given in a solution formulation may compromise the continuous epitope presentation 
due to rapid decrease of antigen concentration intracellularly. However, prolonged epitope 
presentation was promoted by the PLGA microparticle formulation, which favors the T cell 
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activation.   
PLGA-rAg induced TB10.4 specific MHC I immune response can not be evaluated in 
the present study due to the lack of sensitivity of TB10.4 antigen presentation assay. Efforts 
in the future should address this problem by either improving assay sensitivity or increasing 
the loading of encapsulated antigens.  
Figure 4.5 illustrated our current knowledge of MHC I and MHC II antigen 
presentation pathways. Soluble antigens and PLGA-rAgs are taken up by antigen presenting 
cells (APCs) via pinocytosis and phagocytosis respectively. They are processed by the MHC 
class II pathway in the endosome/lysosome or phagolysosome. MHC II epitope loading 
occurs in these cellular compartments. Epitope loaded MHC II complex is then transported 
onto the surface of APCs, where it recognizes DB-1 T-hybridoma and induces IL-2 secretion. 
In order for MHC I epitope presentation to occur, soluble antigens or PLGA-rAgs have to 
leave the MHC II compartment and enter into the cytoplasm, where antigens are processed 
by the proteasome. Transporter associated with antigen processing (TAP) assists in the 
translocation of processed epitopes into the lumen of endoplasmic reticulum for MHC I 
epitope loading. Epitope loaded MHC I complex is then transported onto the surface of APCs, 
where it can recognize YB8 T-hybridoma. This process is termed MHC I epitope 
presentation, which is the basis of TB10.4 specific in vitro antigen presentation assay. 
TB10.4 specific MHC I response was observed when two highest concentrations (10µg/ml 
and 1µg/ml) of homologous peptide were added to antigen presenting cells. Such epitope 
presentation does not require intracellular processing because the peptide (MHC I epitope) 
was directly loaded onto the MHC I molecule extracellularly. 
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4.5 Summary 
The efficacy of PLGA-rAgs was evaluated by in vitro antigen presentation assays in 
this chapter. A predominant Ag85B specific MHC II immune response was observed for 
formulations that contain Ag85B. Powder formulation is much more potent than the solution 
formulation to induce Ag85B specific MHC II response. Moreover, a prolonged immune 
response was observed for the powder formulation. Antigen blend (Ag85B+TB10.4) showed 
much better Ag85B specific MHC II response than antigen fusion (TB10.4-Ag85B). With all 
current information, a recommendation was proposed that antigen blend in the particle 
formulation should better be used for multiple-antigen TB subunit vaccines. 
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Figure 4.1 Schematic description of two in vitro antigen presentation assays. a, Ag85B 
specific MHC II epitope presentation; b, TB10.4 specific MHC I epitope presentation.  
 
a 
 
 
b 
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Figure 4.2 Comparison of Ag85B specific MHC II immune response induced by different 
formulations after 1-day antigen exposure. (Powder (black bar): antigens encapsulated in 
PLGA microparticles; Solution (grey bar): antigen solutions, n=3, mean ± SD, Ctrl: PLGA 
microparticles w/o antigen, Ag85B: PLGA-MDP-Ag85B, TB10.4: PLGA-MDP-TB10.4, 
A+T: PLGA-MDP-Ag85B+TB10.4, T-A: PLGA-MDP-TB10.4-Ag85B). Antigen solutions 
failed to induce IL-2 response and, therefore, no grey bar. Antigen concentration was the 
same for both powder and solution formulations (Ag85B:28ng/well, TB10.4: 9.3ng/well, 
TB10.4-Ag85B: 37.3ng/well).  
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Figure 4.3 Kinetic study of Ag85B specific MHC II immune response. (Powder: TB10.4-
Ag85B (37.3ng/well) or Ag85B (28ng/well) +TB10.4 (9.3ng/well) encapsulated in PLGA 
microparticles; Solution: TB10.4-Ag85B (6.67µg/well) or Ag85B (5.0µg/well) +TB10.4 
(1.67µg/well), n=3, mean ± SD) 
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Figure 4.4 Titration of TB10.4 specific MHC I response with various concentrations of 
homologous TB10.4 peptide (n=3, mean ± SD). LLD: lower limit of detection. 
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Figure 4.5 MHC I and II antigen presentation pathways 
 
CHAPTER 5: DEVELOPMENT OF A PARTICLE SIZE COMPARATOR TO 
EVALUATE BATCH-TO-BATCH REPRODUCIBILITY OF INHALATION 
PRODUCTS 
In previous chapters, recombinant TB antigens were designed and characterized; TB 
subunit vaccines were prepared by encapsulating recombinant antigens into PLGA 
microparticles; the efficacy of TB vaccines was evaluated by in vitro antigen presentation 
assays. This vaccine is intended to be delivered to the lungs via inhalation aerosols. Lung 
delivery requires an aerodynamic diameter in the range between 1 and 5 µm. Particles with 
larger sizes tend to deposit in the mouth and upper airways, whereas smaller particles tend to 
penetrate into deep lungs. Therefore, aerodynamic particle size distribution (APSD) of an 
aerosol is the key factor that determines mass deposition in the lungs. Cascade impaction 
experiment is routinely performed to characterize the aerodynamic size property of an 
aerosol. Typical experiment yields a series of mass deposition on different stages with 
defined aerodynamic cutoff size, once plotted, giving an APSD profile. A change of APSD 
profile may shift drug/vaccine deposition from the deep lung to the upper respiratory tract or 
even to the mouth and throat, which may eventually affect the site of action. Therefore, 
batch-to-batch reproducibility (equivalent APSD profiles) should be routinely examined to 
ensure the quality of an inhalation product. In the second scenario, if drug/vaccine 
manufacturers plan to develop a generic version of an inhalation product, an APSD profile 
sufficiently similar to that of the original product should be shown as an evidence of 
equivalence.  
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The purpose of this chapter is to develop a particle size comparator to evaluate batch-
to-batch reproducibility or equivalence since there is no well-established comparator 
available so far. We investigated the performance of multivariate data analysis, especially 
orthogonal partial least square (OPLS) analysis, as a semi-quantitative tool to evaluate the 
reproducibility or equivalence of APSD profiles of orally inhaled and nasal drug products 
(OINDP). Monte Carlo simulation was employed to reconstitute APSD profiles based on 55 
realistic scenarios proposed by the Product Quality Research Institute (PQRI) working group. 
OPLS analyses with different data pretreatment methods were performed on each of the 
reconstituted profiles. Compared to unit-variance scaling, equivalence determined based on 
OPLS analysis with Pareto scaling was shown to be more consistent with the working group 
assessment. Chi-square statistics was employed to compare the performance of OPLS 
analysis (Pareto scaling) with that of the combination test (i.e. chi-square ratio statistics and 
population bioequivalence test for impactor-sized mass) in terms of achieving greater 
consistency with the working group evaluation. A p-value of 0.036 suggested that OPLS 
analysis with Pareto scaling may be more predictive than the combination test with respect to 
consistency. Furthermore, OPLS analysis may also be employed to analyze part of the APSD 
profiles that contribute to the calculation of the mass median aerodynamic diameter 
(MMAD). Our results show that OPLS analysis performed on partial deposition sites doesn’t 
interfere with the performance on all deposition sites. 
5.1 Introduction 
It is generally believed that aerosol particles greater than 10µm in aerodynamic 
diameter deposit primarily in the throat and are swallowed subsequently rather than reaching 
the lungs (196). Lung delivery requires particle size in the range of 1-5 µm (260-262), which 
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deposit either centrally or peripherally in the lungs depending on particle size. Therefore, 
aerodynamic particle size distribution (APSD) is an important in vitro characteristic of orally 
inhaled and nasal drug product (OINDP) because of a plausible link between particle size and 
eventual deposition in the respiratory tract. The interest to develop a statistical method to 
determine in vitro bioequivalence came from the practical need from both the regulators and 
the drug manufacturer. Once innovator companies make changes to a drug product or drug 
manufacturers plan to develop a generic version of a drug product, evidence should be 
provided to the regulators that the new or modified product has an APSD profiles sufficiently 
similar to that of the original product.  
The chi-square ratio statistic (263) proposed in the 1999 US FDA guidance (40, 52) 
was developed using Anderson 8-stage cascade impactor (38) applied to albuterol metered-
dose inhaler data. In order to study this test’s applicability to a broad range of OINDP 
profiles, a working group involving scientists from industry, academia, FDA and US 
pharmacopeia was established through the Product Quality Research Institute (PQRI) (264). 
The working group expended a great effort in investigating this chi-square ratio statistics. 
The work began with developing a simulation method capable of modeling APSD profiles 
and translating the chi-square ratio statistics proposed by the FDA into an executable 
algorithm (44). The working group first studied the stability of the chi-square ratio test on 
pairs of identical profiles, which showed that the stability increased as the number of stages 
increases and less stable for profiles that are common to metered-dose inhalers (MDIs) and 
dry powder inhalers (DPIs) (194). The next study focused on pairs of profiles differing in a 
specified and systematic way on a single deposition site, which gave rise to a total number of 
38 scenarios (39, 194). The findings from this study led the working group supplementing the 
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chi-square ratio statistics with a population bioequivalence (PBE) test based on impactor-
sized mass (ISM) (45) in order to increase the discriminating ability of the overall statistical 
procedure (195). Based on the study of this combination test (i.e. chi-square ratio test and 
ISM-PBE test), the working group produced a final report in 2007 on a statistical procedure 
for determining equivalence (195). Due to the deficiencies of the combination test, no 
recommendations were made by the working group for APSD profiles comparison.  
In this chapter, we proposed another method to evaluate the batch-to-batch 
reproducibility or equivalence of APSD profiles. The new method is based on multivariate 
data analysis, especially orthogonal partial least square (OPLS) analysis. Multivariate data 
analysis can be generally divided into two categories (265). One is the unsupervised method 
such as principal component analysis (PCA). The other one is the supervised method such as 
partial least square (PLS) analysis and orthogonal partial least square analysis. Principal 
component analysis is different from orthogonal partial least square analysis in that a priori 
knowledge of the identity of the profiles was not employed when patterns are assessed (265). 
Principal component analysis is generally employed as a pattern recognition tool before 
proceeding to the supervised method such as OPLS. Orthogonal partial least square analysis 
relates a matrix containing independent variables such as mass deposition on each deposition 
site to a matrix containing dependent variables such as profile membership. OPLS analysis is 
frequently employed as a discriminant analysis to retrieve information lying in independent 
variables that may result in class separation. However, the main objective is not to use OPLS 
analysis to dissect out the independent variables contributing to class separation. Rather, the 
capability to detect difference between test and reference profiles revealed by OPLS model 
fitting is our primary goal. There are three reasons for proposing this method: 1) an APSD 
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profile contains information from multiple deposition sites and, therefore, is a multivariate 
measurement (196); 2) mass deposition on each stage is not independent from each other. It 
has been suggested that the deposition on different stages may co-vary between each other 
(196) and this was indeed considered in the Monte Carlo simulation of 55 realistic scenarios 
provided by the working group (41, 42); 3) principal components calculated in the OPLS 
analysis are all orthogonal and thus can resolve the issue of covariance (265). We began our 
work with first reconstituting 55 realistic scenarios by Monte Carlo simulation. Profiles 
generated were subjected to OPLS analysis to derive a parameter Eq (standing for 
equivalence) as described in the methods. Finally, we compared the performance of the 
OPLS analysis with that of the combination test in terms of achieving greater consistency 
with the working group evaluation.  
5.2 Methods 
Monte Carlo Simulation 
Monte Carlo simulation was performed in ADAPT II (University of Southern 
California) to reconstitute 55 aerodynamic particle size distribution (APSD) profiles provided 
by the Product Quality Research Institute (PQRI) working group (41, 42, 195). Information 
about the mean and standard deviation for mass deposition on each site were readily 
available from the profiles provided. They were used as parameters for Monte Carlo 
simulation in ADAPT II. Population simulation with output noise assuming normal 
distribution of mass deposition on each stage was adopted. Monte Carlo simulations with a 
number of 5,000 were performed and repeated three times for each of the 55 realistic 
scenarios of aerodynamic particle size distribution profiles. The averages were taken for each 
scenario. In some cases simulations with different numbers were performed for the purpose 
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of demonstration. Data generated were organized in Microsoft® Excel for each scenario.  
Multivariate Data Analysis 
Orthogonal partial least square (OPLS) analysis was carried out in SIMCA-P 11.5 
(Umetrics) and was employed to compare test profiles with reference profiles in all scenarios. 
Mass deposition data (X variables) were pretreated with either Pareto scaling or unit-variance 
scaling in addition to mean centering. Reference and test profiles are coded as 0 and 1 (Y 
variables) respectively. In order to normalize mass deposition, absolute mass data were first 
normalized to percent mass deposition data in Excel before proceeding to OPLS analysis. 
The first two principal components are calculated in all cases for the convenience of plotting. 
However, the R2 for OPLS model fitting based on the first principal component was recorded. 
Eq was defined as equal to 1-R2 and served as a measure of equivalence between test and 
reference profiles for all 55 scenarios. 
Chi-square Test 
Chi-square test was carried out in Minitab 14.1 (Minitab Inc.) to compare OPLS 
analysis (with Pareto scaling) with the combination test proposed by the Food and Drug 
Administration (FDA) and the PQRI working group. The difference (Δ ) between the 
working group evaluation and Eq (by OPLS analysis) or proportion (by the combination test) 
was divided into three categories: △≥ 0.5, 0.3 ≤△< 0.5 and △< 0.3. A p-value less than 
0.05 was considered as statistically significant.  
5.3 Results and Discussions 
5.3.1 Monte Carlo simulation to recover 55 realistic scenarios of aerodynamic particle 
size distribution profiles 
All 55 realistic scenarios have been simulated by Monte Carlo simulation. Among 
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these profiles, only two scenarios were chosen to represent significant variability in the upper 
deposition sites between test and reference profiles in scenario 13c (figure 5.1a) as apposed 
to in the lower deposition sites in scenario 2bb2 (figure 5.1b). Profiles simulated here are 
slightly different in appearance from those provided by the Product Quality Research 
Institute (PQRI) working group (41, 42, 195). This is possibly due to the inherent variability 
of Monte Carlo simulation. A simulation number of 30 was chosen for both scenarios.  
5.3.2 Comparison of chi-square ratio statistics and orthogonal partial least square 
analysis with respect to profile comparison 
It was suggested that 30 each reference and test inhalers should be sampled 
individually and subject to chi-square ratio statistics (194-196). A sample size of 30 was 
considered necessary to represent the random sampling of a population of dry powder 
inhalers or metered-dose inhalers manufactured. In addition, this is also a practical number, 
which requires a considerable yet manageable amount of sampling work. Figure 5.2a shows 
the flowchart of the chi-square ratio statistics. Thirty reference and test inhalers are randomly 
sampled from corresponding populations (e.g. 5,000). Sample profiles for these 30 inhalers 
are collected and then subject to chi-square ratio statistics. In an attempt to set up an 
appropriate critical value for the chi-square ratio statistics, such statistical testing based on 30 
samples is repeated hundreds of thousands of times to obtain a distribution of statistics, upon 
which a reasonable critical value may be chosen. It should be noted that the statistics 
obtained based on a sample size of 30 actually gives the possibility of equivalence between 
test and reference profiles from two corresponding populations rather than two samples. In 
contrast to chi-square ratio statistics, figure 5.2b shows the rationale for orthogonal partial 
least square (OPLS) analysis as an analytical tool to judge reproducibility or equivalence 
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between two populations. First, it should be emphasized that the method developed based on 
OPLS analysis is an analytical tool rather than a statistical test. There is no p-value associated 
with this method. R2 or its derivative Eq was instead used as an indicator of reproducibility or 
equivalence between test and reference profiles (see explanation in the following section). 
This method also begins with a random sampling of 30 samples in consistent with the chi-
square ratio statistics. The sample mean and standard deviation of mass at each deposition 
site was calculated based on impactor data from these 30 samples. Rather than statistical 
testing, the sample mean and standard deviation was used for Monte Carlo simulation to 
obtain simulated population profiles. Ideally, the population mean and standard deviation of 
mass deposition should be used for the population simulation. However, these numbers won’t 
be known until all the inhalers are characterized, which are not practical. Therefore, we 
consider a sample size of 30 as both necessary and practical since the more samples collected 
the more accurately sample mean and standard deviation can represent population mean and 
standard deviation. The size for population simulation was also studied, which suggests that a 
population size of 5,000 may be relevant and more importantly the R2 based on this size 
tends to stabilize. Consequently, the R2 (or its derivative Eq) for OPLS model fitting based on 
5,000 profiles may serve as an indicator of reproducibility or equivalence between test and 
reference populations of at least this size.  
5.3.3 Orthogonal partial least square analysis of test and reference profiles 
Profiles generated by Monte Carlo simulation were analyzed by OPLS analysis as 
described in methods. OPLS places the first principal component onto the largest difference 
between test and reference profiles. The successive principal components will span the 
difference which is not represented by the preceding component (265). Therefore, OPLS 
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score plot consisting of the first two components provides a visual impression of the 
comparability between test and reference profiles. The larger the difference between the test 
and reference profiles, the further they are separated from each other on the first principal 
component. However, this separation is only a qualitative impression rather than a 
quantitative measure. In order to derive a semi-quantitative parameter which may serve as a 
measure of equivalence, R2 for OPLS model fitting (based on the first principal component) 
was initially selected. R2 represents how well the model fits the data or how much variability 
in the data can be explained by the model (265). R2 equals to 0 if test and reference profiles 
are identical; on the other hand, R2 approaches 1 when test profiles are completely different 
from reference profiles assuming a right model is used. Apart from model fitting, R2 also 
depends on the variability in the data as will be seen in the following section where different 
data pretreatment methods (i.e. different treatment of the variability) were employed. Based 
on this rationale, we define a parameter Eq = 1-R2, which may be considered as a measure of 
equivalence or comparability for the test and reference profiles. Strictly speaking, Eq is not a 
statistical value that can be used for statistical testing but rather a semi-quantitative value 
defined by us for the purpose of interpretive evaluation of aerodynamic particle size 
distribution (APSD) profiles.  
5.3.4 Studying 55 realistic scenarios with orthogonal partial least square analysis 
Based on the description above and in the methods, OPLS analysis of 55 realistic 
scenarios was carried out with different data pretreatment methods. The absolute mass 
deposition data can be used as is or normalized to percent mass deposition data. All the data 
were mean centered to avoid greater deposition on particular sites dominating the whole 
distribution. To account for the variance on each deposition site, two scaling methods were 
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employed. One is unit-variance (UV) scaling in which the base weight is computed as the 
reciprocal of standard deviation and the other is Pareto scaling which gives the weight of the 
reciprocal of square root of standard deviation (265). Pareto scaling is between no scaling 
and UV scaling and gives the variable under evaluation a variance equal to its standard 
deviation instead of unit variance. The effect of both scaling methods was investigated 
comprehensively.  
Before performing OPLS analysis on all realistic scenarios, we carried out a test 
analysis on the feasibility of this method. In figure 5.3a, Monte Carlo simulations were 
performed twice (5,000 for each) based on parameters from reference profiles in scenario 1a. 
The first simulation generates 5,000 reference profiles and the second simulation generates 
another 5,000 reference profiles yet considered as test profiles. Predictably, OPLS analysis 
on such reference and test profiles should yield a R2 approaching 0 and both profiles should 
be completely mixed without any separation on the first principal component in the score plot. 
Indeed, we observed the same phenomenon as shown in figure 5.3a. Then OPLS analysis 
was performed for all realistic scenarios. Figure 5.3b-e represents such analysis for scenario 
1a-1d, which was considered by the working group with decreasing similarity between test 
and reference profiles. OPLS analysis showed the same trend as evidenced by more and more 
separation between profiles on the first principal component in the score plot (figure 5.3b-e).  
5.3.5 Effect of different data pretreatment methods on the performance of orthogonal 
partial least square analysis 
The Eq value (defined as 1-R2) for each scenario computed by OPLS analysis based on 
different data pretreatment methods, the probability of equivalence derived from the 
combination test (chi-square+ISM-PBE), and the working group evaluation of equivalence 
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are all tabulated in table 5.1. It has been proposed by the working group that agreement to 
within 50% (or 0.5) of the overall frequency of equivalence declarations between the 
working group and the combination test was interpreted as adequate for the statistical 
procedure to make correct decisions (195). In cases where the differences were more than 0.5, 
the combination test was considered not be able to make the correct decisions and inputs 
from reviewers’ experience were necessary to determine APSD equivalence. Similarly, we 
extended this criterion to the performance of the OPLS analysis (i.e. the difference between 
Eq value and the working group assessment less than 0.5 was considered adequate). The 
differences between the working group evaluation and the combination test are plotted in 
figure 5.4a. The difference between the working group assessment and OPLS analysis for 
each of the data pretreatment methods are plotted in figure 5.4b-e. We noticed that OPLS 
analysis with Pareto scaling works better than UV scaling as evidenced by less 
inconsistencies no matter whether absolute or normalized mass was used. However, UV 
scaling on normalized mass works better than the same scaling on absolute mass. The effect 
of different scaling methods on multivariate data analysis has been studied in other fields 
(266). Van de Berg showed in his metabolomic study that Pareto scaling, compared to unit-
variance scaling, was more stable in terms of generating reliable rank of the most important 
metabolites (267). Noda examined two scaling techniques (Pareto scaling vs. unit-variance 
scaling) to enhance two-dimensional correlation Raman spectra and concluded that Pareto 
scaling was able to circumvent the amplification of noise by retaining a portion of magnitude 
information (268). Therefore, it is not to our surprise that Pareto scaling works better than 
UV scaling since the magnitude information about the mass deposition on each site was 
retained. Moreover, this magnitude information was not changed from absolute to 
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normalized mass deposition data when used with Pareto scaling. However, the inaccuracy of 
mass deposition may be amplified to a different extent with or without normalization since 
the magnitude information was completely lost in unit-variance scaling. This may provide a 
possible explanation for the different performance on normalized or absolute mass data with 
UV scaling. Finally, we compared the performance of the combination test with that of OPLS 
analysis based on Pareto scaling by chi-square statistical test according to the criterion 
proposed in the methods (figure 5.5). The p-value (0.036<0.05) suggested that multivariate 
data analysis may be more indicative than the combination test for the purpose of interpretive 
evaluation of reproducibility or equivalence of APSD profiles.  
5.3.6 Three scenarios mis-predicted by orthogonal partial least square analysis 
When OPLS analysis with Pareto Scaling was employed, three scenarios with 
differences exceeding 0.5 are 12a2, 12a3 and 12b1 (figure 5.4c and table 5.1). An impression 
of equivalent test and reference profiles was given when these scenarios were reconstituted 
by Monte Carlo simulation. However, OPLS analysis clearly separated the test profiles from 
the reference profiles in the score plot with large R2 value (table 5.1) possibly because of 
very small standard deviation relative to the mean in certain deposition sites. OPLS analysis 
appeared to be sensitive to small standard deviation/mean ratios while at this stage no efforts 
haven been expended in correlating the sensitivity of OPLS analysis to the standard 
deviation/mean ratios. On the other hand, the combination test predicts pretty well in these 
three scenarios (figure 5.4a and table 5.1).  
5.3.7 Orthogonal partial least square analysis of mass deposition on partial deposition 
sites 
Comparison based on the whole deposition profiles was recommended by the FDA and 
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PQRI working group since a change in mass deposition outside the impactor may affect the 
performance of the drug product (196). However, researchers are sometimes interested in 
only a part of the APSD profiles (e.g. mass deposition inside impactors and on the filter 
(192) ) for two reasons: 1) there was no clear cut-off size for mass deposition outside the 
impactor; 2) mass deposition on these sites is important for the calculation of mass median 
aerodynamic diameter (MMAD). Therefore, we performed OPLS analysis with Pareto 
scaling on mass deposition profiles inside the impactor for all 55 realistic scenarios. Then, we 
compared the R2 obtained from partial deposition sites with that from all deposition sites. In 
scenario 13c, the R2 for partial sites is 0.08 as opposed to 0.51 for all sites. This difference 
may be explained by the greater difference between test and reference profiles outside the 
impactor while the difference inside the impactor is very small (figure 5.1a). In scenario 2bb2, 
the major difference comes from the deposition inside the impactor while little difference 
exists outside the impactor. The R2 for partial sites is 0.46 and 0.48 for all sites. This modest 
increase in R2 is due to a mild contribution of small difference from deposition sites outside 
the impactor (figure 5.1b). Our analyses indicate that OPLS analysis performed on partial 
deposition sites doesn’t interfere with the performance on all deposition sites.  
5.4 Summary 
Multivariate data analysis may open a new way for scientists in the field of 
pharmaceutical aerosol sciences to evaluate the batch-to-batch reproducibility or equivalence 
of aerodynamic particle size distribution profiles. Our study shows that orthogonal partial 
least square analysis coupled with Pareto scaling works best among all the data pretreatment 
methods investigated. It is not our intention to replace the combination test proposed by the 
FDA and PQRI working group; rather this new method may serve as a semi-quantitative tool 
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to evaluate particle size distribution profiles before a robust and well-established statistical 
test can be proposed. In addition, orthogonal partial least square analysis should be 
performed with caution in certain situations where the standard deviation/mean ratios are 
relatively small where the combination test or more statistically relevant test should be 
considered.  
 142
Table 5.1 Equivalence value determined from different analysis methods and the working 
group evaluation. Column I: scenario ID. Column II-V: equivalence (Eq value) determined 
based on orthogonal partial least square analysis with different data pretreatment methods. 
Eq values in column II-V are the average of three individual simulations (n=3, 5,000 each). 
Column VI: likelihood of equivalence based on the combination test proposed by the US 
FDA and the PQRI working group. Column VII: equivalence evaluated by the working group. 
The likelihood of equivalence from the working group evaluation and the combination test 
were retrieved from reference 195. 
Scenario UV-Abs Par-Abs UV-Nor Par-Nor Chi-2+ISM WG 
1a 0.64  0.73  0.68  0.77  0.70  1.00  
1b 0.53  0.62  0.60  0.65  0.22  0.79  
1c 0.34  0.46  0.42  0.47  0.01  0.07  
1d 0.20  0.28  0.20  0.26  0.00  0.00  
1aa 0.76  0.86  0.79  0.87  0.81  1.00  
1bb 0.55  0.61  0.56  0.60  0.48  0.79  
1cc 0.39  0.51  0.47  0.51  0.01  0.36  
1dd 0.20  0.29  0.25  0.28  0.00  0.00  
1ee 0.18  0.25  0.20  0.22  0.00  0.00  
2a 0.67  0.74  0.68  0.78  0.89  0.79  
2b 0.45  0.51  0.46  0.53  0.92  0.50  
2c 0.43  0.46  0.44  0.47  0.89  0.21  
2aa1 0.66  0.70  0.67  0.70  0.88  0.71  
2bb1 0.47  0.51  0.49  0.60  0.80  0.64  
2cc1 0.48  0.57  0.54  0.60  0.74  0.50  
2dd1 0.46  0.55  0.48  0.54  0.89  0.29  
2aa2 0.49  0.52  0.49  0.53  0.90  0.64  
2bb2 0.48  0.51  0.49  0.52  0.89  0.29  
2cc2 0.41  0.41  0.42  0.43  0.94  0.14  
4a 0.90  0.93  0.91  0.94  0.88  1.00  
4b 0.07  0.51  0.19  0.51  0.89  1.00  
4c 0.08  0.26  0.11  0.26  0.68  0.21  
4d 0.07  0.21  0.09  0.19  0.45  0.14  
5a 0.72  0.78  0.74  0.80  0.89  0.93  
5b 0.35  0.42  0.39  0.44  0.86  0.86  
5c 0.12  0.16  0.15  0.16  0.50  0.29  
7a 0.21  0.21  0.23  0.23  0.89  0.29  
7b 0.44  0.48  0.49  0.53  0.95  0.50  
7c 0.71  0.76  0.74  0.79  0.92  0.93  
10a 0.18  0.17  0.17  0.16  1.00  0.14  
10b 0.20  0.17  0.20  0.17  1.00  0.29  
10c 0.41  0.41  0.41  0.41  1.00  0.50  
10d 0.71  0.73  0.73  0.74  1.00  1.00  
11a 0.36  0.39  0.49  0.51  0.78  0.64  
11b 0.59  0.62  0.72  0.74  1.00  1.00  
11c 0.82  0.84  0.83  0.87  1.00  1.00  
12a0 0.05  0.06  0.05  0.06  0.07  0.07  
12a1 0.07  0.09  0.07  0.10  0.82  0.14  
12a2 0.10  0.15  0.10  0.16  1.00  0.86  
12a3 0.12  0.27  0.13  0.29  1.00  1.00  
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12b0 0.11  0.16  0.11  0.17  0.03  0.29  
12b1 0.17  0.26  0.19  0.31  0.93  0.86  
12b2 0.25  0.44  0.27  0.47  1.00  0.86  
12b3 0.31  0.55  0.33  0.56  1.00  1.00  
13a 0.46  0.71  0.69  0.74  0.40  1.00  
13b 0.29  0.60  0.43  0.65  0.38  0.57  
13c 0.22  0.41  0.24  0.49  0.26  0.36  
13d 0.12  0.38  0.29  0.43  0.00  0.21  
13e 0.07  0.35  0.23  0.44  0.00  0.07  
13f 0.38  0.87  0.50  0.90  0.84  0.93  
13g 0.29  0.71  0.42  0.75  0.83  0.50  
14a1 0.06  0.20  0.07  0.13  0.00  0.00  
14a2 0.06  0.25  0.09  0.18  0.00  0.07  
14a3 0.07  0.23  0.12  0.22  0.03  0.43  
14a4 0.07  0.26  0.15  0.28  0.37  0.71  
UV-Abs: absolute mass data were pretreated with unit-variance scaling  
Par-Abs: absolute mass data were pretreated with Pareto scaling 
UV-Nor: normalized percent mass data were pretreated with unit-variance scaling 
Par-Nor: normalized percent mass data were pretreated with Pareto scaling 
Chi-2+ISM: chi-square ratio statistics supplemented by a population bioequivalence test for 
impactor-sized mass 
WG: working group evaluation 
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Figure 5.1 Reconstituted aerodynamic particle size distribution profiles for scenario 13c and 
scenario 2bb2 (Monte Carlo simulations with a number of 30 were generated for each 
reference and test profiles). a, Scenario 13c; b, Scenario 2bb2. 
 
 
a 
 
b 
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Figure 5.2 Comparison of chi-square ratio statistics and orthogonal partial least square 
analysis with respect to profile comparison. a, flowchart of the chi-square ratio statistics 
developed by the PQRI working group; b, flowchart of the orthogonal partial least square 
analysis developed in our group. 
 
 
 
a 
 
 
 
 
 
 
 146
b 
 147
Figure 5.3 Score plot of orthogonal partial least square analysis to compare reference and test 
profiles generated by Monte Carlo simulation (5,000). Each data point in the score plot 
represents a whole profile (deposition on all sites). Reference profiles are colored blue and 
test profiles are colored red. a, reference profiles from scenario 1a were compared with itself 
(two separate simulations); b-e, reference profiles were compared with test profiles from 
scenario 1a, 1b, 1c and 1d respectively. 
 
 
 
a 
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Figure 5.4 Differences between the working group (WG) assessment and statistical analyses 
based on different methods and data pretreatment. a, differences between the WG assessment 
and the combination test (chi-square plus ISM-PBE); b, differences between the WG 
assessment and the OPLS analysis based on unit-variance scaling on absolute mass data; c, 
same as b except that Pareto scaling was used; d, same as b but absolute mass data was first 
normalized to the percent mass data; e, same as d but Pareto scaling was used. The working 
group evaluation and possibility of equivalence from the combination test were retrieved 
from reference 195. 
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Figure 5.5 Comparison of the performance of the combination test (chi-square plus ISM-PBE) 
with that of orthogonal partial least square analysis based on Pareto scaling. The difference 
(Δ) between the working group evaluation and each of the two analysis methods was placed 
into three categories as labeled in figure 5.5. The number of scenarios falls into each category 
was plotted in the y-axis and labeled above corresponding bar. Chi-square statistical test was 
then performed to compare the two methods in terms of achieving greater consistencies (Chi-
Sq = 6.632, p-Value = 0.036). The working group assessment and the possibility of 
equivalence from the combination test were retrieved from reference 195. 
 
 
 
CHAPTER 6: DISCUSSION AND FUTURE STUDIES 
Tuberculosis (TB) is one of the leading causes of mortality in the world. The only 
commercially available prophylactic vaccine for TB is BCG. However, there are several 
shortcomings associated with this attenuated live bacterial vaccine such as waning protection 
over time, variable efficacy in different populations, interference by environmental 
mycobacteria, and inability to be used in immunocompromised patients. There has been long 
interest in developing the second-generation TB vaccines, among which subunit vaccine has 
drawn significant attention from researchers in this field due to its simplicity and safety. 
Various TB antigens have been identified so far and characterized both biochemically and 
immunologically. These antigens or antigen combinations were incorporated into appropriate 
formulations for the development of TB subunit vaccine. Particulate system was mostly 
studied as the delivery vehicle for subunit vaccines since it contributes to both dosage forms 
and adjuvancy of the subunit vaccine. Moreover, the characteristics of a particulate system 
determine the flow property of the powdered vaccine, which is particularly important for 
vaccines intended for pulmonary delivery. Since particle size distribution plays an essential 
role in vaccine delivery into the lungs, the batch-to-batch reproducibility of vaccine powders 
should be examined, which requires the development of a particle size comparator to 
evaluate the aerodynamic particle size distribution (APSD) profiles.  
The research described in this dissertation began with recombinant TB antigen design, 
expression, purification and characterization (chapter 2); purified antigens were then 
encapsulated into PLGA microparticle formulations at optimized spray-drying conditions
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followed by comprehensive formulation characterization (chapter 3); the efficacy of vaccine 
formulations was subsequently evaluated by in vitro antigen presentation assays to 
understand the nature of induced immune response (chapter 4); to examine the batch-to-batch 
reproducibility, a particle size comparator based on orthogonal partial least square analysis 
(OPLS) was developed (chapter 5). The overall goal of this research is to compare the in 
vitro immune response of newly designed respirable TB subunit vaccines based on 
Ag85B/TB10.4 and their different combinations in order to make a recommendation of the 
best antigen/antigen combination for future animal protection study. The second goal is to 
develop a particle size comparator to evaluate the batch-to-batch reproducibility of inhalation 
products with an ultimate goal to use it as a quality evaluation tool for making highly 
reproducible TB subunit vaccines suitable for lung delivery and immunization. 
There were four specific aims in this research and four corresponding hypotheses 
associated with each specific aim. The results and achievement for each specific aim were 
comprehensively documented in each previous chapter and will not be reiterated here. Rather, 
discussions in this chapter will focus on four hypotheses proposed.   
z H1: Milligram quantities of soluble recombinant antigens can be obtained by rational 
design of the expression constructs. 
z H2: Respirable PLGA-rAg microparticles can be manufactured with a target size by 
optimizing the spray-drying parameters.  
z H3: PLGA-rAg microparticles can induce stronger and prolonged immune response in 
vitro compared to antigen solutions. 
z H4: Particle size comparator constructed on the basis of orthogonal partial least square 
analysis has a better performance than that developed on the basis of chi-square ratio 
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statistics. 
6.1 Milligram quantities of soluble recombinant antigens can be obtained by rational 
design of the expression constructs 
This hypothesis was successfully addressed in chapter two. The expression of TB10.4 
on its own led to the exclusive formation of inclusion bodies. Similarly, Ag85B-TB10.4 or 
TB10.4-Ag85B, when expressed on their own, was found exclusively in the inclusion bodies. 
However, N-terminal fusion of thioredoxin to TB10.4 (Trx-TB10.4) dramatically increased 
its solubility with a yield of approximately 14mg/L when overexpressed in E. coli culture. 
This initial success with TB10.4 stimulated our effort to improve the solubility of the fusion 
antigen by the same strategy. However, the fact that N-terminal fusion of thioredoxin to 
Ag85B-TB10.4 only slightly increased its solubility requires further optimization of the 
expression construct by rational design. The construct was redesigned to change the order of 
fusion to TB10.4-Ag85B. The resulting protein (Trx-TB10.4-Ag85B) showed significantly 
increased solubility with a yield of approximately 2.5mg/L. Interestingly, free TB10.4 and 
TB10.4-Ag85B could be released after protease treatment without compromising their 
solubility. The yields for these two proteins are approximately 4mg/L and 1mg/L 
respectively.   
Purifying recombinant proteins from the soluble fraction of E. coli culture is highly 
preferred for several reasons such as the ease of purification, better chance to retain native 
conformation, and cost saving. Among them, a better chance to retain native conformation is 
the mostly favored property since these proteins are intended for use as antigens to develop 
TB subunit vaccine. Antigen conformations are mostly likely to be associated with their 
immunogenicity in terms of both humoral and cell-mediated immunity. To better mimic 
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pathogen invasion, antigens delivered from the subunit vaccine should better adopt a 
conformation sufficiently similar to that of native TB proteins. This research represents one 
of few studies that used soluble recombinant TB antigens to develop the subunit vaccine.  
The success is based on a good understanding of protein structure. Two mechanisms 
were proposed in chapter two to explain the increased solubility and yield of Trx-TB10.4-
Ag85B in comparing to Trx-Ag85B-TB10.4. The spatial effect suggests that direct 
solubilization effect of thioredoxin on TB10.4 is important, which may be compromised by 
the long spacer Ag85B in the Trx-Ag85B-TB10.4 design. The linker effect suggests that the 
shorter flexible linker (between Ag85B and TB10.4) in Trx-Ag85B-TB10.4 design may 
compromise the folding of the two fusion partners and thus leading to poor solubility. 
Although the validity of proposed mechanisms should be addressed in the future, they did 
play a pivotal role in guiding our successful design of a novel recombinant TB antigen 
TB10.4-Ag85B with great solubility.   
6.2 Respirable PLGA-rAg microparticles can be manufactured with a target size by 
optimizing the spray-drying parameters 
This hypothesis was successfully addressed in chapter three. Highly reproducible 
PLGA-rAg microparticles were prepared by emulsion/spray-drying method with very similar 
particle size and distribution, surface charge and morphology and thermal characteristics. 
The concept of Quality-by-Design (QbD) rather than trial-by-error was employed for the 
optimization of spray-drying parameters. Five process variables including atomization 
pressure, spray flow, aspirator flow, inlet temperature and pump feeding rate were optimized 
with respect to two response variables, i.e. particle size and yield. The optimization criteria 
were as follows: a) a VMD around 3µm (greater macrophage uptake), b) a yield greater than 
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15% (cost saving), c) a single mode of size distribution and a span less than 1 (uniformity) 
and d) mass median aerodynamic diameter (MMAD) between 1 and 5µm (aerosol delivery to 
the lung).  
A half-factorial design (25-1) was chosen for this optimization with reduced number of 
experiments by half yet without losing statistical powder to dissect out significant main 
effects and two-way interactions. This was again determined by the high-resolution nature of 
this particular design. Under optimized spray-drying conditions with atomization pressure (3 
bars), spray flow (700 L/hr), pump feeding rate (4 ml/min), aspirator flow (100%) and inlet 
temperature (55 ˚C), manufactured particles showed a unimodal and narrow size distribution, 
which meet the proposed criteria for optimization. The VMD is approximately 3 µm, a yield 
of approximately 18%, and an MMAD of 3.3µm. 
The VMD was successfully optimized to the target size ideal for alveolar macrophage 
uptake. The yield of 18% is relatively low possibly due to the small bench scale but could be 
much higher once this process is scaled up. An MMAD of 3.3µm falls within the range of 1 
to 5µm, considered as suitable for pulmonary delivery. Moreover, the fine particle fraction 
(FPF) of the emitted dose was 61.5±6.4% and FPF of the total dose was 37.0±5.5%, which 
suggested that optimized formulations could be effectively delivered into deep lungs where 
alveolar macrophages are populated without the need of carrier excipient (e.g. lactose) in the 
formulation.  
The successful manufacture of respirable PLGA-rAg microparticles can be attributable 
to, among others, the selection of an appropriate solvent (dichloromethane in our study) to 
dissolve PLGA and the selection of an appropriate statistical design with a high-resolution 
nature.  
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6.3 PLGA-rAg microparticles can induce stronger and prolonged immune response in 
vitro compared to antigen solutions 
This hypothesis was addressed in chapter four. PLGA-rAg induced much stronger 
Ag85B specific MHC II immune response than antigen solutions. At the same antigen 
concentration as in PLGA-rAg formulation, the solution formulation failed to induce any 
detectable IL-2 secretion. Antigen solution induced response could only be observed at very 
high antigen concentration. Therefore, encapsulation of antigens into PLGA microparticles 
dramatically increased the potency of antigens. Second, PLGA-rAg induced prolonged 
Ag85B specific MHC II immune response than antigen solutions, which may be correlated 
with the sustained protein release from PLGA microparticles.  
6.4 Particle size comparator constructed on the basis of orthogonal partial least square 
analysis has a better performance than that developed on the basis of chi-square ratio 
statistics  
This hypothesis was addressed in chapter five. The major difference between the two 
comparators lies in their underlying mechanisms. Comparator developed on the basis of 
orthogonal partial least square analysis (OPLS) is an analytical tool rather than statistics. 
Therefore, no statistical inference could be made by using this comparator. Rather, this 
comparator gives an equivalence value based on OPLS model fitting, which can be used to 
judge equivalence or batch-to-batch reproducibility. The performance of OPLS method was 
superior to that of chi-square ratio statistics. However, rigorous validation is required in the 
future to further develop this comparator. 
6.5 General conclusions  
The first research goal was to compare the in vitro immune response of newly designed 
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respirable TB subunit vaccines based on Ag85B/TB10.4 and their different combinations in 
order to make a recommendation of the best antigen/antigen combination for future animal 
protection study. To make a fair comparison, antigens should be prepared from the same 
source, either from native antigens, inclusion bodies or soluble recombinants. Since Ag85B 
is a soluble recombinant protein purified previously in our lab, extensive efforts were first 
spent to make other antigen or antigen combinations soluble as well. With rational design, 
TB10.4 and the fusion antigen TB10.4-Ag85B were successfully expressed as soluble 
proteins and purified in milligram quantities. This achievement made it possible to make 
appropriate comparisons among Ag85B, TB10.4, Ag85B+TB10.4 and TB0.4-Ag85B. Useful 
physicochemical information was obtained by characterizing newly designed antigens such 
as pH-stability and temperature-dependent stability, which offered invaluable information for 
vaccine formulation development.  
PLGA microparticle formulation was selected to manufacture TB subunit vaccine by 
encapsulating prepared antigens into PLGA polymers for several reasons such as potency, 
delivery, targeting, and sustained release. PLGA-rAgs were successfully manufactured with a 
target size of 3 µm by systematic optimization of spray-drying parameters and at the same 
time a thorough knowledge of particle engineering with spray-drying technique was 
developed. To ensure prepared PLGA-rAgs have similar physicochemical properties, these 
microparticles were characterized with respect to particle size and distribution, surface 
energy, charge and morphology, flow property, thermal behaviors and release profiles. 
Although different antigens were encapsulated, PLGA-rAgs showed highly reproducible 
physicochemical properties as mentioned above. This achievement justifies a fair comparison 
of different antigens or antigen combinations by in vitro efficacy evaluation.  
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The efficacy of PLGA-rAgs was evaluated by in vitro antigen presentation assays. It 
was shown that PLGA microparticle formulation significantly increased the potency of 
encapsulated antigens and improved the kinetics of antigen presentation. A comparison of 
antigen blend (Ag85B+TB10.4) and antigen fusion (TB10.4-Ag85B) with respect to Ag85B 
specific MHC II response suggested that antigen blend should better be chosen for future 
animal protection study.  
The second research goal was to develop a particle size comparator to evaluate the 
batch-to-batch reproducibility of inhalation products with an ultimate goal to use it as a 
quality evaluation tool for making highly reproducible TB subunit vaccines suitable for lung 
delivery and immunization. A particle size comparator was developed with some success by 
employing orthogonal partial least square analysis (OPLS). A comparison to chi-square ratio 
statistics suggested that OPLS method has a better performance which deserved further 
development. A successful particle size comparator is highly desirable which will serve as a 
quality control tool for particle engineering in the future.  
6.6 Future studies 
Some questions emerging from the present research need to be addressed in the future. 
a) Antigen structure after PLGA encapsulation 
The secondary structure of Ag85B, TB10.4 and TB10.4-Ag85B were studied by 
circular dichroism before PLGA encapsulation. It is not clear whether PLGA encapsulation 
or spray drying will alter the secondary structure of encapsulated antigens. The SDS-PAGE 
experiment in chapter three suggested that the formulation process didn’t compromise the 
integrity of encapsulated antigens; however, this experiment didn’t provide information on 
antigen secondary structure. An experiment in the future should address this question. It will 
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be ideal to study antigen secondary structure in the PLGA microparticles rather than the 
released form. This is because factors such as pH change, temperature fluctuation and 
agitation during antigen release will most likely to affect the secondary structure of released 
antigens. FTIR experiment may be performed with PLGA microparticles as the reference and 
PLGA-rAg as the test sample. After appropriate subtraction, the secondary structure of 
encapsulated antigens may be deconvoluted. This structure information can then be 
compared to that of soluble antigens to make a conclusion.  
b) Structure comparison of soluble TB10.4 and TB10.4 purified from inclusion bodies 
TB10.4 will be needed in large quantities in the future since antigen blend 
(Ag85B+TB10.4) was recommended for animal protection studies. Although the solubility 
and yield of TB10.4 have been improved dramatically by rational design of the expression 
construct, the purification procedure is still laborious which include three chromatographic 
steps and one enzymatic treatment. If TB10.4 can be purified from inclusion bodies with 
verified the same secondary/tertiary structure as of soluble TB10.4, this antigen can be 
directly purified from inclusion bodies in the future without tedious purification procedure. 
Therefore, an experiment will be extremely useful to compare the secondary structure of 
TB10.4 refolded from the inclusion body to that of its soluble counterpart by circular 
dichroism. 
c) Manufacture of PLGA microparticles 
In this study, primary emulsion/spray-drying was used to manufacture PLGA 
microparticles. Antigens and MDP were dissolved in an aqueous phase while PLGA was 
dissolved in dichloromethane. Both antigens and MDP were not soluble in dichloromethane 
and, therefore, emulsion was performed to disperse antigen/MDP into PLGA solution. This 
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emulsion procedure is difficult to scale up, which may result in heterogeneous particle 
distributions. In the future, PLGA may be dissolved in a water-miscible organic solvent such 
as acetone so that water soluble antigens and MDP may be simply mixed with acetone 
dissolved PLGA. Compared to emulsion, this process can be scaled up very easily. However, 
spray-drying should be performed in a closed system with nitrogen as the drying gas rather 
than air since acetone is extremely flammable when spray-drying is operated in an open 
system as we did with dichloromethane.  
d) Improvement of release profile 
PLGA microparticles manufactured under current protocol resulted in a poor release 
profile of MDP. This molecule displayed an almost complete burst release during the first 
half hour. Studies in the future should first verify the necessity to include this molecule in the 
vaccine formulation. If this molecule is beneficial for the potency of TB subunit vaccine, 
effort should be spent to improve its release profile. The method mentioned in the last 
paragraph may improve MDP release since MDP and PLGA are co-dissolved in the 
water/acetone system.  
e) Improve TB10.4 antigen presentation assay 
We were not able to evaluate TB10.4 specific MHC I epitope presentation of 
manufactured TB subunit vaccines due to the lack of assay sensitivity under current 
experimental conditions in our lab. An existing radioactive assay was considered and in 
consultation with immunology faculty at University of North Carolina and Dr. Majlessi it 
was concluded that no better sensitivity could be achieved than with the ELISA. Future 
collaboration with Dr. Laleh Majlessi may address this problem since this assay was 
originally developed in her group with sufficient sensitivity.  
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f) Study of TB10.4 specific MHC II immune response 
We were not able to study TB10.4 specific MHC II immune response since there is no 
TB10.4 specific CD4 T-hybridoma available at the moment. This hybridoma can be 
developed in the future to evaluate TB10.4 response by in vitro antigen presentation assay. 
Alternatively, TB10.4 specific MHC II immune response can be studied by immunization of 
animals with PLGA-rAg. T-lymphocytes from vaccinated mice may be isolated from the 
spleen followed by in vitro stimulation of T cells with TB10.4 specific MHC II epitope. After 
activation, T cells will undergo clonal expansion, which results in an increase of T cell 
numbers. This increase can be quantified by flowcytometry. 
g) Study of Ag85B specific MHC I immune response 
We were not able to study Ag85B specific MHC I immune response in this research 
since Ag85B specific CD8 T-hybridoma was not available to us at the moment. This 
hybridoma may be developed in the future to evaluate Ag85B response by in vitro antigen 
presentation assay. Alternatively, Ag85B specific MHC I immune response can be studied by 
immunization of animals with PLGA-rAg. T-lymphocytes from vaccinated mice are isolated 
from the spleen followed by in vitro stimulation of T cells with Ag85B specific MHC I 
epitope. After activation, T cells will undergo clonal expansion, which results in an increase 
of T cell numbers. This increase can be quantified by flowcytometry. 
h) Optimization of molar ratios of the two antigens 
In this study, Ag85B and TB10.4 were used at a molar ratio of 1:1. In the future study, 
different ratios of two antigens can be investigated.  
i) Formulation optimization 
In this study, MDP was the only adjuvant used in the subunit vaccine formulation. 
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Other adjuvants such as IL-2, IL-12, IC31, MPL (monophosphoryl lipid A), DDA 
(dimethyldioctadecylammonium), TDB (trehalose 6, 6'-dibehenate) could be screened 
systematically with antigens in order to find the best subunit vaccine formulation.  
j) Animal protection experiment 
After the formulation is optimized, animal protection experiment could be planned. 
First, the efficacy of subunit vaccine by itself should be compared to BCG. Multiple doses of 
subunit vaccine may be needed for effective immunization. Second, the efficacy of subunit 
vaccine as a BCG booster can be studied in a heterologous prime-boost protocol. To be 
valuable, TB subunit vaccines should at least offer some protection by itself and provide 
improved protection once given as a booster to BCG. 
k) Further development of particle size comparator 
In the present study, a particle size comparator was developed based on orthogonal 
partial least square analysis. It showed better performance than chi-square ratio statistics. 
However, the equivalence criterion was not proposed in this study and should be studied in 
the future. In addition, a larger validation dataset are needed to validate this method.  
6.7 Concluding remarks 
The current study of TB subunit vaccine with different recombinant antigens, Ag85B, 
TB10.4, TB10.4-Ag85B (fusion), and Ag85B/TB10.4 (blend), clearly suggests that antigen 
blend is a better option for multiple-antigen vaccine development. Microparticulate system 
not only served as a delivery vehicle for aerosol dispersion but also dramatically improved 
the potency and kinetics of encapsulated antigens. A thorough knowledge of spray-drying 
technique was developed in this study, which may help the scale-up of vaccine 
manufacturing in the future. A particle size comparator was developed with some success 
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and may serve as a quality evaluation tool to ensure batch-to-batch reproducibility of 
manufactured TB subunit vaccines.  
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